var title_f26_27_27056="Classification of biliary cysts";
var content_f26_27_27056=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F80937&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F80937&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Classification of biliary cysts according to Todani and colleagues",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 405px; height: 307px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (IA) common type; (IB) segmental dilatation; (IC) diffuse dilatation; (II) diverticulum; (III) choledochocele; (IVA) multiple cysts (intra- and extrahepatic); (IVB) multiple cysts (extrahepatic); (V) single or multiple dilatations of the intrahepatic ducts.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From: Savader SJ, Benenati JF, Venbrux AC, et al. Choledochal cysts: Classification and cholangiographic appearance.&nbsp;Am J Roentgenol 1991; 156:327. Reprinted with permission from the American Journal of Roentgenology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_27_27056=[""].join("\n");
var outline_f26_27_27056=null;
var title_f26_27_27057="Ligation uterine vsls 2";
var content_f26_27_27057=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F82120&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F82120&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ligation of uterine vessels during laparoscopic hysterectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas Lyons, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_27_27057=[""].join("\n");
var outline_f26_27_27057=null;
var title_f26_27_27058="Tonsil blood supply";
var content_f26_27_27058=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F78639&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F78639&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Vessels supplying the palatine tonsil",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 430px; height: 458px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The tonsillar vascular supply is from branches of the external carotid artery. Superior pole: Descending palatine artery. Mid-fossa: Ascending pharyngeal artery. Inferior pole: Tonsillar branch of the lingual artery and ascending palatine branch of the facial artery.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_27_27058=[""].join("\n");
var outline_f26_27_27058=null;
var title_f26_27_27059="Cerebrospinal fluid manometry";
var content_f26_27_27059=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F54738&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F54738&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 495px\">",
"   <div class=\"ttl\">",
"    Cerebrospinal fluid (CSF) manometry",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 475px; height: 363px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFrAdsDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooA4z4u3euWngm5bwreWlpq0kkccTXE0cRcFvmSN5PkEhGQCwI/HFeZeGPiZqVosWm2/2+XUp9YTTJ4vEFxHItmzQu+VmhUCRflHB5HtkV7tqem2OrWT2eq2Vte2j/fguYlkRvqrAg1zOt/Dnwzq1rpFnJpltb6dpt39sjsba3iS3lfYUIkj2kFSG6cdBzQB51p3xTv8AULjS76a0RZo9P1iSRbe5f7LO9qQAyj+JWxwTyOcZpy/GPXtO0+4vNb0TTnjl8Mx+I7NLGeQttZ408uQsvrIGJA4APXrXr48O6KI4Ixo+nCO3ge2hX7MmI4nGHjUY4Ujqo4Penx6FpETRtFpVgjR2v2BCtug223H7kccR8D5OnHSgDypvi1qOnXc1jq9vpEk1rrGm2E97aTt9l8m7UsXBboyBTnJxyDxmodY+MGqrY6jPo2l2d1Fa65daabiNmnCwQxRv5vlIQz5MmCVOF4z1Fepx+FfD0ejy6THoOkppUrb5LNbOMQu3ByUxtJ4HOO1Qy+C/C01p9ll8NaJJa+aZ/JawiKeYQAX27cbiFUZ64A9KAOY174gz6f8ACnTfFllFY3s12bVQA0iQkyyKhILDcAN3cZ4rnR8VfEH2z+yoNM0e71Ua9/YwmjuJFtHzAZQwYBmBXowwf8PR/F/hHTPFXhxdDvxJDp6yQyBLfauBE4ZVwVI2/KARjp6VYsNC8PQRw2mn6VpMcenT+bFDBbxgWspXO5VA+RirdRg4b3oA83uvilrFn4mazudP0sWtrq1potzAkzm5kmmRSZYgQMxgtwCMsATkVAPi3qy+E9V8VvZ6MdKtzcpBpouWF/uikKAuMYHTcwAyqkHmvV5dD0iXWI9Wl0uwfVY12peNboZlHTAfG4D8aiTw3oaalcaimi6YuoXKsk9yLWMSyq33gz4ywPcE80AeRH4teLI9FuZG8PWU12tzbrFNAzMrwSo7GRYN3mOVMeMKeQ2R0NV7742anDY6Nfw2+lHSbm2Wa41IJPJCjmZo9hRR5kQG37zKQSSBnGT6yPA3hIWctoPC+hC1lkEskP8AZ8Ox3AIDFduCRk8+5qxL4T8Oy3NncS6BpL3FkqpaytZxloFXlQh25UDsBjFAGB8RPF1/oOr+HtH0iPT1vNXa4IutRkZLeFYYw5B28lmzxz2J5xXBaR4u8QeOvHXgCW3lfS9HvNLfVZ7OO4dC7JKqsGIHzr0wDwQTmvaNY0fTNbtRa6zp1nqFsGDiG7gWVAw6HawIz706PS9Pju4LqOxtVubeH7PDMsKh44uPkVsZC8DgccCgDgb3xVcWHx9GiX2qRW2hnwz9sEMzIiG4+1bN24852AjGfwra1jWpr211ixuYNY8MwQ/IuszPaxxv+8CjymLvgvnALoPvdM8Vra34T8Oa9dpda5oGkalcogjWW8so5nCAkhQzKTjJJx7mtHUrCz1Oyls9Stbe8s5RiSC4jEkbjOcFSCDyO9AHmvwB13UdX0rxFbaxqc+oXOnarJboZ3jleKLapVWljASQ9SSOnT0r1OqWkaVp2i2YtNHsLSwtASwhtYViQE9TtUAZq7QAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUVyem+OtOvLNJ2huIixYbdobGGIPIPqDQB1lFcXqfxG0ixidhFdyyAfKgjAyfTJPFdF4b1aHXtB0/VbZWSK8gSdUbqu4ZwfcdKANKiiigArjda2+HfHFhrIOyx1nZpl76LMMm3lPpkloie5eMdq7Ks3xJo9v4g0G+0q8LCG6iMZdDhkPVXU9mUgMD2IFAGlRXPeBdXn1bQEGolP7WspGstQVRgC4j4Ygdgww4/2XWuhoAKKKKACiiigAooooAKKKKACiiigAooooAKKKY80aMFeRFYkAAnkk9B+lAD6KMiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAEJwCea8K0dHgn1q0k/5ddVu419kMpdf0cV7sa8e1m1+yeNvEgHSeaG5/FoVU/wDougDlfES4ya9K+A90J/hrYQj71nNcWpB7bJnx/wCO7a878Qr8rV23wBO3w1q0RABXU5GwD2aOM/40Aen0UUUAFFFFAHGaip8O/EC11JPl03XwtjeeiXSA+RJ/wNd0R9xEK7OsrxTo0XiDw/faXNI8IuEwkyfeikBDJIvurBWHuBVbwPrM+t+HoZr+NYdTgZrW+iXolxGdr4/2SRuX1VlPegDeooooAKKwr7xHFZeK7DQ5rW533sLSw3CrmNmU/MmfUD5vpWysiPJJGrgumNwHUZ5FAElFJVHS7570XTPEI0iuHhT5slgpwWPpznj6UAX6KKhubu3tRm5uIYR1zI4X+dAE1Fc/c+MdEhkaKK6e7mBx5VnC87H8EB/OmrqutajE/wDZujmy6bZdUcL+UaEk8epWgDoqKwYNK1Ypm78QTtKTn9xbRIg9gGDH8yaZ5HiOyucw31lqNoSMpdRmKVfYOg2n8VpXQHQ15/49torTxV4e1RG2ym5RJEOMOBlA2euV81j9K6n7Rrf/AED9P/8AAxv/AI3Xn/xivtQstN0O/vdPijS11WBhPBclxGSdvzgoODnGeecU0B1mo3lyl9qBhf8AdtCDGFOd2Aen6Uy815/tUTWpG3yVIO7KsTz09Peq0iK93Ht5AhkiwfunBUEEd+lYo8wvbSSIIy1pGDGvIUgnof8APSvOrVJxvZnoUqcJWujt/D2sNqGjWVxdBEuXjHnBPurIOHA9MMDWwrBlBBBHtXB+Fj5eoa7AMFBcR3AOOcyQoWB/EfrXRRuyElDg+1dHt2nqjzpe62jcorOjvmH3wGHqODViO8ibhiVPvWsasX1C5ZooBBGQciitBhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFeVeNj5Pj6WHaqifTophhcbisjqxJ9fmWvVa8z+KcPleKfDN2E4liurRm9Mqki/+i2/OgDjNfXMbVs/AO5Kav4ksXb76W9ygz/vo3/oK/nWZra5hP0pnwdkS3+IpADb7mwnjY54IV4mX8eZPzoA98ooooAKKKKACuLu2Phv4hQXJO3S/EQFtL6R3sany2P8A10jUoT6xRjvXaVk+LNHGv+H7zT/MMM0ihoJx1hmUho5B7q6q34UAa1FYfgvW28QeHre8niEF8ha3vLf/AJ43EZKyJ9AwOD3BB71uUAcf4xhkHi3wXdRsMJeTxMhj3bg1tI2c5+XBQc++O9Hht3TVtTunP/IRunKqE+6I4kUZPvg+3I960tfJ/trQOcZnl7d/IkqrPaWGlXkV7CkUEs0whclyocuQOnQtkLjvxiok2mXFXNxWYNnNcs+tPZ2Elppe2TVtQvbpLUbd6JiQ7pXx0Rc8+pwOprpgSHAwfeuJ8Kpb2viXUbWPY80FvsbaPmBa5mck+mQyk/gaiMrDmizPYbJ7aDxdf3l9byoB9rWZre3aQZyjxJgKOhBYtnkZ6Zl8O6TpkutTy6dpdhFYWrFBMVEz3DkKVZHOcKASOD1rrEijmtHimjWSJwVZGGQwPBBB4IqWJFjhRI41RFAVUUYCgdhT5myCK9hmlsporOcW07KRHJsDBD2O3v8ASs+FdZkurZb2awhhVt7/AGdmLyYHQBhwM9etbA68dK5vxFd6VLerZXdkbvUoyjW8SELMQxPzRsSCANpyQeMUJXA6TrxWTNrtna6nc2d7PBb+UkboZJAGk3bhgDqfu9vWjw5DfxR3J1DeiPJvhhkm814lxyC/fntzj1NajRxtIHKIXHRiORSsAyW4gikhSWVEeY7Y1Y4LnGcD1OKxvH9vJeeCdbtotweW0kRSPUrxWjqMNnf2Ei3W2SBDuLI3KMpzkEcggjtzWNpGoNqWg6jGZkvlgjMS3sR+S5+TO4dgw6HHGfyFR0YGDpjrd6fpN1bI21odwZ1AKBogcH8cflULII1t1Du4SHGT/Fzx17/41D4Qy3h22eRQ8aAKhiy2NkjqMeoC7QPar2oFkuwmSUbc3JHB4z+BrhxP2j0KHQf4UOdV1wgg82vPr+5FdL9Olc/4diSLU71omJ8+2t5JFHQMPMTgdvlUflXQUS/RfkedV+N+oh6dKMjBPYdaO3oaAeOaRmOV2U5RiPxq5b3pBAm5B7gdKo8A8daDVRm4vQaZvA5GR0oqhp0zEmJjwB8p/pV+u+ElNXRa1CiiiqAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK4n4qLGul6XcSYBh1CPDHtvV0/wDZq7auJ+MsJk+HepSKSGtnhucgdAkyM3/joNAHAauuYDWZ8OL1LP4i6VFKSFuWkiUcYz5Tnn8gK2NTXMB5z7+tcKs/2DxToV8ThbXUreRjnopkCN/465oA+qh0ooFFABRRRQAUUUUAcY5Hhv4hKcbNN8SjaT/Cl9EnH/fyJcfWEd2rs6xfGWh/8JD4durCOX7Pd/LNaXAHMFwjB4pB9HVT7jI707wjra+IPD9rqHl+TOwMdxATkwToSkkZ91dWH4ZoAq+JlY634b2lh/pUuQDgY+zy8n9KpXsl61xFDD9mvLSebCu8gV4sAZGD9/nJ7H9KZ8QLmaz1LwhJbkBpNYSB8ngq8MqkY79c/hUrx20k7WShFkS4NzsaAkSAndlW6Kc9xzx0rOe5pDY3JGIA2jJLAc59a4kQyWXxUe7gSJINVsRFOS3LSQN8rfUiTAH+yc9M10dvqateLbTSxNIsYMij7ysWKjOOME8Vy/iO5d/HehJsJS1kXcyncf3rOo78DKD86lLRjmd1dGT7A0cdwLZnBCz4B8s+uDwTWZ4Nuri4hv0urqS4eK4Kq8i4LIVUq2McZBzjtzWyiq1tiTBGeh6Vg+H7C5tfFOvXUkE1vZzmPyw0waORgMF1XqpxgEH0oWqMxtjrA0271n+3LqcbJw0cjxERrCQNuMDAwc5J+tdIFhleOdVjkcD5JMAkA+h9DVe2WW6jka/t0jEi7PIJD/L33EcHPpTNLazRPs2nxbIYRsGxCqLjjaP/AK1MC9IGZHVWKsRwR2rM8SNd23hvUH0yN5LpIG8tF5YnHb1OOnvVDUPEdxa6jJaxaPd3ixsqSS2zphC3Kj5iMtjB9ORzXRRszDLLtz0B6/jTSuBh+FrnTUsYdP03zAkAbarWzxcZznkf7Q68n86vatKmn6DfzwxhUgt5JQkeF6KW44wDVlL22e7NqtxEboJ5hh3jeFzjO3riqHitd3hXWRzzZTD5ev3DQnqBynhW3Nt4b0q2cgMtnHkKe5AP9etR6mxXVAhTbujDb+x5xj8P61c0Ah9D0xxnm0i4PX7gqlq0bhrN9hDAPuOfunHGa8+tqmz0qWjSLHgaAJplxcklpru4eSRz1GCVCf8AAQoGP8a6PtznIrlfCd5KlhqUMcL3LW14yIqsq7t2H6ngferca6vty+Vpu4EZJa4Vcc9O+aZ5dT436l459qQ5/wD1VAXuiOIYlfBxmQkZ/AUv+k5GfJ9+DxTIJgPc5+lC5x3pgM3O7ywO3BNVpTf+eBCtsYW6liwKnPt1oAvxP5bq6ggg1tRusiBlPBrmM3ykErbupK5Ckg4yM9fbJ/CtXTLtWG0SKyk8FTkZ7itqM+V2ZSNSigUV2FBRRRQAUUUUAFFFFABRRRQAUUUUAFFeDa5+0EmkxeLYZND36npGpSWVnbiY4vI0eQPLnb8oURMWGDjK8813Gp/FXRdGutIttat762fUUgZZhGGhVpQMDOQxAJwSFIHegD0GiuBj+K3h5/ECaUYtUQtqUukfbHs2W2F0hIMfmdMnacYz74pdI+KvhzVPPaEX8UK2c1/bzT2xRLyCI4d4SfvY9Dg85xigDvaK8tb44+FkgknltdejgSKC5aR9NkCi3l4Wcn/nnkgZ7/whhzWpf/FjwzZeKG0J3vJLlboWJlig3RC5IyIc5yWPA4GMkDOaAO+oryzQPjPpN74Lstf1TTNQ0+S8untLe0CGRp3VnH7tyFDABCWJwFORnPXT0r4s+G9WuNLt9MXVLufUYDcRRwWMkjIom8lvMCg7Nrg5J4A5zyMgHoFFFFABRRRQAUUUUAFZHi+w/tTwnrVgV3farKaED3ZCP61r0jqGUqwyCMGgDwtDv0e1YnJMKZPvtGa4TXoGlZ0RQz/eAPqvzf0rrvDMnm+FrZTu3w77dw3UNG7If1WuY16LfI6biu4FcjgjPGaAPqaJw6KwOQwDD8afWD4Cv/7T8EaBe5y09jC7f72wZ/XNb1ABRRRQAUUUUAFcZAv/AAjnxBlizs0zxGDLGOyX0afOB/10iXdj1hc9TXZ1g+N9Ek17w9PbWkiwajEy3NjOR/qriM7o2PtkYI7qWHegDI+JZIufB2Oh1+3z0/55y1sSXrvDdmGGVWgI+ZxgOO+OvQZ7Vz39p2vih/Bd9LEElMs1wbR3+aC4jhkR1I7sjllPoRXRsl6SwiW3iVzuLMSx7Z46dPesp7mkNiK/sY/tQv42SOZQoLhASy7h1PUjH4VwFtvn8a3Cqu1X1hYgpG7ZHBGZTgg4ALyD/voV6PIjRWkSMXlIKIzEDLcgZPtXAiVrLUbbVNiNBDq1wl0wGR5ckpQvx/dKxnPoKUexTR6JLeQ2FlcXFw22GIb2OM/kBUtpcm5t1leGW3yThJQFYgdyMnGfzqlqlot3ZXNo7FRKhTIJBHoePTg1jaPcapeSHTNX8lYrWILPOjFmuGIIH+703H8KSstDI3rLUoL++vbOFJv9EKrJJ0XcedoOc9MZ+tTX8zW9uYrXyRdMrC3WTIjL44BI6Csj+w4EvUu0v74S7g8ixSbEnOAMyKBgnAxkAGmXOlyXPiCHUWkSNIc/u4wQZuON56cHp1ockBN4XsJ7KzkfVZVku552un9VZgOODjAHAx2ArXlucI3lDLY4LdM1h6lrmn6bPFBcTO91KcR28KGSR/UhR2Hc9B61nXmr63cSBNJ0uCCPGTPqMmBnPQIhJPryRS1ZSi3sSWXh1or6LULm5MuprJvkuQuGkXBHl+ygHgfnk10jxfaraeGfmGSNkcN0wRg1x0+n63dbWm8S3UB2kFbO2ijH1BYMeK8++JccvhqDT5BrGpXaTMymK+vJGhGF5ZlH3up+Xv2xQpRh7zZtSwtSrJQitWd14ElMng7SNz+YyQCMtnOShKnnv061Y11VK2zupOyXIwOhIxn9a5r4Ram+oeGSs0UMMkNxKFSCPy4wjNvAVMnAG7pXV6wAbItIQAjqQc45z/8AXrjqe9F2OzkdKfLLdFXw5ka5rZ4DSraygqM5G0ocj1yh/Sun5z2x+tcppDg65JCxxvsxhgQMkScZP4n866s+o60RlzJM8yvHlqNGdq+pf2Zb7zC080kgjijUhd2SBkk9AM5JrQQkopddpIBI9Kz7u0+1arH56sYI4tyMrEHcSQQfwIPWtAjamEwDjjdyKZkQwXBcfNG6kMykgHGQccZ5pzSbYXkCs2wEkYwTj0zRbJJHGDMyGQks5QcEn0/CnSDcFQBtrdWBHy9+c/lQBDO8htZGWJlJjYg5AKnH1p1nsFtH5YKoFGAVxjjvUzuEUsQT7AVTutVtbedopWl3L94rEzBc56kA4HB59qYG7Y3W4CNz9G9avVzzTIhUFiCxwPlNa9hOJomX5i0Z2sSOpxmuqjUb91jTLVFFFdBQUUUUAFFFct8RfGdr4H0W11C8tLi7Fxdx2UcUDIpLvnbkuwUDjqTQB1NFcNofxO0DUfCi69fNNpVsbt7ER3ShneZSQVj8ssJOhwVz0Poal8QfEvwvo/h6HVRqlvdJd28txZRwsWa5CAkgbQSoyMEkYB60AdpRXHaP8RfD974dg1S8voLFjZ2d3cW8jktbi5UGJTxzktgECuxoA4C7+E/hu70nXbKdLh31e5urmS7PlmeA3DK0ixNs+VcqOCD7k1S1f4M6BqeqSXr6hrELSraCWKKWLZIbYKIyd0ZYcKMhSAeuM816ZRQBw3/CstFKIrT37KviF/EmGdCDcNuyh+T/AFfznjr/ALVVdK+Eug6ak0aXeqzwfYZ9NtIp51dbGCb76w/LnPu5Y4AHSvQ6KAPOL34P6BeaTcafLeaoIZ9HtdEZllj3CC3YMjD5MbyRycY9AKuH4Y6Oni6XX7S71G0mnu0vp7aJojDLMpB3HdGXXO0ZCsua7uigDzb/AIU9oP8AYEGkfb9X+zWl497YsZYy9k7Fiyx5jwUJdshw+c1seGfh9p3h/XrfWIL3ULm9hsJNPzcNHtaN5hMWKoigNuGBjAx2712NFAFLWNJ07WrM2es6faahaFgxguoVlQkdDtYEZrC/4Vx4H/6E3w3/AOCuD/4muqooA5X/AIVx4H/6E3w3/wCCuD/4mj/hXHgf/oTfDf8A4K4P/ia6qigDlf8AhXHgf/oTfDf/AIK4P/iaP+FceB/+hN8N/wDgrg/+JrqqKAOV/wCFceB/+hN8N/8Agrg/+Jo/4Vx4I/6E3w3/AOCuD/4muqooA8HsrBNLudf02GNIYbbU7gRRooVURyJVAA4AxJwK5XXhtmyOMGvQfEZVfHXiKAHtbz7eON0e3P8A45XCeIVw5oA9c+BUzSfDPTY2XD20txb4znAWZwP0xXoFea/Aa5SXwpfW6ZBtr90IJyfmRH/9mr0o9KACiiigAooooAKKKKAPJL22l0T46aXbrLt0rV4rq9iiIztuxEFkA9AyAPjjLbzXY6pd30etwQ2it5Rj5IjLgsc9egGAM5z3rjPi94fv9W8ceF59Kngh1KGC5ksjJ3mj2SKpPZSRtI7qzVo+H7uXWZRrqQOYdTjgSHYPmiCOTLFMv8LIwZc/7OOD1zmuppA6iIXgnj+1KpdWjjHlMVD4BZmwT09uuR1xXJvCbuy1qFofPDvcgxfdZ1MzfLnscAge9dvfuiGBnYhQ/OPTBzmua02BY9R1BkiXyjcTg8dT5rHH6mo6XNYb2LHgvV01GzksZJ2lv7ALHLvXa7Jj5HI5BJGAcH7waui+grkbvw9Zzi3YNcx3ER+S6imKSoMdQR16DjGKsrBq8SiO21pjGBx9ptllf/voFc/jSdm7kulJbHRSusaMzHoMkDkn6Cua1vXGnkm0/RVhvdRMfMbviKEEgFpWByvU4X7xx2qtc6LcXqv/AGzrF1PETkxwAW647jIJYA47MPyrYt4IbaBYraJI4lACoigDFCsthxov7RV0nTY9PSU+Y9xdzsZJ7iTl5GP8l9FHAq9kd+DR9KWpOhK2iGEZ6jnOBzmvMvjtbGfStFcJHIiXhXEhwuWQ4J5HpXp0jBFZmzgDJAGa4D4zRudA0+ZNv7m+jch+QR06fjUVPhZ2YF2xEPUq/CV7hDexXB/1ircHC7V+8y5x2+6Biu8vSz2EwwpJBUDsTnj+lcT8MpVN7diTJka3Chsd/NkJ+nGcfSu4nGYGKOTkghkwcfN2rJKyRONf+0T9TDtG8rxBIsjNGv2XBccbT5nH15AzXVWN0l3G7R7so+xs8DcOuPWuVjJl8WzxID80BAx3yecV0ehqRYK7nLuxYkdDj5Rgfw8AceuaxpPRo8vFr37k9zJMJFWKNmUEbtuASPx449KZZyzIqRXTK8pHUMCfxA/n7irbDHLNhR78UxCinCtHntjqc/8A6q1OYWJmI2yBVkxkqpzTUkZriVSF8tQuCDznnOf0pHi/fidF/eKpQ5OMjPrUke5kyyKjnqAcjP170AQRm4a8kEkafZwMxMp5Jxzn8zVM/bBqE0sUKhjAAiNL0Kluo6EHI/rWqBwMYwPSjHPTn1oAhKie3Ed1Gn7xNskZ+ZTkcr7iszTvh34KdX3+D/Dhwe+lwH/2WtrvV7TOj8fpW1B++NbmJ/wrjwP/ANCb4b/8FcH/AMTR/wAK48D/APQm+G//AAVwf/E11VFdpRyv/CuPA/8A0Jvhv/wVwf8AxNH/AArjwP8A9Cb4b/8ABXB/8TXVUUAc3Y+A/CFheQ3dj4V0C2uoWDxTQ6dCjow6FWC5B9xVH4qeCm8d6DZ6cl/FZNa30V8HmtftCOY8/IyblyDnnmuyrxX4tePvEPh3xRe2mnXUNkLayguNOtJLQzNrEzylXiU9RgADC/NznpQBoaZ8H30vT7ZrHXlh1m21eXWIZ1sALWN5E2NGtsHwE2+j5zzntUI+DEllZ2q6N4ja2vP7Ou9NvZ7ixEwuI7iUyuVQOojIYnGCeMDnqV+GFjd3fxe+IOrapdmea1uIrSGNk5gRokcIp3YAA4OByfm71V8CeNbaz+I3xA0W/wBVSTVZdU26XYXNwwD4i4RDg7FJ9B74NACXPwpuD48+HzKrzaToOlxW+oXe5US7ktgPs6+VuLZD5fuMcZr2qvG/i9qUcngR/wDhOPsfh/VWaUafFHqt01vIQq/M8kMaEsMttQggkDrk47T4P3Nzd/DDw1Nf/bzdNZJ5jX3+uYjjc3rnGQTyQRmgDsKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDyHx3bra/FAyqoX+0NIUsQPvNDKRk++JQPoK4fxGvLV6V8WoCviLwleKpxvurVm9A8QcD84hXnniRfvUAdJ+z7dBdZ8S2RJy8VrcqD9HRsf98r+de114H8DoQnjq5nyMS6a0RGecpKjDj0+Y175QAA5FFFFABRRRQAUUUUAec+Kr+ST4weFNOiCYt7We5csCPvkINvrwrfTA9aqaVc3nhrx3qWiyQg2OtyS6jaXO9Vjim5MyEdc42PjuS56c1B4iuCf2gNFtEhy8mlbi/OAFlZiceo6Dt8xrb8YeGGvvDTiyHnatZSC8s3kY5klj+6jseoZd0ZJ/hc1E3sXA3bidSbZjLyGdT5YyHYL2H5msfRjvS8ZSeb24zn18w5/WrWjXtjq+jaXqWkRRx21xE08a7NpQlDlSADgg5B7gisTwhIs2kBSjxO9xNIYmJVk/eE4IwDxkDmofwm1P4joO3SjgnHegkKMk9Oc1WlVmcYaRHfO2RVB2Dj145x3BrM3JySzleNmOuM5NOJA9gTikVdqhVzgDGTzVHV9VtdMi/wBJn8uZ8KkarvkJJxlUHLc+goDbVl8kZAzhjyBTJ54bePzJ5Y4ox/FIwUfmaz7ey13UoN1rAujRSNuaa7Almx3KxAlVJ/2jx6VqReDNIe8a8v0kv7vb5ay3L5aNcEYXGAvXPABz3rRU31MpVktjnbjxHpUgKjU7HYX2uGbcJR02Lz1P41yPxYuzeaPbW0UolkuLuKKOO2/eLF1JLOBjcVBOB0xzXo2s3Gh2d1LZX9uYpRF+6luiwikyrYw2eTyVOPm5x6Vg6/8ADnSPE/h621C305tK11IhPE0DbD5u0YWTI+YZ45GeTQ4KUWkPD4r2dWM3smYHw5VF1K6SOMERwqCQeFIeTJyevXnFd1eFVs5H/gRd42nGcc9q5DwPeNcmO4ez+zSizghuIomLbJWkkJ+gBHI7dO1dbqEmLKUqyjK8E9B6/WuSV46djqq1VWquourMXQ03+MpWHDC03H5fVsde9dXYRtDaRpIQSuRx6Z4rnvDIB8Q6juK7xbQgc843PXUgADGc4rGkrRuefi3eq0BGe565oGO2KTcCSARu9KXBxmtDmAjJB9Kr3izNbTCFyHZSFxxt46j3qdWBztYHHHHY0vGOKBFSKySNvNjykxPzN18znuOn9RmrecHgGms6IfndVzzg8UueeFPPX2oGGduAMgE9a0NLHEnXgiqDdOav6WeHA6cVrR+NAty/RRRXcWFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAcL8XyItB0y6Yqqwanblnb+EOTH/wCzgfjXmPiNOG4r1T4y2xufhprhVQxt4lu8Fc/6l1l6fRK8x8Q7ZIy68qw3A+xoAz/hjfGx+IehIW2x3bzWzD1JiZ1/VP1r6SFfKOm3Bstc0e9GAtpqdrK59EMgRv0c19WjqaAFooooAKKKKACiiigDzrUrWe2+Nunag0YMF3pE1ojBhncjK+SMZ24Ygc9c8YrpL65eC9jZpFW3ACsrg4JOTkEDrxjHuKzNfMMfxH0KTZ++Fjdk4GWZRsx27c9+9b1jOLq1jmwCHJIx6ZOO3WspvU1grI898E6mtl4jjt2t7i0sdcE2q2ELHIjf/l4jBHBBOyUevmt0xVzwRHtsLubaVEl5OFVuqgSNkH33Fqm+I+l3F1YwXWkqF1TTA13YqG2hnXhoiOwdC6f8D9azPCmvWCeErG9kuMi8dmgjjUtJMzHO1E+8zZPTt3ofwl09JHTyN51ykSsdifNJjoT2Gf1qBtQEk08OmxSahdKdhSH7sZ9HYnavf39qk0TRtR1CBLvVZH0+Kc+a1hH/AKwZHR5M8dshcY9etdTp9nbafaR21lCsNun3UUcf/XNRyjlW/lMCHQ9RvNg1G7S2h/jhtsl39jIcYH0GfetbTNF0zTZGksbSKOYgBpOWcj03HJx+NWbhlnSW1jn8q4ZCAycsmRwf/wBdc94e1R7fRbx7yR5P7NaWG5Zh8xdGLbunQqVP41SRg5OW5Y8WajqEVolto8EbXN03krNKw8uNiD19TgHHv1rRgSLSNNt4I9o2hYwXbaXY4GST3NRXek2uq2YEz3BjkdbhCkpUxsOQVI6VNZaRb2kRjDzTqXEmLh/MwwxyM+4z9elUl3FctrH8iifbIQd2duAD2wO1Sc84NQX0/wBnsp5xyYo2cA98AmszwrdyTaVBHealBf3wQSSSRKFyrfd+UdPT8KS7gcJ4atmsvE/inT7jcJIpUlRiOHR2kdWX6FsexWuglSYoFkO7ZDndn7z4waNeieHxYkw4Se1O7eM4CSEk9enzLinpOJXlUFTiNW+9yMg9V7dK5aq95nbSfuoy/Dp2+KbsDcd9lGTn2dgMfma6tFCg4A5OTxXMaEM+IZMgj/RPz+cV0kcoeSZUXPlnbnI64zj26j86wp/Cc2K/isGhiedZjGhlQFQ3cA9R/wDWpZEV+DyAc4/Co3kmLMqQA4BIJfAJ44PHH/1qFkuGdQbdVBByxlyAeMDGO/PPtWhzkqqsanACjOTgYpJZNkRZULnsBxn0+lKTJvXaq7edxJ5Hpioybg7f3cXXkbz6fT1pAZVzpkkccYjSW5leRQ8skxJQDncVJAYcDj6Vet47sKTNMC/Td268kL24xjryfwqwryeZgqpXqTnkfhSo0mFJiAyeQG6defyx+dMByghQCxZgMFsAE+9XtM4mb/d/rWfC8jl/Nh8sA/Kd4bcPX2rQ0w/v3GOi1dL40C3NKiiiu8sKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAo69ZrqGh6jZOQFubeSEkjOAykf1rwFZXudAsnlGJfIQP0+9tHpX0YfevnGxieLRTDKMPBNLbt9Y5Gj/8AZaAOS1FFe1uw/ARfNB9CpDA/mBX1xG4dUYdGGRXyhOm+WePpvRl/MYr6R+Hmof2p4E8PXuctPYQO3Ofm2DP65oA6GiiigAooooAKKKKAOH1gS/8ACz9IYj9wbG4APX5vl7fjWn4YjvI9P230At3G1FjyCflUKScZ64yBk8Y+lUtWnQ/ErRrUYMq2NzOeOVTMa9fQkjj2qy8moS38E8aq9msxjeNRh0IJXdnuDnJHGMdTWD3NlsLrcaSXMYYIHK7MkbsqWAwQeOp/WvOvgrFDZeINRW+gj+0ajLc3+nzMmDEvnlZ7Zc8KEbY2F6+afSvSL65EepRiRAq7FJyQed/AI6+uOorzbSIbm78FXVzpURbWfDmtXdxbxq2WmHmOzRn/AH4pGQe+D2q02okT3PRvF+o3trc6NYafKLZtRujDJdFVbyVCk8A8biQAOvWm6bpsdxFFNHf3t7BKSzy3UrMGxxgKMBRnJ4qWw1XQfFtrCIJYrxDDFd7CpO1JAGTd2BIwcda0NVvV07TL2a3iSRrWEzGEMFGBk/h0P5UkSTaRp0GlWQtbbcUDM2XOWJYknJ/H8gKoSeGNIlvLmee0WRrht7q5O1jjBJHf8av6Xcm90+3us5EsavwMYJFWiCU+UgfWkBWvJZBAy2kkMcvRHlHyE+nUdR6VHot+uqafFdKpjLFldCc7WVirDPQjIPPeqNl4b0mEy7YFmTeSEnbzFh77UB4UA5OB61o6dPYSWanTpIDaoxRTARsBHUDHFAFvAIIYAg9QRVHS9I0/SUddOtY7cNgHbnkDoM+gycDoKj1TW9P0uNXvbqOPe21QQSSfTABNTafqFvf28dzazLJDINyODwRRe+gHOa+znVrdkjLuLS42oGKk/vE7npURUxmfliREuGPpz196m1/aPEdhEAU8yzuDgf8AXSMn+f61WlULJdSAn5olG09Byec+tc1Z6s7aPwoi0BhJrN0SCPItY16dd7OSf/HRW5E7faJ0aPao2sHBHzZHp6jFc74KRmvNeuBjyTcRQof9yIZH0BNdIiESyNuyHxgenFZRVkjkxP8AEZICG4/Qikbrz0780kinYVUlSf4gM4qtfREojESSRKSZI4xkuOwx35xTMQkuJXwtnH5h6F5DhBk9fU/hViMGOICRy7dS2MZ/AVWNyWRY4reZC6kAsAmzHrk56+gNRXUSTxeR5UzpGAdiSFN5OfvYIO3I/XpQBojJAP6UmeeMYpItxXcwZWbB2kj5eOnFK2FGW2igAH51d0v/AFrf7v8AWsqeVwqrBGzbmHzYICj1rU0v/XN2+WtKXxoFuadFFFd5YUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB5t8SfEenXWrWHhJdR1K0urmeL7VPYB0MStnZE0wGIzKwCjnOD7ivM7S3ex8V+LfD2l6Zqd2ltqIkiFraO8ccckUbYLk4Bzu6nnk85ru/jD4EubnSde1zQtTe1uWhW8ubVot8dxLbDfDIuCpSQbQN2SCAAQcCuT8Q6vr2l/GXWJvDuqW1umo6LZ3zrdWnmh1VnQBcMuMZJzz1x2pgRSeBPFz3CS2uhFhuOfPuooxjJx/ET0wenc+nPdfCq08V+GE0/w54httKGmlLg2f2WV3nhVZAQJCRtYEPgEYxgcenn134+8cfavLm1i2AzlXgtFRfoVJJP516D8HIbnUrjVNZ1/VbnVdZglNnHI/7qKKApG4CRA7VLHGW5Jx1oA9RHSiiikAUUUUAFFFFAHD38BPxahnAxt0ORAxOeTOvatOys72VZDqU6+YV2hrZyAQRz8p47DFZEc0jfGHVUkJ8mDRLUR8cBnnmJ/PYPyrqUmLyyoI2GxVIc9Gznp9MVjLc2jsY2uzvbDzYIseQY8uxAyhcb8Ensua5T4dsINQEgB36pp4ujGCQDMsjMwx2O2ZB9BXR+MbpF0DWbaSJftclhKsUxUbMspGOvUZB9+1YHiK1c6NbXNlM0d9o0qTNKkQZm8vHmLgkZBXPGeelV0SYJc1zR+Guiaxomo6zbXsNpHpTTvc2bRcviVizRt6BWBI46OAOlafjqAXNjFbzTPbW08iwTyh8YjbI57dTjn1rXsbuG5tYbqxmSW3njEkUq8hlYZBrLmt9SvGe3vJiLKRmD4CkuuOMccA8cY9ai7V0ZG1BP5cMccSr5aqApznj61hW97eHxVIbaS6nsHBSeOaMrHA6jgxkgZB6EZPrWhb3NtFff2akEiGGBJAf4duSoH14pXn+zgtdzRjc58sDqR2UepxUXYzM1m1kj0yx0q1E5tJJis+yTErpyxG4/3j19s1q2EQhtIoI08tY12qmB8o7AY4q1EPMGRwuMkmuZ1DU7m81ZtP0ifyoIgHuLoLkr1Hlrn+I9SegAHXPDSctWNK7sjd1FYrOB726+yxrGPnknIUBRn+I9Oa81g+Ilp4S8E2txfaXcXU0s0iqlpGRAAXZhtkcDcMdwDmugXw1pwl85xPNN08yednbOScgseCcnpXCfGO3tnGiRhtztd/MXO4hgFKr+JwOc/ezT5lFXSOzDYVVakYTejOo8M3+o6xrh1DU5kVmsFEdjEuEs8yEFcnlmIVcngccCui1BhHZXDnBwucVxXw0mN5f6hcsz7UhihQZzkFnOSe56c12GsOEsiS2ADyT0rkqT5k5M6KlFUarpx2RW+H7BtP1bYoCjUpMY6fdXpXTe/euU8AMy/23A3CC6SYL6M8YLY9siurB5IxjFKPwo8vEfxZDJEVx8xx6MDgikRGXbmV2AHO4Dn61JjjnpSnBHWmYkQSM7QwLnnBb5u+ev5flTo1UM7L1Y5JOacfXJ+lJ1Y4Y9PSgAB3DoQD6jGKYnLZeMqTg8nI708g9P1BpeSTmgCN2cyIBGChJDEnGPQ4rR0z/XP/ALtUmBParelHM0g9F64rSl8aBbmnRRRXeWFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAQX1ul3ZXFtKMxzRtGw9QRg/wA6+bLy8kvtY8B6o67FvdBuLIrngSRSoWx7cV9NGvmCcra6b4ftLgqP7L8V6ppkeepR/Mdce2Sn6U0BV1Ubbxf96vSvgfN5Gt67aszHz7e2ulz04MkbAfgqfnXnWtqftDE+vFdx8HX/AOKtUkH57CZM/SSI4/mfxpAe2UUUUAFFFFABRRRQBxFud3xW19MqVGkWBIJ5z511jA9P/rVpa1cSWj6etq0hlkuVVo15MinqTkdAOc/hWNM6W/xN8RXSxI9zHotisfA3FTNdEqOehIH44q9pET6jfNq6vPDFKQqQzLhkCg5GO3zE1lPc1hsc98SLoTavodlE3mLNeRLMi5Bwrhscdu//AAHv2kRfN0q+UJJHJeXskY3HDHL7TjGeNoJ+nWrHiTTY/wDhLNFv5IEDNM6ddzfLDIQfYZGabpVgSmnC5BElu8twF3ZwxJA57gKxpy0saUtmWvDoXRNVGjecn2G8Ek1khXBSQcyRgjgg53AYGPmrqU2HKOMf8CIwa5LxFYXF9BC9kbdby0kFxbSSDOyRemfQHofbin2fjjTHZ4Nd8zSL+OTypFnR/Jc4yHSTbgqe2cHsam3Nr1Iqw5Xpsauh6elq15czzyz3ty4LB+PJUZ2xgegyee+c1XuItD8PsLueKOKRyRGAC7ux5wg5P5e1Zmp+MbFozH4ec6hdh/m2RkRYAPLSHCqucDPPfAJ6Y66vo1lMup+I/EWmnVDEYjNJcxokSbvuxjPA7ZPJxz6BODW5MI8xt3ratrr/ADTNpWmlMLCqKbhm/vEnITgkAcn19rum6faaZZx2tjAkMCfdVRjnuT6n3NcHqPxl8CWIH/E7F1IekdpFJKT7ZAx+tc1eftDaDFMEtNA124D52MyLGHPtkk07SZ0Jwhsz2O7uRAkRZC8juEjUDPzH+Q968x+NMsejWXh2ZI2nljvHkVmG5i4XJbA6nrXLj4peONb1IXnhrwRcm0YCOE3ivhc9TkADs2TnGMDr1x/GGp/FFLzR5NfOnWfnGVYEtI0bYcDcXznjABznHPrUzg1E6cHVXt427npfwZgme31J3AUtBbTeTnHlhg52/h3967TVb3T2tZ7e4vrWFsHPmSqoX654H4189af8Pta8b3KzyeKyY1hSZXjjeMMnmMrLwAexxmum/wCFD+H7WAy6tf3+pSkctLOVB98dvTkn8M1hJQ5E2zXGOf1mSS7fkepeApraS71sWd3a3UavAA9vIJEOIhnkE9K69cLjt+NeVeE4NJ+G8WoQ6ZpUkejG4jN7erIXNtuiUh3U8lM5yV+71Ixkj1ON1lRXjkV0YAhlOQQehBFZ2SWmx4tVuU25bla5uJ2UNYCOYxyhJY24OOMgHsQDnms77LcWepW15JcM0DRstwoJHmSsRtYKB2+6BxgGtYGMXbqDidkBI/2QeD+tUP7ZiXUlsWWT7RJO8UYwApCorE59MHg+vFMgLq8nURyy/wCi2zvtyF3Pjnk9hnI469asWctyLAPeLHJchNxSI8n069zVqeNJYiske9O6kZzWfpzbYZmhtDHIX3FGBDNuOck+vXjoKAL6XETKjb1w/A55z6UpkBQH5huxjIwfp7UkW1h5hi2P3yBkHHODTZbmCFo1llSNpTtjDNgucZwB60gJcBRgE5HrzV7TP9c/+7VI9hxV3TP9c/8Au1pS+NAjSooorvLCiiigAooooAKKKKACiiigAooooAKKKKACiivL/inrWrWfiKysdO1i4022a1M7iCOMtI2/H3nVsAcdPWgD1CqV/qunacM6hf2lqP8ApvMqfzNeCXt7cXsXl3+ratdJ3D3roD9QhUfpWTDYaPavvh02zEn/AD0aMO//AH02TQB9E6b4i0XVLo22m6tYXdwF3+XBOrtt7nAPStWvmS9ud/ly20r215b5e2uIjteF8YyCO3qOhHBr0T4e/GfR9f0hzrUc+m6nb4SWMRPKkpx96Mopz/ukAj6c0Aer0V5re/Fm1yV0rQNXvD/fmRLWP85GDf8AjtZd/wDF68sTAbnw7F5MziMumoZEBPQyHy+FPqM4NAHr1AOeleF+P/iD4hm8NTCzks9BCTI1zdQytcypbhgZGQFAAQM9c8A+oNGreI/Efg/Xn0a18RJqVje2qajZXeo2/nTIhO14wylFYA7CCQTh8dqdgPdM0EgDJOB7186T+M9ekfdc+Ib6Q/3YkihX/wAdXP5k1z2q3R1R9+oNc6g3YXVw8q/98sSv6UgPpO68VaBasyz63pkbr1VrpNw/DOa8QvfDet+Kvh/P4i0i0juLu/8AEia/aWOfLYQACMKWbjcyLuP+9XGXtlPPpN5a2MaWjSwuitEgXaSuM8Yr3lvElz/wjPhWz8NLafbdUsllhadGkihiSNNxKqQTy6KBnvz0poDwkatNqDTQajYTaXqtucXFhcZEkXoeeqkdDXT+Bdbg0XxboFxezpBZytPBJI7AAZiZhnv1UDj1pvxiW4kiXXtRgthruh3qafqZswyi7tZVDxuAScAZ3YOcbWGcVX0BUM0ZKqXTlT3GaGB67d/FnwlBcSW8V7dXdwgzstrGZ9wzjIbbtIzxnOM8Vlal8YYIbOS4sPDWtXKRrvYyCOHKg/NgFi27GSBjnpxXH+KbJJl0y+XzBcWl1GA8feORlSRWHQrg59ioNbC20asPl6GkBtf8LNv762SbRtGtZIZFDRzy3pKOpGQwCocj8qXTvHXiSNydT0vTbiMjgWkzxuv/AH2CG/Na47wexTQ5IJNgFlcz2u8LsUhHOD19CKlm13TUuBC+r2IlJwIo5Q7n2wMmgD0zS/iHol0/lX7T6RcDqmoJ5a/hJkofwauriuYJbdLiKaN4HXcsiuCrD1B6YrxE6Xrvie1vtO0izayt5YngbUNTgZYzlcELGQC3DcE4GfXFZXhX9mXT7VgPE/iPUdUtlXalrCTBGB7/ADE/gMU7AdTq/i/wpYfFHVzq2t6YlvdaNbRrMLkZRknmymR3O8HrxtpZvjV8PdLjit4dXa7aNf8AVWsMkxAHbIBBPvnHvXFeGfgl4Oj+JfiLTZLcXVjptjbtFFLIXbfM0hJc9yAgA4HBB68165pfhDw7o+RpmiWtsZAULxx4KrgjGTyByenrUvlW5UbvY8Vn+MVjbX9rHaeHvEN0F1OecSSWwhEhkjcBfmJwwzzn0JqWX4peK72Rv7I8FRWw2BYpr2ctnLY2EIOpbpkjpXpeo2sQvNId4YZo4ppGjXaxJby5cnLHPIVRjHGDyQah0+VLjU7dHkDTgm4dW5IBzjPsCR+QrNzTex0U6cuV2Z5rLf8AxjnltYYW0e1WVygkgt/M2kAkly2do49vShfCXxW1a3hn1XxlHAy7vkjIiGOn3o1BGRz+XSvbUJIzMw29MnK7j3OPT061XDvLhp41WLeViQAnfxwWz90cHg/4U+ddEP2d92eEj4LajrRR/EGs3U6s3CG6kmI7BzvbheOvX5unFdfH8CPCCz2skkUpEUarJGuFSZwPvnuO/AIHtXqjERRl5WVVAG52OB/9aspvENg5b7FLLqLj5TFYRmc5/wCA8A/Uik5yewKlCO5mW/w/8LW8qFdHtWZH82IMuREw/u+nf9araxeWenXkGi6Jo8l7ctlns9ORchT0Dk8IpJ5JPTNb1no2va3l7+d9Bs920wQbZLqRRzky/dTOegBI55FW9MXTtCNzY+DtGa7kMmbho3CRCQDB3yt1b1AyfpTV/tMiVSK0gjCi8N+OtQuA17rWm6LZqcrBZQ/aJFTB+UtIApPQ5ArK8dfBy112xhvTrmt3Oo2bCWNrq6BjdRyybAAq5HGQB2zkV3enHWLjUmbXdMRYS4aDyp/MWDC/ePA5znpnHFb98yLp9xubavlsDzjHH6U7+Rlzybvc8X+E7QESC2dHeK12SbScEmZ2DfQqwIx612niJlOllXB2McHBx+H41z3h2wjttYvZbIgJHpun2h2Ich1ViTx14ZTz2IzW74gZBp6+W2c3ABwM4bNcOISV0j0IVJVWpzd2T+EELWmpzS7Xiub2QqCvO1QE59fu/lWPMX+HrNKiSzeD3bLog3NpZJ5ZR3g7kDlO2V4Xe8JNnw/buDnezuSM85YnPvW1z90gFcckn+lJaKx5lT42NingmSKSF0kSZQyOh3K64yCCOMYPFUDHphv1lmFvJeglI22/Og5+Udx908965maKXwJNJPaxvJ4SkYvPbou5tMYnJkjHeHPLKPuckcZA6v8AtGxFst2lxC1s6CRZ0bcjKRkEEcEEdDQ0QPt763ury6tYjJ5tsVEmVKjkZGD3+oq2SMdCfasvTkR5xeLboDMnEwYk7CchTyc888cc8VduUd4nEcjISMB0xuHvzxQASSuZ/LWJSuASS+D37Y9qcjxl3TYVKYPI459Kr21t5NzLcSSeZcTKqFug2rkgAdB941U0iS8OtavFdAeSjRtAQ2cqQfy5BGD6D1oA03H7rbC4UjoWG4fzrR0kfM+SMgAHFUSgz8uBzmtLS1Ox2Ixk4rSivfQ1uXqKKK7igooooAKKKKACiiigAooooAKKKKACiiigArxT4+l7XxJ4ZuV+5NBd27H/AGgYnX9A1e115h8e9O+16Fol0q5e01NMnH8Mkbxkfmy/lQB481256ZqMzSt0BrVTTj6VYTTf9mgDCAlY96wPCU82ma9rNpHkBiHwPYnH6NXokem/7Ncja2623xZa1kACXdvxx325H/oNAGmbm7k6Bqhu7GfUbSa1nz5U6GNvoRiu6j0qFeoH5VYSyhXGFFAHmelz32q6JFb353SFGt5iONxBKMfxwTXSeKre4v8AQfhVLI7u4sLqFmx1AjjxnHsg/KkW/wBG0HSL2/1O6t4UjuLmQIXG58Stwo6kk4H41Jo+q3HibSfBUfhTR7vWI9ItJvtjw4jjjmlQbYt8m0EgbiSMjoM807AQQaKc/MrH8K1bbQ0GCRiut0vwr4ouiTeWumacvYGZp2/QKPb6/nWnH8ObyZwdQ8S3Sx/xRWNvHDnjpubc3XuCKQHIwaXEmPlyfYVn+Er650jUrSygil1XUfD7XPkadFKDNLps7IUdSSNxjdApXrjFeq23w+0CKIpcQ3V6CMH7XdSSZ/AnH6Ut18PfDU0ES22lW+mzxbjDc6cv2aaFj1KyJg/UHIPcGmgPEvivp+sah4XknvtIvF1fxNqyGLSopMypHFCUQPt6gffOBxwD3NWvCHhfxlfCZk8PpYiJtqm/uDHvPPIAUkjPevVPhz4e0p4ofEsWo6trV1Orrb32qShnWLO392qgIFbYGDYyQ3J5xXeUXA8hm+GviXVYbePUfEVjp8SyRyvHYWZdiVIbbvkbBGR/d/wrptO+HVnBH/p+r6vfyEfMzziIZx2WNVxXcUUXA4q2+Fvg6KHy5dFhu85Ltdu8zOx6s24nJJ5J9a6bTNG0zSoBDpmn2lnFx8sEKoOBgdB1q/RSATaMYxRgZz3paD0oA4LS7i8Nx41ntZEaZdTCRGQYwFtocr0+uM+tamnzMtneOLj7XhjjZgAED5sZPTOeO2Kp6EqXFz4tjmCyxNqbIyg8Ffs0Ix/jV60ntIrJLOzZsRRnaHycquN2WI9/rWc3qaw2ON1CcvLpiL5QaIbwqSZwTaSsFOe3TnvmptF8y41u4XywlnFbRKcxgFiR9zrnjAP/AALFGux7tTktfMle5axaULFECYJGCxI/OATgsB9DxxTHW48OSXrW7tf3eqXCmytZTtxJsRSgYfw/KXJwO9DRpCXfY0dX1XT9NMJ1K4SCHd5cMBXc0rAjG1ACTjjp69KZbQ+IddL/AGCA6JbfdW7vYi0rD1SHjH1f8jW/4Z8M22jq13dlb/Wpcme+kT5iT/Cg/hUcAAdgM1Y1TxBaaVqdlp8wuJLu8SV4UjjyW2AEg+nXAoUUtyJVm9tDPtvA2mSRo2vNJrV0vIe7OVHIPEf3ByPSujtooIMQwQLEgAxtTAIHA/KoIL4S3U1uwCSqSVXdncB3z0+o6iprtTcQzW6lkDLhpASMZ64I5zTbMvUkmZQNj4XedoBbG7Pp71zsWm6loc0g0eNLjT5Tva3G1JI5D1YEkKQe/Q555zis/wATaWtrZC1trzU7nV7xiLJWvXyjY5fg8KoySfw5ziuxtoltLZYw2FRcMzH0HJJP51IGFLK+p6Pc2Nwt3FflTL5EpXzMKwxgrhSCQPzqrp8l/p/hc21/p8tulvas01zJco/IGWIwST3xnsK37NzdzfaRkRKCqFgMuOPmBz09Kw/iVd/Z/CVxESoa8eO0HzYLGRwuB68E8fWn1A57wxbzxaPbXUwRXvCLhlVQCoYkhTwOihB+HGKZ4tuFi0CWWAAlmeRSFz8yg84/3gK1ZZre2uXJMa20TSsSoAVFQBc8e1c7rcok0e3DlwzRZCsdxYtIv+R9a4sRK92ehRVkjq/C9l9j8OWNsjn93EqAnngcf0rW6d8j0xVfTgw02DeRvKAkqMDJ54/OrBBwR1HvUo8yTvJsE5XDIQPQkdK8v1Xw3J4Qu7a9sVln8MQSGaa3RmL2LFtzSxIBzHwCyDpyVHUH0i+uJIYCYbdp5M/KittB+pPSquu6aNY0trVpp7OTKSRzRY3xSKcgjseR07jNUnYRa09rZ7KCWxeKS1aMNE0RBRlIyCpHY+1VZNV23ywJaXUgdN6sFCqemeWI6c1xR0bV/A8zXun39xfeHmYyXlhFbr5luTkmaFQPu5OWjUAdSozwe+s5ra/sYbm2mju7aZBJHKGDK6kcMCOMEUNAJa3sVzE7gFAvDK+Mqfekg1C3kJVWw+SFU43SY7j25psdk4nLPLG9sBxCse0BuPmOOvSrRAyC3/ASe1IBkbuS8jhgD91MdB/9euitl2W8YxjjmsaNS0yKcnJA47c1u10YdbsaCiiiuooKKKKACiiigAooooAKKKKACiiigAooooAK434wEp8PdTnAz9naGc8dAkyMT+QNdlWJ4408ar4M12wIBNxYzRrn1KHH64oA8rFmoJ6VItugqHRrg3ej2Fw33preOQ/UqCauUAMESjtXmPxLkTRvG/hzWXISFcCRsdAr8/o9enyukKlpmWNR1LnA/Wp/AugWvirxO+s38FveaTpJ8mx3EOkl0cGSTHQ7BtUe5Y9QKAKiw65ebBo/h3ULnfyJbnbaxAHuS/zfkprai8A+IL+123+s2mllxhlsITM4z6SPgA++yvUaKAOe0XwX4d0a0t4LLR7EGBAqyvArStj+JnIySeST6mt2GGKCMRwRJGg6KigAfgKkooAKKKKAA1ynxIu5v7Ei0bT5THqWuTDToGU/NGrAmWUf7kSyMPcKO9dXXHaMf7d8fapqpy1noyHS7T0MzbXuHH0xFHnsUcd6AOrsrWCxs4LS0jWK2gjWKKNeiIowAPYACpqKKACiiigAooooAKKKRjhSfagDgfCG57TxYYsFm1RzgN3MERPKk/T+naujtlheKXyEEcTE9Fxuz1OPf6Vx3wsup5dD1e+uYVia91W8nWIAphY38nkMeDmLJHbcK6p72O6tLWSISRrJOi/3SvOcY/T86ynubQ2OYu1WLxHrd/PIFt0uIYmYnGxI4Qev+854qbwZA+ra/davfWmw2Y+zW7yHq55dl9AAVXOOfmrJvtUSOy1K4v0Y51W43rAhbKxuV5x/spz685re0/Uf+Ed8L6Yl9b3ss8kJmuRDCZCkjfMwOOAMkj0GBVN2TYpPRRNjWdSOnarpsjzKLOTdFKN3CklQrEemeM9iR61zkUV1bePNRuIC15dXKfZo2lIb7GgwVYL/AHCcg98heo5qLxTeQ6rL4bjs4xK9+zs8cpMYW2AHmFjg7cZHX8MnFdzZ3FreFms5UkAwpkQghuMjnvxUra7Mya0t0tIBGgLnOWY8liep5pGgWS5E7O5whj8vOUIJGcj8Kp39reSKqxatLbKOTtgRmb8SMD8vyrG0W711L42lwsdxp8TOBfudkkg7KU7sD1IwuOnNK6A0bHw/Y6bq93qkCzeZKhURFsrHk5fYD03HBPuKydVk1LX7C80prGK2tp8o1yJiSqHOMKBndx9BXQyEyKd5P59K5jWtZubW5OkaFELjVEVXdrkkRxo38bsBz7AcnB7ZNJNvYaR1qzpFEqwooSNcAk8BQP0rzzxh4l0vXtY0rw9aSpNqEGoR3U/lIZBCkStIDvHygkqBjOeTUk2lyQQS3uv6rc6mUBYRSMI4VPYBFwD/AMCzmvP/AIShrvUrqQOgZrWWfaMHa8j4UEjsAvTtlvWk6igdlLBTnB1OiPToIj/Z4l2ANJCQU24BLEknHTJzmuf1V4jqttZxHDvcQwqFbG3B3fgQF/UV1LnybFCxVGAXdzjnIzXNW8TXHi7T2+dTFJJKTgHcu1R6Hj5j+XauGo9UjVaQk/I7wEqi5Xc2AM04dwQAPzpGJCnByTnHvUTvsUO24hSGOP1+taHkkoU9h+XagYPIbvisgaQ0l41zeXk00eAFt0cpF064B56A/n61eYmVFaMqsO3dvA3MfoKALPTucepOa4vULO+8IXkuo6FbvdaFM5kv9NiXLwMeWntx39WjHXkr82Q3XRSMQABn5cjdw7fhU4QAnGfXFCdgKunXltqFhb3mnzR3FnOgkilRsqynoQatD1PIrh7+C88J6tfalodrJdaNJie/06H5nDsSWmgX+9xlk6NnI+YEN12j6haarp1vf6bcxXVnOnmRTRnhgf5fTtTa6gXrPieIO2SDzW5WPaAm5j4HXNbA6V04f4WUgoooroGFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFBAIwelFFAHl+lfDnWoEWC41+0itIfkiS3scuUHTLOxGenRa03+GOnXBH27WNcuF7xrdCBT/36VT+td7RQBzGleAfC2lktaaHZlz1knUzP/30+T+tdHBDFbxLFBGkUa9ERQoH4CpKKACiiigAooooAKKKKAMXxlrJ0Dw3e6hFGJrlFEdtCTjzp3ISKP8A4E7KPxp3hDRR4f8ADdjpplM00SZnmPWaZiWkkPuzszfjWLqo/t74hadpw+ax0OMalc8cNcOGSBP+AgSuR2Pln0rsqACiiigAooooAKKKKACo7lzFbSyAgFELfN04HepK5v4k3seneAPEN3OGMUVjKW29cbSKAOc+F+nXml+B9Hjvo0gX7M9wyhtzNJK7SMW65BDA5z1JrW8PX8mqyKJhbP5LFv3EgbZ8zKoI+gzTtHuvK02ys3gmCx2UYMpTK5CKME9Aeent0q5psi2+nib7OIo1i808BTxk/Nj2Gc+9ZSd2bJWR5zbl7jSNIi3Yl1HUWadtxG3zLglsAHoQGGOnNdl40a4W0kmjKmCQ+VOGO1gjHHB9OmR1xXE3MFzpug+GNSjcn7E8N3dRHjMZJdz9V3fXANemX0C3AiyqSQn5snDDsVYVNVtx0JmrMydRlhgWO0mt3eJFjO22iJHl7hkE+nHI/rV3UfEEen3aWv2KQQHCiREypY/wjHAI9DjPbPSp7u7jtbcEsrsSEjjDcs3TAqOyN00crS28ce59wDPuBHHoPyrNT6ElqW8iit4p5d4WVkVRtO4liABj8atyyIvEfJ7kjmsy4t4p5obq8JiS2bdGWfYqn1PODWRq3iyBHNn4dRdV1Yt5S7c/Zrc/3pZAMcddoyT+tUk2C12LHi7WLjTrYWmkpDca/cIWtoJHwiKOssh7KP1PAqpounRaPYy/O8ksztcXM0hy0sjfeYn9ABwAAKj0Gwawt5ZZ7mS5vJ38y5uJjku/A4z0UYO1RwBV2WIzxgEFST8p67PRvrnH0qnZaI6qcOXV7mB4yvUXQL+4lAWK2jcg4J+YqcD6gdfc1zXwc04WUd8y7yHWPBc88qCRj23AU743atFpnhmxtGDk3l4qNHGm52QDc2AMcngfjWv8MLyLU9BudTt3V4bu5cow+XKjAH8unrXPV+JHq05KOEl3bOp1L5bKTYCScdO3NYHh0CbxYsgJIS1ZvTG58ZI7H5f0rX1g5tljJZHdgQwwRxzUPhO3aTUNVvW4y626n1VVyf1Y81zT1mkedVfLRfmdDlt7A48sAYYHn3BH5UrQq0RWUBxjHI4xT84HbHencr6mtjzCBUdE2xEcdN3IJ/nSsjlsusRXjjbk47//AFqmIz14PrSD/IoAPlLZwMjjpSKzNI6FGVV6McYbgdO9Pxwcniq63cDuELNG+TgOpXOOuMjmkA+O3VA+0kFzljnJNcnqWm3Phe/n1nw9bvPYTN5mo6XEOXPeeAdpB/Ev8Y/2uvXwlHBeNiyt6k449Kt2tuZjk8IOp9aqKbdkBF4YvbPV9Pi1PTbiO5s51zFLG2QR3+hB4IPIIINbVcRqei3XhfUbjXfCls81vO/m6npEZ/4+PWaEHhZgByOBIOvzYNdVo2qWWtaZb6hpdwlxaTruSRfyIIPIIOQQeQQQea74R5VYtaF2iiiqAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAqvqN7b6bp91fXsgitbaJppZG6KiglifoAasVxvj0/wBr6ho3hWPDLqEv2q+HpZwlWcH2dzFH7h29KALHw5s7iPQn1TUo2j1PWZm1G5Ruse8ARxH/AHIljT6qT3rqqKKACiiigAooooAKKKKACuH+MY87wWLHzUi+36hZWm513cPcxg4HrjNdxXG+P447/UPDWmTuVhm1KOchThiYQZlH03ICfYHmgEdBICXY5wxzgY6VkeLbhrXwxq0wYg+QY1H95n+UDHqSwrVZgrfMRljkDNc/4jjW6vNGj5eMXD3DpnjMaYUn6MwOPXBrGOjubtX0CWCGRXspQHhaIxsp/iHQ1zNtaeIvD8rWvhyWGfRIVEcdpeEymM8fcYkHAB7k/TpXVISzuFypHBJXGfT601JUKK0Z3hj1PqOufSkpNG8oKW5y2mapeWc0+par4ekS7YsUkZv3cYOSSdiE+2T+ma2EvNfv7t2a4hsbYAhI7aLO4/7TyLnr6KMY79a02Kq+1CNx54bp9aFjBAyPc561XP5EKjEx49Agku1udUmfUrpeQ905cRnvsU8L+ABrVhWFPMhiDKqHD9fQfnkYqR/l4HBNNVAFRQu1UGAuelS23uaKKWwzaJflZSERuA2QDjH6U2ebEsMOf3krcLz0HJ/SrKbWYqOw54pLmaK3UGaSOLPyqZGC/wA6m5R4r8UvKX4kPdNLPK9rpysIskLHySSmO5A5J+la/heGfwHb6WJ3zpGrsizsQAtreORyM9I5OhHZgP7xxzviaRtZ+KNxaoJCs8sdvn+Exx4L9ePvKen0717JqdhYanaNp95HFLaNGyPG2Nu0rjBHbgk1g5Xkd+JiqeHhTW71/r7ylrd0qXOZZQsECeYwI9ASf0xWp4dhktvD1vLOoW5lj8+XK87my2CB6ZxXmmi3CyPJ4f1aZp7lSv2OeU/PfW0kgUN67wDtb8G4DCvZNoUtt4yeD1rJKzbZ5OKlpGIilti7sBiO1Iu4scjHPHfNORSFALEkdTjrShcdKo4hCcAkjoaFIK8Nu96je1ikn85k/e7PL3Z6rnOPzqYAAAAAD2oAimmMbwqqM5kbbkfw8E5PtxUWo2S30UcUksiRK4dlQ4347E9cZ9Kt1NbQmaTHRRyaaTbsgHWsBmfLfcHX3rTVQqgAAAelNijEUaovQU+u6nTUEUlYK4rWdFv9B1efxD4VRplmO/UtHBwl4e8sWThJwPwfADYOGHa0VoMoaHq9lrulw6hpkwmtpQcHBBUg4Ksp5VgQQVPIIINX65i58PXVl4lTWPDs0NuLqRRqlpKD5VyvTzVx92YAAZ6MBhuilenoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArjvAh/tjU9a8Utlo72X7HYk9PskBZQw9nkMr57qU9Ks/EW+uYNAXT9MlMWq6xMunWjqeY2cHfIP9yMSSf8Arf0yxt9L020sLGMRWlrEkEMY6KigAD8gKALNFFFABRRRQAUUUUAFFFFABXBeIY5Lj4s+HY2kdbaHTru6Cpj55VaOMbuM4CzPxnqa72uBgga7+MmpXIiIh0/RorcyFsAyTTFyAO52xLz9KT2GtzpQyNcRoqndGD82OgI6Z/p7VzlxdTXPil4l2NBZW+c5OWaVz+gEWMep9q6GOZnV5mjCKBuHzbty+p4z+FczpMUh1fWLmULuZ4ovl6fKm4498yGsejZ0R1ki9cqY4LiTzGQEFiePl4xkVFYOTZRyL++L/ADDnsSSOenQ/jRq6STaZcpEDvZCAAQM+2T/n6VNaK0VlBHIctHGoY7s4IAzz3+tLob9R0cSozFECkknceppiPJKQyttQH8W9D9KotrWlNcmFNQgmdflMUDbyT2GFzz7U1dQvry58nS9FuZRnaZboi3jA9Ru+ZunZaEmS5RW7NYMeMIzH16ViX2tDzZrbT0OoXkeF+z2wyQ5OAruflT3yc8itSPwpe6g8h8Ram72xI2WdgWgjAH95/vsenQr9K6bTNNs9Ls0tdPtYbeBTkJGuBn1Pqfc81SSW5lKt2ORtfCesXkttNquuTWUC5L6dpqqiNkcbpSN5PfjANa8fhDQopnkGkWs7FcF7keazEnnJfP51sandQWVjLcXl1HZwqMGeRgFQk4BJPHUjrVHwnfzajpAluZEmdJXiFxGuEnVTgSL7EY6cZzindowbb3PK7DwPFZ/E29ntrRYvD1nAiwxNKX23Jw77c84+b1xmut1LdA8sioCzxkKyAbmY4UBs9evH0NP0Vy66pNJK0hfULlsschQshUAewCCmX0JK27ux+UhserAH09yPyrkqtKTZ3wlKaXM7nK+JNHk1G70VdEMVtqtrdGe0mZPlQRxN8rY58s5VSB2PqBXb+Fdaj17SVuhE9vcozQXVq5Ba2mXh42x6Hoe4II4Iqnoe1tbIAGYbXcT6F34HtwlUfE8cnhrVz4qskZrJ1WPWYEBO6JeFuFA/ij7+qZ7qtZ09Y2OPFSTqNLodljjFR3MbyQlY32vwQ3Tp9KdFIksSSwurxuAyupyGB6EH0p9M5iNHc53R4I688E47UsZO07s7gTT6D0ODg+tAxF5AJGPY1pacoELN3JrLiQopBYscn5j161q6d/x7/wDAjW1D4wW5aryb4b+KPFfi7S4fGM2o6PaeHJpbgf2U1sRLHDGzqC05fAfK5OV24OeO3rNcZF8MPB0OtT6pHokS3c7yPIomk8lmdSrt5O7y8kEgnb3NdpZxdv8AHez/ALO1y5vNDnjbTbGPUUENwJUuImlEWVfaBkMeoyDg4NdD4l+KVvo2vaposOk3N5qdtd2FjbxrIqLczXauyDcfuACNsk5q9ZfCjwZZ293BFo7PDdWQ06VZrueYG3DbhGN7naAQCMYIxxikt/hP4Lt7O7tYdGKx3TwSSt9rnMm+Dd5Tq5fcrLub5lIPPOaAOL0v4s6rYaHqlzrNhDeaiuv39hBZLcpG8ccOCEXapMpXONwX3JHFdy3xD0xPhYvjqaC5TTjaC6MGAZOTgJ1xnccZzisweBPh8dVj8NrZMNStxLrCxLd3IlVZj5cknmB8lXKYK7sHHIrrbTwtotr4VXw1FYRnQ1gNsLSQtIvln+EliSevUnNAHn1n8ZftMBgHhq9GsyX0FjbWomHlTtKrMGExAACiN93BwQOuc1r+Gvihba3rGi6adLuLa41K51C1+aRWET2m3fnHUHdxj0qbUvh/4K0rw/c/b7K6/s+F4rku17dTSQtFkRmNt5dNu9sBCOpqnoHwj8Ow6JBZ6vGNUWDULnULOX95A0AmbJTKvlhjAOThscigDBh+M9vLFHrYtb0aefDkusfYP3f8F0Ic78Z3e33ce9a4+LDQweIF1LQH06/0pLWZLe6vogs8dw2EO8ZAYc5UZPGBknFbR+GPgy20o2p0jbZR6c+mFftM3Fq0nnMmd+fvjOfvds44pIvCngvxnpsmrw2i31rqsNuPtCzTIXSEkxFfmBQqc8jB9TQBa+GfjaLxzot7epYTWE1leyWM8EpziRFViQcA4w46gHrxXXVi+FfC+keFLS6ttCtXt4rq4a7m3zyTNJKyqpcs7MckKvft9a2qACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooqvqMlxDp91LZQC4ukiZoYSwUSOAdq5PAycDNAHK6d/xPviJfX5+ax0GM6fb8cNcyBXmcf7qeUgPqZB612VYngvRm0Hw1ZWM8nnXgDS3c3/Pa4kYvK/4uzH6GtugAooooAKKKKACiiigAooooAD0rj/DUwvdb8VX8KuR9vSwClgBiGNQzdP7zv65wK69unfiuE+GCOvg6G8nIe51S5n1KV1JKlppCwAzyAqlV/4DSlsOO50C+ZLbiSO4CTNnJGHVRk5GB/P2rlvCd099pkt24Aa4uJZMpkqQGKAgnk5Cg/jXX+bBGJp3UKIFZ3YrjAAJ59utcn4NVk8KaQsiFSbdTtI5wef5GsX8J00/iG6pJe6lfQaZoQzeRzK9zOSfLtE2kgv/AHieMJnvk4HNaT+GNMstPmn1ye41LA3TPdMWTg9FiX5QD0wBVnwKyPp99PuVnlv7gkgD5grlF+uFQD8KuDxHpbWcV1Bc+eJpvs0SIDuabn93js3BznGO9UtNEZTm5MoaPeJaahZ6TLp8NgLmJp4IkYBwEI++AAuTnOFzjFb0moWkUpSS4jUhtrHPCnGcE9AfrUs0EEzxPNDG7xNujLKCUOMEg9jgkcU4QReU0ZijMbZym0YOaRmYfhDxC/iKC4nFi1vbRyMkchkDCUA8MMccjn2zWpqmp2mlwLNfTCNHcImFLMzHoAACTT9PmtZrUfYNghjZogqDaFKkqRjtgg1S1LRU1DWLK9mlby7VHAi9WbHzA9iMUAWdKnk1PSIpb+zEDzKd9u/zADJHOQOoweR3o1eYWWj3cyFYhDCzJ2AIHA/PHFX+grm/H8rL4dNshxJeTw2qnqRvcZIHqF3H8Kpu4IztN0+DStOgsrXIjjXaWbq7nlmPuzEk+5qpduc+QE2ndu69z/n9a0L+QJGXLbfmBAx174rnr6aT7IZVLefcSLBD6mRzhfy+99Aa82pJyfKt2elBKEeZ7I2/DFuF+33YYP8AaJyqkdkjGwD8wx/GtiZo0jPnFQjEKd3TnjB+vSo7C0isLG3tLcfuoEEa+4A6n3NSyxpLG0cqK6MMFWGQarY8qT5ndnHaCG8I62nh2ckaNeFn0iRukLAbntCfblk/2dy/wc9nWD4h8MWetaZNaSPPDuIkikjkYGGVTuWRfRgwBH0pPBOqXmpw3OnaqiJr2msIrxE4WQH7kyf7DgZHoQy9VNXZy2EbqkknII9j/OnVdSwJHzuB7Dmp47SJDkgsferjQmwsyhBC0zYHC9zWrGgjQKo4FKFCjAAA9qWumnTUCkrBRRXl+vfFn+ydd1Kz/wCEdvJ9P0zULfT7y/W4jCxtMF2FUJ3Ny4B6fWtRnK6t4P8AGVx8YLfXINKeC2i1uKQ3drdxrHJYbNrbw0nmFugKBQvoDnNUdD+G3jCwtfDN5ZreWXiBoNYg1O6k1HzBH5iTC0JXzCCAxjOEBweTzXYR/GrTm8S3didIvjpdtcXFq+oId214VYsxjAyEJUgNnOeoFU9P+OtjPpGp6ld6BqNvbW9il/bsrCQTq8iRohOAEkLSR8ZPBJycUAVvg74M1nQ/G8WpX/h2bSLYeHorC4kmvY7hri8E26R8q7H5uvOPwPFZfi/wj4qX4i6tr1vZTSaZmSVrm9uUZYYlhIHkMkgkU5/5ZtGVz1PrZufiN4tTxZe2V5HFpvl+JNF077H+7n8qG5j3Sr5gHzFuDnqM4FdT4O+Llp4p8VW+l2ej3qWV29xHbX24MCYc58xQPkDbW2nJzjkDNAHlfhfwp4u1zwNJqWhWN7Z/bPCyWu+TUlZ9TumdGWVQXPlhVDDcxU84AxXT+MPh54m1O98X6nb2162prPpUuhOmo7ApjSJbkhfMCg4D/eAJ7ZrrvGnxHXwl4i18XMV3eW2nadaXP2WMRqC01z5IKsec5IyCcYFdB4G8Yy+JNS1/TL/R59I1PR5o454JJkmBWRN6MGTjleo7epoA8r1HwX41uPiq2sxaS9vbjVJt1zbXcQimsmjYKWDSeYWJxlcBR/CD1HqXwh0e/wDD/wANPD2lavB9nv7S1Ec0W9X2tk8ZUkH8DXmx+Kfi278N2mof2PFaXH/CVw6QI4Hjb7VEZXV4RuYhX+VQXJAJbIwM1sz/ABthgs44pvD1zHrrajdaa1g9ymxHt0R5CZQCCMSJjA5J9BmgD2Cisfwhrsfibw1p+sQ2tzaLdx7/ACLlNskZyQVYexB+tbFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAGD43OsJ4fmk8P3aWl3H87ObI3jlADlUiDLuYnGOfWuP+HnxJW88BaLqXixn/ALUvJJ4XXT9PuJwrRybcSLGj+U2CuQxHU4746zxdpPh7xJ9k0TxC8Ukzubq2tlu2gmYoCC6bGVyAHIOOPm5q94a0DS/DGjwaVoNnHZ2EOdkSEnknJJJJJJPckmgDz64+NWjWeqiw1CyuLeWO9vLO7YupFsYAuHb/AGZC6hfrVLxB8b4NE0zTNQuNBle3urCHUJ40u1M9vHKxC5jCnttOWKg7sAkg12WsfDTwjrE2uS6jo0c0mtiIX7ebIpm8ogpjDDaQVGSuM980zxF8MfCHiGZpNV0jzGe3S0cRXM0CvEh+RWWN1DbexIJFAGePifaHxofCg024/toan9iMG9f9R5Pm/av9zb265r0OuPtvBFvH8Ub3xrPOktzLYJYQQCDb5KhssxbJ3MeBnAwBjmug0TWdP1y3mn0q5W4ihnktpGUEbZEO1l5A6GgDQooooAKKKKACiiigAooooAyPF+pjRfCusamUMgs7Oa42Dq2xCcfpWPoVmNF8MaHbRnKWdqkfloOGOwDknpzmovi5C974OfTVkiiTUbqC1leVSwWNpAX4BGcgEY966KQrHGrIn7gKDgAkgY4wB1qJ7Fw3MLxFd+X4fvUdkbzrOffLG23aQmMj8cCotDjMOkadGy7WSCNSvTBCjik8dwFPDd/dElnAUIAdu3JAA9+Tz6iriFQ2xTkrx+VZy+FHRS1bKnw8IbwjphAIxvHIx/y0apT4Z0uDxn/bkrSxXbEGKISERSSFdpfZ0L4OM8cdemazPC9xdW+j3MVjbswttTuBhuR5PnMSF5AyMniu0a58yGKRQyK/ZhyD6fWhNJu5zMknuViimbHMfHzHaCfrTGmjnSSLzvLlUhWxwQeDxmhLhlPI3CsnxQt3PY+fphkF7AdyRh8JKP4lZTwwIz6exFHMhFHxNoF5m4u9DjR7i4Tyrm3aQxrcZ43kj7rr1DDmt420g0BLa9vZIpVt1SW7jcKwYAZcMenTOTUcAlihiSOQpGoGUI3fgDnI/Wi5hS6heG4USwupVo2GVYHrmk5oZB4M1C41PQY5rxSZEkeETH/l4VGKiUf7wGaoeI5zdeJbCzVN0dnG13KxHCuwKRge+PMP4D1rRvtTstCsxdajOLe2yEUEFmdj0VVGSx9gDWPpltfXLXeqXtm1vNfzZjibG9IVAEYfHRsZJHbdiiV+VuxVNLmRS1aUE4zhVUnNM04rca1a27w5NhEbl2HRZJPkQfXb5h/EV0TaA9xMkkzhAPvKOc1e0nR4tPa7k3tNNdSeZI7ADgAKqgegAx+frXPSw8+Zyeh0V60XDkiV6ligkl+6vHqelavlp/cX8qdW8cP3Zw8pWgtEj5b529+lc5410q7Se18R6BF5mtaapUwKdv262Jy9uT68bkJ6OB2LV1lFbxio6Ioo6FqlnrekWup6ZL51pdIJI3xg4PYg8gg5BB5BBBq9XDXRHgnxMbwYXw1rVwBc/wB2yvGOFl9o5ThW9Hwf4mI7mqAKO/WsDx9ZXmpeDNYstM+1fbJ7Zo4vss6wy5PHyu3AP1x9R1rxTw94M8eaJpum3MGiq7WGtxXX2NLuO3nubcRMjGQCV4QQzA4DfNgkgcCgD3q41nT7bW7PSJ7lU1G8jklggIOXRMbjnGONw6nvWVfeBvDt9/af2rTt/wDad1DeXf7+QeZNFt8tuG4xtXgYBxyDXh03gPxhcXNlea14VutVAfVi9omqQqU891MPzmQZUYzxnGOmcCovG/w9+It3pWlW8Nm9/qlhpFtDBqVrexpILhHLOrtLIpGAeGRctxubsAD3IfD/AMMrrk2rJppS7nlM8ypcyrDLIervCG8tmPclSTVS1+GHhC2sryyj0pjZXcDW0ltJdzyRCMsGKojOVj+ZVPyAEECuNvPBWvvH8RdQSykutXu7iUaPBc6lIIJIHjQH5EkCqThsbsHIHIFclpHw+8bW2n6lbvpt8dFOq2d42kPfwxNdwCFhPGpjcovzlDtJAYAZJxkgHqNj4M8B2niNtHgtnbWQ1trjRy3dzLITCxjhmLM5zg5GM89wa29L8CeHNK1w6tptg9teGR5tsd1MIQ7ghmEO/wAsEgnkL3ryLWfhhqOtXeo3Mfhq6023TwtNa6banVQzRXwuZ5IkLLJzw6MMkouduflqLVvh14v1C08Q6jPb376+g0aTSZP7TC7ZI4oVumAEm0HKyZLdeozmgD2TXvA3h3X7m+uNW077RNfQw29w3nyJvjik82MfKwxhxnIwT0ORxRo//CO20Or+L9PBij1KNbm9unEo3rAhQMUb7u1VI4UZxnmvOLfwZ4sT4ljUGt5gw16S+bWvtwMb6aYyFs/J3bsgkD7u0YznmuZk+H/jSXwh4cs9a0e61gwaLeWj2X9pRqba+eRjHO5MgWQbDjgtj0oA9c0fwT4Ov7WHVtMsjJa395Br0TLczCNpwTJHMqFsL98kqAAc8g4FWbz4c+FbxbgT6Wd81/JqbSx3M0cq3DqFd0kVwyZCqCFIHHSud1fwzrUvwF0rw7BBex6xDptlbTRWdzHHKrRrGHUMzBGHykEbgGGRnmvJjoHiLT9T8PaHrPh97ua5ttUePSrK9Fv5q4hEby5mMasDklVZgOCATmgD6c0fTbXR9NgsNPR47aEEIryNI3JJOWYlicknJJq5XzL42+H3xFu9J0q3hs3v9UsNHtoYdStb2NJBcI5Z1dpZFIwDwyLluNzdh2s3hLxD/wAJpr91c6TcXt7eXbS6Vry6kEj06ExBUQw7t3ytnICkNnkjrQB7LRXivwO8HeJPDevSz6/bajb79P8AIuXku4pYLm4DqRKArs5cjf8AMwXg45r2qgAooooAKKKKACiiigAooooAK4r4waNqOveCLjT9HS+e5kljJWznjicqGyQfMKqy8cqWXPrXa1zPjnxUPDEGmJDYyahqGp3i2NpbJIIw8jAtlnPCqApOcHtxQB4/4W+HXiKz8TeCdY1nw7HJ9ikuIrhLO98s2ymRGhldDKV4+cskbMOgwaoS+EfF+g6Brl/qEdxaTWehax/auqfbxKNXkdGMDogYshTGcsFI6CvQ1+LTXceiQaR4bvL3V9TkvoPsX2mKPyZrQqJFZ2O0j5uCPy7VuWPxCtr34VL44ttMvprdrU3H2KFQ82QxUqMdQCDz6DOO1AHkeieDfGOreFtRvdBgutHg1DRdPjEE2p7n1KZXV5Zg6s3lb48oMkHnkDtsax4L1e5ttNbT/Bd7b6JDNdmbQTrEYdpXhjWK43eYUAVlcbQ2R94AliK6HSfjEuqW+mCx0VLq91G9ksYIbbUY3UOsXmfOxAKehBUHjIB4zUX4xQy+Rqn2W+it49Hvb6404iM4kt5hGy7+ucg4xwQeeaAMtPBHiuC80l/FGmXPi1ItHt7WPydUFv8AYrpWJkdtzKWzlf3i7m+XpT/h74N8YaF49hvtXsmuNBkvtReO3juY1+xtLLuS5Zd+JNy/LjqvoDnPRQfFoiLWRqWgSaZc2Nlb6hDHdX0IWeGZtqkuCQhz/DyT0GTgHL0r4sXfiTX/AAvbWFpJpiy6xPpuoW8wD7wlt5qlWKggcg9AaAPZ6KKKACiiigAooooAKKKKAMfxNoia9bWsEsrxRw3CzkoSCdobA/Mg/hWoIUAUAcKMCpKKLAY/inSX1fQLqwt5FjeXbgv04YHn8qp3Wk3ETExjzV7FetdJRUSgpGkKsoPQ4iR4dEvYY9Zlt4rLUpP3HncFbnHKk4xhlXIyeoI710guXW3328QuV6qEYcj2PStGRFkUrIqsp6hhkVgnwdoQmeWGxNszncwtppIFJ9SqMBn3xSdPsS5XdxsjahcarbzRRta2aKRPHNtbzPTaAeDnqSenGKludSsLXP2q/tIcHB3zKCPwzmmt4Q0V8CW3mlTukt1K6n6qWIP41pWGk6dpyKlhY2tuq5wIolXGevQUlS7iuYdlriakGbR7C+vY1HExj8iIn2aTBP1AIqaDT9avi7313HpkWfkhssSPj1aR1xn2C9upro6KtRS2EY+leHNP066N2qzXN8Rt+1XcrTSgegZvujk8DArYHSiiqAKKKKACiiigAooooAralY2up6fc2GoQJcWdzG0U0TjKujDBB/A1y/gy+udM1Cbwnrc7zXlpH5thdSHm9tAQAxPeSMkI/rlW/jwOxrn/ABnoMmtafFJp8y2utWMn2nT7ojIjlAxtb1RgSrDuD6gEAHQUVQ0G+n1LR7W7u7KawuZF/e2033onBIZc9xkHDDgjBHWr9ABRRRQAAYooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKyvEnh7S/EtglnrVr9ogjlWePEjRvHIv3XR0IZWGTyCDyfWtWigDnNN8E+HdNm0WWx01IJNHWdbIrI/7rzseaTz85bAyWyc80+08HaFaeEU8MW1k0WiRrsS3WeTKjfv4fdvB3c53ZrlPiR4NvPFXjPRTNb3E2gRafeR3QjvDCvnME8oEK6luQexAxzXmeqfDvx7e6X4aTU4tSu1t9GS0eK1v4hPZ3SyMfMBeRVJK7BvViRtxjFAHp2rfCDQLu40c2RmsrazvJLy5VZ5nnvGeIx/NceYJFI45yemOM0/XPDXw70RLDS9Us4LRH0u7s7eFZJgDZqBJcD5T15DFj8xJODkmuHtvA3jNfiXBq2prqV0q6lBcxX9veQhY7YKoeCRWcNtA35VEIYnPHWsbT/hv4u+22El7oMz6nDZazDqGqyahFIL+WeMrAyqX3KDwMEDGeemaAPY/+EM8HeKNMS/Fgl5Z6lp9tCkomlXfbIRJDt+YFSMghhhvU1NpPw48LaTd291Y6a63MF218ksl3NI3ntH5bOSzncSvHOR36814xqfw38bsmhhrfUJUttF062tvsN7Cj6bcwxqJB88gXlhkum7IGMGvpWgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACsrxXrcHhrw1qetXcUksFhbvcOkeNzKoyQM8ZrVrF8a6F/wk/hHWND+0fZf7QtZLbztm/y9wxu25GcemRQBTufFsEWk+GdQSJBFrlxbwxrPMI2Tzoy4xwdzAD7oxnnnio7L4heFL7UZLC01u2lukMoKruw3lDMm1sYYKOpBNc5a/DnWZNM8NWOs+KIL2LQNStL618vTBCSkEbp5Z/enJbeDu7behzxxHhD4aeK4te0nT5zc6Z4d0O11O2sbtjAtwgugVUoY5HLMudwZlToOM0Aer2nxG8JXVjqN5HrUC2+nqkl0ZUeIxKxwrFWAOCeMgYqLT/ih4K1G/tbKy8R2M11c3BtYo1Y5aTsvTjP8JPDds1wMPwIl/sbX7K48SRPNq2nQWDTx6cVIMcofzWBmJdmxg5I559q6bUvhd9t1271L+2Nn2jxBY675f2XO37MoXys7+d2PvY49DQB0UPxA8Kzand6fFrdo11apLJKuTjEQzJtbG1ivcKSRjmsbUfjF4JtdG1TUbbWI9QXT4FuJYbQbpGRmCgqGwG5YDrwTg4rndN+CUWnXNyttq8DWJS9W2Waw33EH2iORCPN8zBA8wn7gJxgmreofB2O+0+C1l1plWLwqvhnctrySrown+/6x/c9/vUAdpZ+N/Dl3atPFqkGxNPOqPuyClsCymQj0BVh+FU9Q+JvgzTruK2vvEVhBNKsTqsjkfLIu5GJxgKQQcnA5Ga5jxF8LNX1mU3P/AAliW17caFJoN86aYrJPCzOwZVMmUI34PJz6imS/B3zLXU4f7dx9tTSEz9k+59gGP7/O/wDDb/tUAeieGfEekeKNOa/0C+ivbRZWhZ48ja69VIIBB5HX1B71rVzXgrwv/wAIxJ4if7Z9q/tfVptUx5WzyvMVF8vqd2NnXjr0rpaACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArgfj1PeW3wh8Tz6bdvaXCWpPmJ97bkBgDkYyCRn3rvqKAPmyzvZfh5deMvslzMv2LRtL2S29uGCNJJJufY7bVGWOSSQOvPSpNM+Lview8K3PiDU57TU9N0nWmsb17eNT5sDwgxOGUAfLIyjIADbh9a+j6KAPBtY+JfiPwpF9n8U3VvBfTeEH1K3zaEB9S3SHyhgY+VdgI9snrVDxL8SfGMFrfX+n6jYwRabpmj30kElkJPtD3TqjqW3AqvzZ454wCK+iKKAOC+FWt6zqcvinT/ABBeQ31xo+qvZpcxwCDzE8tHGUBIGCxHXpXe0UUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAf//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Midsagittal section through lumbar spinal column showing positioning for measurement of CSF opening pressure. The manometer is attached to the spinal needle hub with a three-way stop-cock. CSF is permitted to enter the manometer; opening pressure is recorded at the highest level attained by the CSF in the manometer column.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Dieckmann, RA, Fiser, DH, Selbst, SM, (Eds). Illustrated Textbook of Pediatric Emergency and Critical Care Procedures. Mosby, St. Louis, 1997.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_27_27059=[""].join("\n");
var outline_f26_27_27059=null;
var title_f26_27_27060="Dermatosis papulosa face";
var content_f26_27_27060=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F73398&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F73398&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Dermatosis papulosa nigra",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple hyperpigmented papules are present on the face of this patient with dermatosis papulosa nigra.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_27_27060=[""].join("\n");
var outline_f26_27_27060=null;
var title_f26_27_27061="Omeprazole and sodium bicarbonate: Patient drug information";
var content_f26_27_27061=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Omeprazole and sodium bicarbonate: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/28/10697?source=see_link\">",
"     see \"Omeprazole and sodium bicarbonate: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/47/38648?source=see_link\">",
"     see \"Omeprazole and sodium bicarbonate: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F2874244\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Zegerid OTC&trade; [OTC];",
"     </li>",
"     <li>",
"      Zegerid&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10029289\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10029291\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691849",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat gastroesophageal reflux disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691876",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat heartburn.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691535",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat ulcers of the swallowing tube (esophagus).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691503",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat GI (gastrointestinal) ulcers caused by infection.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10029290\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to omeprazole, sodium bicarbonate, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10029295\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2738439",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you need Zegerid OTC&trade; for more than 14 days in a row or if you need to take it again before 4 months, talk with your  doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high bicarbonate levels, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697292",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have low calcium levels, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697297",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have low potassium levels, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697055",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are on a low-salt diet (this drug has salt), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697754",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use care if you have risks for soft, brittle bones called osteoporosis (alcohol use, cigarette smoking, other family members with brittle bones, taking drugs to treat seizures, taking steroids).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10029296\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698217",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low potassium levels like muscle pain or weakness, muscle cramps, or a heartbeat that does not feel normal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2769639",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hip, spine, or wrist fractures may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10029298\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699072",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low potassium.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2769659",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad bone pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699038",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad muscle pain or weakness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699003",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Seizures.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10029293\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705343",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Capsule:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695809",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take 1 hour before a meal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2925160",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with water only; do not take with other drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695700",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow capsule whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705506",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Powder:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694368",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a powder if you cannot swallow pills. Mix it with 2 tablespoons (30 mL) of water and drink. Rinse cup with more water and drink.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695809",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take 1 hour before a meal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696115",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the powder. Hold feeding 3 hours before and 1 hour after giving the liquid from the powder. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10029294\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10029299\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10029300\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11511 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-194.187.108.93-F5F47B5EFB-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_27_27061=[""].join("\n");
var outline_f26_27_27061=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2874244\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029289\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029291\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029290\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029295\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029296\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029298\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029293\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029294\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029299\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029300\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?10/28/10697?source=related_link\">",
"      Omeprazole and sodium bicarbonate: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/47/38648?source=related_link\">",
"      Omeprazole and sodium bicarbonate: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_27_27062="Subcutaneous immunotherapy for allergic disease: Therapeutic mechanisms";
var content_f26_27_27062=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Subcutaneous immunotherapy for allergic disease: Therapeutic mechanisms",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/27/27062/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/27/27062/contributors\">",
"     Philip S Norman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/27/27062/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/27/27062/contributors\">",
"     Peter S Creticos, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/27/27062/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/27/27062/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/27/27062/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subcutaneous allergen immunotherapy (SCIT) for allergic disease involves the gradual administration of increasing amounts of allergen for the purpose of inducing protective immunologic changes. Immunotherapy is currently the only treatment that alters the abnormal immune response underlying allergic disease. However, the mechanisms responsible for clinical improvement have not been fully revealed, despite extensive investigation.",
"   </p>",
"   <p>",
"    This topic will discuss the known immunologic changes that occur during SCIT. The indications and efficacy of SCIT are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/8/39049?source=see_link\">",
"     \"Subcutaneous immunotherapy for allergic disease: Indications and efficacy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ALTERED RESPONSES TO ALLERGEN CHALLENGE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Allergic patients who are challenged with an allergen to which they are sensitive often display a biphasic inflammatory response. This occurs after both nasal and bronchial challenges, and a similar phenomenon can be seen in the skin after allergen testing. Nasal challenges are often used as a model for studying the effects of immunotherapy on both clinical symptoms and cellular events [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27062/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Briefly, the biphasic response consists of an early phase of symptoms that develops within minutes of challenge and, in some but not all patients, a later phase that begins several hours later. The early phase corresponds with the release of various mediators from local tissue mast cells and circulating basophils, including histamine, prostaglandin D2, kinins, cysteinyl leukotrienes (LTC4, D4, and E4), cytokines, and chemokines. These mediators can be measured in nasal secretions during nasal challenges. Some of the mediators stimulate cell recruitment to the area of challenge, leading to a secondary influx of inflammatory cells, including T lymphocytes, eosinophils, and additional basophils. The newly arrived cells release specific inflammatory mediators that perpetuate the underlying inflammation and contribute to persistent allergic symptoms.",
"   </p>",
"   <p>",
"    After several months of immunotherapy, patients undergoing nasal allergen challenge demonstrate a significantly blunted early response, although complete inhibition is uncommon. The late phase reaction is even more effectively reduced [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27062/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. A similar inhibition of both immediate and late responses to intradermal skin testing may also result from immunotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27062/abstract/4\">",
"     4",
"    </a>",
"    ], and careful dose titration can demonstrate a shift in sensitivity to allergen. However, these changes in skin test responses do not always correlate with improvement in symptoms of allergic rhinitis or asthma, and thus repeat skin testing is not recommended for monitoring the effectiveness of SCIT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CHANGES IN HUMORAL IMMUNITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subcutaneous allergen immunotherapy (SCIT) characteristically results in changes in several types of allergen-specific antibodies (",
"    <a class=\"graphic graphic_figure graphicRef60233 \" href=\"UTD.htm?26/45/27359\">",
"     figure 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Allergen-specific IgE levels in serum initially increase, then decrease slowly",
"     </li>",
"     <li>",
"      Allergen-specific IgG levels in serum increase and remain elevated, beginning several weeks to months after the changes in IgE",
"     </li>",
"     <li>",
"      Allergen-specific IgA levels in the serum and secretions increase",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Changes in IgE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of SCIT is not dependent upon simple reductions in levels of allergen-specific IgE, and clinical improvement develops before decreases in specific IgE antibody levels occur.",
"   </p>",
"   <p>",
"    Allergen-specific IgE antibody levels initially increase in most patients and may continue to rise, even after the maximum prescribed dose has been reached. This trend reverses over time in some patients, with levels gradually decreasing within several months after reaching maintenance (ie, reaching the maximal allergen dose and continuing at that dose) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27062/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. Levels may even drop to below pretreatment levels. However, in other patients there is no appreciable decline in allergen-specific IgE, which remains elevated as long as SCIT is continued. What happens after SCIT is discontinued has not been studied.",
"   </p>",
"   <p>",
"    Allergen-specific IgE levels typically increase after seasonal allergen exposure in untreated individuals. This post-seasonal spike is reduced or eliminated by SCIT [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27062/abstract/5-7\">",
"     5-7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Changes in IgG",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some of the most dramatic immunologic changes observed with SCIT involve allergen-specific IgG antibodies, although none of these changes clearly correlates with clinical relief of symptoms.",
"   </p>",
"   <p>",
"    Allergen-specific serum IgG antibodies are often present at low levels in allergic patients. Immunotherapy generally results in an increase in allergen-specific IgG antibodies, which lags behind the rise in IgE antibodies by weeks to a few months. Levels may continue to rise over many months of maintenance dosing and elevated levels may persist for many years after immunotherapy is discontinued [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27062/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    High levels of allergen-specific IgG as a result of SCIT do not necessarily correlate with clinical relief of symptoms. However, the failure to produce allergen-specific IgG in an individual patient receiving immunotherapy does predict a lack of clinical response [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27062/abstract/1\">",
"     1",
"    </a>",
"    ]. This finding can be used clinically to assess the efficacy of a patient's previous immunotherapy. If the patient reports that a previous course of SCIT did not seem to help, the finding of low allergen-specific IgG levels to the allergen given essentially confirms that the therapy was not effective.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Blocking IgG4 antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Before starting SCIT, allergic patients demonstrate allergen-specific IgG in serum that consists mostly of the isotypes IgG1 or IgG2. With immunotherapy, IgG4 becomes more prominent, a pattern which is called the \"modified Th2 response.\" Specific IgG antibodies (both IgG4 and other isotypes) are capable of blocking in vitro mediator releases from allergen stimulated mast cells and basophils (the early phase response) and are sometimes referred to as \"blocking\" antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27062/abstract/5-8\">",
"     5-8",
"    </a>",
"    ]. IgG4 may be functionally monovalent and therefore more effective as a blocking antibody than other IgG isotypes [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27062/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A protective role for allergen-specific IgG4 antibodies is also suggested by the finding that bee keepers who develop immunity after multiple stings have high levels of venom-specific IgG4 [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27062/abstract/9\">",
"     9",
"    </a>",
"    ]. In contrast, individuals who have been stung only a few times typically have mostly IgG1 antibodies to venom. Thus, it may be that chronic stimulation with allergen induces a predominantly IgG4 response, while limited allergen exposure results in an IgG1-dominated response.",
"   </p>",
"   <p>",
"    Precisely how IgG4 modifies the allergic response is an area of ongoing research. The two leading theories are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Allergen-specific IgG4 molecules may compete for allergen with IgE bound to mast cells (ie, the blocking antibody theory). However, the steps subsequent to the binding of allergen to IgG4 have not been defined [",
"      <a class=\"abstract\" href=\"UTD.htm?26/27/27062/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Allergen-specific IgG4 may reduce the sensitivity of antigen presenting B cells and therefore T cells to allergen by competing with IgE in a mechanism called \"IgE-facilitated antigen (or allergen) presentation\" [",
"      <a class=\"abstract\" href=\"UTD.htm?26/27/27062/abstract/11\">",
"       11",
"      </a>",
"      ]. IgE-facilitated antigen presentation refers to the observation that antigen presenting B cells with the low affinity IgE receptor, CD23, can be activated by low levels of allergen in the presence of allergen-specific IgE [",
"      <a class=\"abstract\" href=\"UTD.htm?26/27/27062/abstract/11\">",
"       11",
"      </a>",
"      ]. However, if IgG4 is added, the amount of allergen required to activate the B cell becomes much greater, presumedly because IgG4 competes with IgE. This attenuated antigen presentation then interferes with the activation of T cells.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite the above data suggesting that IgG4 is important for successful SCIT, not all studies have found that increases in this isotype correlate with clinical improvement. In a retrospective review of six immunotherapy studies, only two found an association between increased IgG4 and clinical benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27062/abstract/12\">",
"     12",
"    </a>",
"    ]. Thus, simple measurements of the levels of allergen-specific IgG4 do not correlate with clinical success. It may be that some type of functional assays of allergen-specific IgG, such as detection of IgG-associated serum inhibitory activity for IgE-facilitated allergen presentation, basophil histamine release, or both, might be more closely associated with the clinical response to immunotherapy, although this remains to be tested.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Other changes in IgG",
"    </span>",
"    &nbsp;&mdash;&nbsp;SCIT alters other properties of allergen-specific IgG antibodies, such as their specificity (ie, the set of epitopes on allergens that are recognized by antibodies) and avidity (ie, the collective strength of the interactions of antigens and antibodies within an antiserum). This was demonstrated in a study of ultrarush insect venom immunotherapy (VIT), in which changes in IgG specificity to the major bee venom allergen, phospholipase A2, were analyzed [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27062/abstract/13\">",
"     13",
"    </a>",
"    ]. Within 12 hours of starting therapy, the patients' specificity patterns came to resemble those of healthy nonallergic individuals, and the highest avidity antibody fractions were reduced. This preceded the increase in IgG titers [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27062/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Changes in IgA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunotherapy results in an increase in secretional and serum allergen-specific IgA antibodies. The clinical significance of this is unclear, although one study suggested that the isotype IgA2 may function as blocking antibody at the mucosal surface [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27062/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     ALTERATIONS IN CELLULAR IMMUNITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunotherapy results in several changes in T cell responses to allergen. These changes may contribute to immunologic tolerance to the allergen. Immune tolerance can arise from different and overlapping mechanisms, including a relative decrease in antigen-specific responsiveness, immune deviation, or anergy. Findings that are consistent with the concept that immunotherapy induces a state of tolerance include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      CD4+ helper T cells shift from producing Th2 (especially IL-4) to Th1 cytokines (eg, interferon gamma) following stimulation with allergen [",
"      <a class=\"abstract\" href=\"UTD.htm?26/27/27062/abstract/17-19\">",
"       17-19",
"      </a>",
"      ]. Increased production of IL-12, a strong inducer of TH1 responses, contributes to this shift [",
"      <a class=\"abstract\" href=\"UTD.htm?26/27/27062/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Lymphoproliferative responses to allergen are reduced with immunotherapy [",
"      <a class=\"abstract\" href=\"UTD.htm?26/27/27062/abstract/20-25\">",
"       20-25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Successful immunotherapy generates populations of T regulatory cells (ie, CD4+CD25+ T lymphocytes that produce IL-10, TGF-beta, or both) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/27/27062/abstract/26-30\">",
"       26-30",
"      </a>",
"      ]. Cytokine and mediator release from these cells has been described in allergen immunotherapy with Hymenoptera venom [",
"      <a class=\"abstract\" href=\"UTD.htm?26/27/27062/abstract/26\">",
"       26",
"      </a>",
"      ], grass pollen extract [",
"      <a class=\"abstract\" href=\"UTD.htm?26/27/27062/abstract/28\">",
"       28",
"      </a>",
"      ], and house dust mites [",
"      <a class=\"abstract\" href=\"UTD.htm?26/27/27062/abstract/29\">",
"       29",
"      </a>",
"      ]. IL-10 reduces B-cell antigen-specific IgE and increases IgG4 levels; reduces proinflammatory cytokine release from mast cells, eosinophils, and T cells; and elicits tolerance in T cells by means of selective inhibition of the CD28 costimulatory pathway [",
"      <a class=\"abstract\" href=\"UTD.htm?26/27/27062/abstract/29,30\">",
"       29,30",
"      </a>",
"      ]. Costimulatory mechanisms are reviewed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/27/10682?source=see_link&amp;anchor=H12#H12\">",
"       \"Transplantation immunobiology\", section on 'T-cell costimulation'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     CHANGES IN TISSUE CELLULARITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Allergen immunotherapy decreases the recruitment of mast cells, basophils, and eosinophils in the skin, nose, eye, and bronchial mucosa after provocation or natural exposure to allergens [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27062/abstract/31-36\">",
"     31-36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Basophil function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Changes in basophil function occur with successful immunotherapy. Specifically, more allergen is required to trigger histamine release, and the ability of basophils to fully release histamine in response to the allergen is reduced [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27062/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     IMPACT OF SYSTEMIC MEDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The impact of systemic antiinflammatory medications on the efficacy of immunotherapy has been questioned. A small randomized trial evaluated the effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/49/37654?source=see_link\">",
"     montelukast",
"    </a>",
"    on the efficacy of SCIT in 36 children with allergic asthma and monosensitization to dust mite. All patients were treated with the lowest effective dose of inhaled glucocorticoid, plus either montelukast or placebo, and underwent immunotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27062/abstract/38\">",
"     38",
"    </a>",
"    ]. Children in the placebo group experienced more labile asthma symptoms and had higher drop-out rates from the study. However, among those who successfully completed 12 months of SCIT, those receiving placebo were able to reduce their use of inhaled glucocorticoids by 50 percent, compared with 33 percent reduction in the montelukast group. Induction of regulatory T cells, one of proposed therapeutic mechanisms of SCIT, was diminished in the group receiving montelukast. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Alterations in cellular immunity'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    These findings require confirmation, and additional studies are needed to determine if systemic glucocorticoids or other antiinflammatory medications are capable of altering the therapeutic efficacy of SCIT. The potentially detrimental effect of these agents on SCIT must be balanced against the clinical benefit in patients who clearly respond to antileukotriene agents with improved asthma control. Until more information is available, the clinician should limit the routine use of antileukotriene drugs in patients undergoing immunotherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subcutaneous allergen immunotherapy (SCIT) alters the abnormal immune response underlying allergic disease, although the mechanisms directly responsible for this effect are not yet defined. (See",
"    <a class=\"local\" href=\"#H1\">",
"     'Introduction'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      SCIT results in partial blunting of both the early and late phases of symptoms and tissue inflammation after allergen challenge. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Altered responses to allergen challenge'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In most patients, allergen-specific IgE in serum initially rises and then gradually falls. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Changes in IgE'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Changes are allergen-specific IgG are believed to be important to clinical efficacy. Levels of this antibody increase, and the dominant isotype changes from IgG1 and IgG2 to IgG4. These allergen-specific IgG antibodies can block in vitro degranulation of mast cells upon exposure to allergen, and may also alter the presentation of allergen to T cells. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Changes in IgG'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Immunotherapy results in several changes in T cell responses to allergen, most of which indicate a shift towards immunologic tolerance. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Changes in tissue cellularity'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27062/abstract/1\">",
"      Creticos PS. Immunotherapy with allergens. JAMA 1992; 268:2834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27062/abstract/2\">",
"      Creticos PS, Adkinson NF Jr, Kagey-Sobotka A, et al. Nasal challenge with ragweed pollen in hay fever patients. Effect of immunotherapy. J Clin Invest 1985; 76:2247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27062/abstract/3\">",
"      Iliopoulos O, Proud D, Adkinson NF Jr, et al. Effects of immunotherapy on the early, late, and rechallenge nasal reaction to provocation with allergen: changes in inflammatory mediators and cells. J Allergy Clin Immunol 1991; 87:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27062/abstract/4\">",
"      Van Metre TE Jr, Adkinson NF Jr, Kagey-Sobotka A, et al. Immunotherapy decreases skin sensitivity to ragweed extract: demonstration by midpoint skin test titration. J Allergy Clin Immunol 1990; 86:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27062/abstract/5\">",
"      Lichtenstein LM, Ishizaka K, Norman PS, et al. IgE antibody measurements in ragweed hay fever. Relationship to clinical severity and the results of immunotherapy. J Clin Invest 1973; 52:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27062/abstract/6\">",
"      Gleich GJ, Zimmermann EM, Henderson LL, Yunginger JW. Effect of immunotherapy on immunoglobulin E and immunoglobulin G antibodies to ragweed antigens: a six-year prospective study. J Allergy Clin Immunol 1982; 70:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27062/abstract/7\">",
"      Creticos PS, Van Metre TE, Mardiney MR, et al. Dose response of IgE and IgG antibodies during ragweed immunotherapy. J Allergy Clin Immunol 1984; 73:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27062/abstract/8\">",
"      Peng ZK, Naclerio RM, Norman PS, Adkinson NF Jr. Quantitative IgE- and IgG-subclass responses during and after long-term ragweed immunotherapy. J Allergy Clin Immunol 1992; 89:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27062/abstract/9\">",
"      Aalberse RC, van der Gaag R, van Leeuwen J. Serologic aspects of IgG4 antibodies. I. Prolonged immunization results in an IgG4-restricted response. J Immunol 1983; 130:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27062/abstract/10\">",
"      Aalberse RC, Stapel SO, Schuurman J, Rispens T. Immunoglobulin G4: an odd antibody. Clin Exp Allergy 2009; 39:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27062/abstract/11\">",
"      Wachholz PA, Soni NK, Till SJ, Durham SR. Inhibition of allergen-IgE binding to B cells by IgG antibodies after grass pollen immunotherapy. J Allergy Clin Immunol 2003; 112:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27062/abstract/12\">",
"      Djurup R, Malling HJ. High IgG4 antibody level is associated with failure of immunotherapy with inhalant allergens. Clin Allergy 1987; 17:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27062/abstract/13\">",
"      Michils A, Baldassarre S, Ledent C, et al. Early effect of ultrarush venom immunotherapy on the IgG antibody response. Allergy 2000; 55:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27062/abstract/14\">",
"      Michils A, Mairesse M, Ledent C, et al. Modified antigenic reactivity of anti-phospholipase A2 IgG antibodies in patients allergic to bee venom: conversion with immunotherapy and relation to subclass expression. J Allergy Clin Immunol 1998; 102:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27062/abstract/15\">",
"      Batard T, Basuyaux B, Lambin P, et al. Isotypic analysis of grass pollen-specific immunoglobulins in human plasma. 1. Specialization of certain classes and subclasses in the immune response. Int Arch Allergy Immunol 1993; 100:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27062/abstract/16\">",
"      Platts-Mills TA, von Maur RK, Ishizaka K, et al. IgA and IgG anti-ragweed antibodies in nasal secretions. Quantitative measurements of antibodies and correlation with inhibition of histamine release. J Clin Invest 1976; 57:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27062/abstract/17\">",
"      Varney VA, Hamid QA, Gaga M, et al. Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutaneous responses. J Clin Invest 1993; 92:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27062/abstract/18\">",
"      Ohashi Y, Nakai Y, Okamoto H, et al. Serum level of interleukin-4 in patients with perennial allergic rhinitis during allergen-specific immunotherapy. Scand J Immunol 1996; 43:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27062/abstract/19\">",
"      Majori M, Caminati A, Corradi M, et al. T-cell cytokine pattern at three time points during specific immunotherapy for mite-sensitive asthma. Clin Exp Allergy 2000; 30:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27062/abstract/20\">",
"      Hamid QA, Schotman E, Jacobson MR, et al. Increases in IL-12 messenger RNA+ cells accompany inhibition of allergen-induced late skin responses after successful grass pollen immunotherapy. J Allergy Clin Immunol 1997; 99:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27062/abstract/21\">",
"      Till SJ, Durham SR. Immunological responses to allergen immunotherapy. Clin Allergy Immunol 2004; 18:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27062/abstract/22\">",
"      Till SJ, Francis JN, Nouri-Aria K, Durham SR. Mechanisms of immunotherapy. J Allergy Clin Immunol 2004; 113:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27062/abstract/23\">",
"      Durham SR, Ying S, Varney VA, et al. Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-gamma. J Allergy Clin Immunol 1996; 97:1356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27062/abstract/24\">",
"      Evans R, Pence H, Kaplan H, Rocklin RE. The effect of immunotherapy on humoral and cellular responses in ragweed hayfever. J Clin Invest 1976; 57:1378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27062/abstract/25\">",
"      Tulic MK, Fiset PO, Christodoulopoulos P, et al. Amb a 1-immunostimulatory oligodeoxynucleotide conjugate immunotherapy decreases the nasal inflammatory response. J Allergy Clin Immunol 2004; 113:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27062/abstract/26\">",
"      Bellinghausen I, Metz G, Enk AH, et al. Insect venom immunotherapy induces interleukin-10 production and a Th2-to-Th1 shift, and changes surface marker expression in venom-allergic subjects. Eur J Immunol 1997; 27:1131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27062/abstract/27\">",
"      Blaser K, Akdis CA. Interleukin-10, T regulatory cells and specific allergy treatment. Clin Exp Allergy 2004; 34:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27062/abstract/28\">",
"      Francis JN, Till SJ, Durham SR. Induction of IL-10+CD4+CD25+ T cells by grass pollen immunotherapy. J Allergy Clin Immunol 2003; 111:1255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27062/abstract/29\">",
"      Jutel M, Akdis M, Budak F, et al. IL-10 and TGF-beta cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur J Immunol 2003; 33:1205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27062/abstract/30\">",
"      Savolainen J, Laaksonen K, Rantio-Lehtim&auml;ki A, Terho EO. Increased expression of allergen-induced in vitro interleukin-10 and interleukin-18 mRNA in peripheral blood mononuclear cells of allergic rhinitis patients after specific immunotherapy. Clin Exp Allergy 2004; 34:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27062/abstract/31\">",
"      Wilson DR, Irani AM, Walker SM, et al. Grass pollen immunotherapy inhibits seasonal increases in basophils and eosinophils in the nasal epithelium. Clin Exp Allergy 2001; 31:1705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27062/abstract/32\">",
"      Monteseir&iacute;n J, Bonilla I, Camacho J, et al. Elevated secretion of myeloperoxidase by neutrophils from asthmatic patients: the effect of immunotherapy. J Allergy Clin Immunol 2001; 107:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27062/abstract/33\">",
"      Wilson DR, Nouri-Aria KT, Walker SM, et al. Grass pollen immunotherapy: symptomatic improvement correlates with reductions in eosinophils and IL-5 mRNA expression in the nasal mucosa during the pollen season. J Allergy Clin Immunol 2001; 107:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27062/abstract/34\">",
"      Furin MJ, Norman PS, Creticos PS, et al. Immunotherapy decreases antigen-induced eosinophil cell migration into the nasal cavity. J Allergy Clin Immunol 1991; 88:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27062/abstract/35\">",
"      Durham SR, Varney VA, Gaga M, et al. Grass pollen immunotherapy decreases the number of mast cells in the skin. Clin Exp Allergy 1999; 29:1490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27062/abstract/36\">",
"      H&aring;kansson L, Heinrich C, Rak S, Venge P. Priming of eosinophil adhesion in patients with birch pollen allergy during pollen season: effect of immunotherapy. J Allergy Clin Immunol 1997; 99:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27062/abstract/37\">",
"      Creticos PS. Immunologic changes associated with immunotherapy. Immunol Allergy Clin N Am 1992; 12:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27062/abstract/38\">",
"      Majak P, Rychlik B, Pu��aski L, et al. Montelukast treatment may alter the early efficacy of immunotherapy in children with asthma. J Allergy Clin Immunol 2010; 125:1220.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 362 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.167.4.114-B39C775BF0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_27_27062=[""].join("\n");
var outline_f26_27_27062=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ALTERED RESPONSES TO ALLERGEN CHALLENGE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CHANGES IN HUMORAL IMMUNITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Changes in IgE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Changes in IgG",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Blocking IgG4 antibodies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Other changes in IgG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Changes in IgA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      ALTERATIONS IN CELLULAR IMMUNITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      CHANGES IN TISSUE CELLULARITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Basophil function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      IMPACT OF SYSTEMIC MEDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/362\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/362|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/45/27359\" title=\"figure 1\">",
"      Ab changes w SCIT",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/8/39049?source=related_link\">",
"      Subcutaneous immunotherapy for allergic disease: Indications and efficacy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/27/10682?source=related_link\">",
"      Transplantation immunobiology",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_27_27063="Ischemic stroke in children: Secondary prevention";
var content_f26_27_27063=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Ischemic stroke in children: Secondary prevention",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/27/27063/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/27/27063/contributors\">",
"     Sabrina E Smith, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/27/27063/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/27/27063/contributors\">",
"     Scott E Kasner, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/27/27063/contributors\">",
"     Douglas R Nordli, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/27/27063/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/27/27063/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/27/27063/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;While more common in older adults, stroke also occurs in neonates, infants, children, and young adults, resulting in significant morbidity and mortality.",
"   </p>",
"   <p>",
"    An overview of the secondary prevention of arterial ischemic stroke (AIS) in children one month of age or older is provided here. Other aspects of ischemic stroke in children and young adults are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/61/23513?source=see_link\">",
"     \"Ischemic stroke in children and young adults: Etiology and clinical features\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/37/43608?source=see_link\">",
"     \"Ischemic stroke in children: Evaluation, initial management, and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Stroke in neonates is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/2/27690?source=see_link\">",
"     \"Stroke in the newborn\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Stroke due to cerebral venous sinus thrombosis is also reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/26/7594?source=see_link\">",
"     \"Etiology, clinical features, and diagnosis of cerebral venous thrombosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SECONDARY PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with acute treatment, there are no controlled trials or studies examining the effectiveness of specific treatments for the secondary prevention of arterial ischemic stroke in children. Thus, the recommendations for children that follow are based mainly upon extrapolation from studies involving adults, and the clinical experience of experts, as reflected in consensus guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27063/abstract/1-4\">",
"     1-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Antiplatelet therapy is a mainstay of secondary ischemic stroke prevention in children and adults. Once dissection and cardioembolic causes are excluded, the American College of Chest Physician (ACCP) guidelines for antithrombotic therapy in children suggest daily",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/10/19624?source=see_link\">",
"     aspirin",
"    </a>",
"    (1 to 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    daily) for a minimum of two years [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27063/abstract/4\">",
"     4",
"    </a>",
"    ]. There is little clinical experience with combination",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19271?source=see_link\">",
"     aspirin-extended-release dipyridamole",
"    </a>",
"    or with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?15/49/16152?source=see_link\">",
"     clopidogrel",
"    </a>",
"    in childhood stroke.",
"   </p>",
"   <p>",
"    In children, limited data suggest that combined treatment with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/10/19624?source=see_link\">",
"     aspirin",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?15/49/16152?source=see_link\">",
"     clopidogrel",
"    </a>",
"    is associated with an increased risk of intracranial bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27063/abstract/5\">",
"     5",
"    </a>",
"    ]. In adults, there is accumulating evidence that the combination of aspirin and clopidogrel does not offer greater benefit for stroke prevention than either agent alone, but does substantially increase the risk of bleeding complications. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/35/2618?source=see_link&amp;anchor=H7#H7\">",
"     \"Antiplatelet therapy for secondary prevention of stroke\", section on 'Aspirin plus clopidogrel'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Given these data, we recommend avoiding the combined use of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/10/19624?source=see_link\">",
"     aspirin",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?15/49/16152?source=see_link\">",
"     clopidogrel",
"    </a>",
"    in children.",
"   </p>",
"   <p>",
"    Concern regarding the risk of Reye syndrome should not limit or preclude the use of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/10/19624?source=see_link\">",
"     aspirin",
"    </a>",
"    therapy in children for stroke prevention, since there is insufficient evidence to establish that aspirin causes Reye syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27063/abstract/6\">",
"     6",
"    </a>",
"    ]. In addition, there have been virtually no confirmed cases of Reye syndrome since the 1990s.",
"   </p>",
"   <p>",
"    Nevertheless, guidelines from the American Heart Association (AHA) Stroke Council state that it is reasonable to verify the varicella vaccination status and to administer an annual influenza vaccine to reduce the risk of Reye syndrome in children treated with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/10/19624?source=see_link\">",
"     aspirin",
"    </a>",
"    for stroke prevention [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27063/abstract/2\">",
"     2",
"    </a>",
"    ]. In addition, the AHA considers it reasonable to stop aspirin temporarily during suspected varicella or influenza infections. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39818?source=see_link&amp;anchor=H32#H32\">",
"     \"Standard immunizations for children and adolescents\", section on 'Varicella vaccine'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/18/27946?source=see_link&amp;anchor=H7#H7\">",
"     \"Seasonal influenza vaccination in children\", section on 'Indications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Risk factor reduction in children",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk factors should be identified and treated when possible in children with ischemic stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27063/abstract/2\">",
"     2",
"    </a>",
"    ]. In addition, consensus guidelines from the AHA recommend the following specific interventions [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27063/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Give alpha-galactosidase enzyme replacement therapy for individuals with Fabry disease (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/49/27414?source=see_link\">",
"       \"Neurologic manifestations of Fabry disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/23/40313?source=see_link\">",
"       \"Treatment of Fabry disease\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Discontinue oral contraceptives and switch to another form of birth control",
"     </li>",
"     <li>",
"      Lower the homocysteine level when it is higher than normal with diet or supplementation of folate, vitamin B6, or vitamin B12",
"     </li>",
"     <li>",
"      Avoid triptans in children with hemiplegic migraine, basilar migraine, known vascular risk factors, or prior cardiac or cerebral ischemia",
"     </li>",
"     <li>",
"      Seek and treat iron deficiency, which may increase the risk of arterial ischemic stroke in conjunction with other risk factors",
"     </li>",
"     <li>",
"      Counsel children and their families regarding dietary improvement, the benefits of exercise, and avoidance of tobacco products",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While considered reasonable, these recommendations are generally supported by limited or low-quality evidence [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27063/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Cardioembolic stroke",
"    </span>",
"    &nbsp;&mdash;&nbsp;For children with arterial ischemic stroke due to a high-risk cardioembolic source, consensus guidelines generally recommend anticoagulation for secondary prevention, but there is no agreement regarding duration of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27063/abstract/2,4\">",
"     2,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For arterial ischemic stroke secondary to a cardioembolic cause, the ACCP guidelines suggest anticoagulant therapy with low molecular weight",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/39/7801?source=see_link\">",
"     heparin",
"    </a>",
"    or vitamin K antagonist (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/4/21578?source=see_link\">",
"     warfarin",
"    </a>",
"    ) for at least three months [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27063/abstract/4\">",
"     4",
"    </a>",
"    ]. For children with cardioembolic stroke and a demonstrated right-to-left shunt (eg, a patent foramen ovale), the ACCP guidelines suggest surgical closure of the shunt.",
"   </p>",
"   <p>",
"    Although acknowledging that high-quality evidence is lacking, the AHA guidelines provide recommendations for a number of treatments that may reduce the risk of cardiogenic brain embolism in children with stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27063/abstract/2\">",
"     2",
"    </a>",
"    ]. The following interventions are considered reasonable or indicated:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Treat heart failure (indicated)",
"     </li>",
"     <li>",
"      Repair congenital heart lesions when feasible",
"     </li>",
"     <li>",
"      Resect atrial myxoma (indicated)",
"     </li>",
"     <li>",
"      Close major atrial septal defects, with the exception of an isolated patent foramen ovale, by surgery or transcatheter techniques",
"     </li>",
"     <li>",
"      Continue maintenance anticoagulation in children with prosthetic valve endocarditis (but not native valve endocarditis)",
"     </li>",
"     <li>",
"      For children at high risk of cardiac embolism unrelated to a PFO, treat initially with unfractionated",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/39/7801?source=see_link\">",
"       heparin",
"      </a>",
"      or low molecular weight heparin (LMWH) as a bridge to",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/4/21578?source=see_link\">",
"       warfarin",
"      </a>",
"      therapy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Alternatively, treat initially with LMWH and continue it for long-term anticoagulant therapy instead of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/4/21578?source=see_link\">",
"       warfarin",
"      </a>",
"     </li>",
"     <li>",
"      Continue LMWH or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/4/21578?source=see_link\">",
"       warfarin",
"      </a>",
"      for at least one year, or until the cardiac lesion responsible for the high risk of embolism has been corrected",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Continue anticoagulation indefinitely if the risk of recurrent embolism is judged to remain high",
"     </li>",
"     <li>",
"      For children with suspected cardiac embolism unrelated to PFO who have a lower or unknown risk of stroke, treat initially with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/10/19624?source=see_link\">",
"       aspirin",
"      </a>",
"      and continue for at least one year",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Since chronic anticoagulation therapy may benefit children at high risk for recurrent cardiogenic embolism, we refer all children with a cardioembolic source other than atrial fibrillation to a pediatric cardiologist for risk assessment and consideration of long-term oral anticoagulation. We suggest long-term therapy with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/10/19624?source=see_link\">",
"     aspirin",
"    </a>",
"    (3 to 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) if chronic anticoagulation is not employed.",
"   </p>",
"   <p>",
"    For children with cardioembolic stroke due to atrial fibrillation, we suggest long-term oral anticoagulation treatment using",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/4/21578?source=see_link\">",
"     warfarin",
"    </a>",
"    , with an international normalized ratio (INR) goal of 2.5 (acceptable INR range 2 to 3).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Arterial dissection",
"    </span>",
"    &nbsp;&mdash;&nbsp;For children with arterial ischemic stroke secondary to dissection, the ACCP guidelines recommend anticoagulant therapy with LMWH or vitamin K antagonist (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/4/21578?source=see_link\">",
"     warfarin",
"    </a>",
"    ) for at least six weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27063/abstract/4\">",
"     4",
"    </a>",
"    ]. Thereafter, ongoing anticoagulant treatment is dependent upon radiologic assessment of the stenosis and evidence of recurrent ischemic events.",
"   </p>",
"   <p>",
"    The AHA guidelines state that it is reasonable to treat arterial dissection in children with either anticoagulation (subcutaneous LMWH or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/4/21578?source=see_link\">",
"     warfarin",
"    </a>",
"    ) or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/10/19624?source=see_link\">",
"     aspirin",
"    </a>",
"    for three to six months [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27063/abstract/2\">",
"     2",
"    </a>",
"    ]. Extending anticoagulation therapy beyond six months is reasonable for children who develop recurrent symptoms. Continuing antiplatelet treatment beyond six months is reasonable, especially when there is radiologic evidence of a residual abnormality involving the dissected artery. The AHA guidelines recommend not using anticoagulation for children with an intracranial dissection or subarachnoid hemorrhage resulting from dissection.",
"   </p>",
"   <p>",
"    For children with ischemic stroke due to arterial dissection, we suggest anticoagulation with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/4/21578?source=see_link\">",
"     warfarin",
"    </a>",
"    or LMWH for three to six months after stroke onset, followed by long-term therapy with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/10/19624?source=see_link\">",
"     aspirin",
"    </a>",
"    (3 to 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/33/32281?source=see_link&amp;anchor=H7#H7\">",
"     \"Secondary prevention for specific causes of ischemic stroke and transient ischemic attack\", section on 'Dissection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Noninflammatory vasculopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;For children with arterial ischemic stroke related to a noninflammatory vasculopathy other than dissection, we suggest long-term therapy with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/10/19624?source=see_link\">",
"     aspirin",
"    </a>",
"    (3 to 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day). While one small observational study suggested that anticoagulation can be used safely for secondary stroke prevention in non-moyamoya vasculopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27063/abstract/7\">",
"     7",
"    </a>",
"    ], the safety and efficacy of anticoagulation have not been compared directly with aspirin. The ACCP guidelines recommend unfractionated",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/39/7801?source=see_link\">",
"     heparin",
"    </a>",
"    or low molecular weight heparin or aspirin for three months as initial therapy for children with arterial ischemic stroke secondary to non-moyamoya vasculopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27063/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Moyamoya",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of moyamoya disease is not established as there have been no randomized, controlled studies. Nevertheless, surgery is suggested in most children and young adult patients with symptomatic moyamoya disease, particularly in light of the ineffectiveness of medical treatment. This is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/36/7751?source=see_link\">",
"     \"Moyamoya disease: Prognosis and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with moyamoya associated with other diseases, it is important to treat the underlying condition when possible. The main example is sickle cell disease, where transfusion therapy is effective in primary and secondary stroke prevention. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/36/7751?source=see_link\">",
"     \"Moyamoya disease: Prognosis and treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/11/31930?source=see_link\">",
"     \"Cerebrovascular complications of sickle cell disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Sickle cell disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;A randomized trial of primary stroke prevention - the STOP study - found that chronic transfusion therapy prevents stroke in children with sickle cell disease who have elevated velocity (&gt;199",
"    <span class=\"nowrap\">",
"     cm/sec)",
"    </span>",
"    in the internal carotid or middle cerebral artery on screening transcranial Doppler evaluation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/11/31930?source=see_link&amp;anchor=H8#H8\">",
"     \"Cerebrovascular complications of sickle cell disease\", section on 'Prevention of a first stroke'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Chronic transfusion therapy also appears to be beneficial for prevention of recurrent stroke in sickle cell disease. The incidence can be reduced to below 10 percent when routine red blood cell transfusions are given to maintain the hemoglobin S fraction at less than 30 percent of total hemoglobin. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/11/31930?source=see_link&amp;anchor=H11#H11\">",
"     \"Cerebrovascular complications of sickle cell disease\", section on 'Prevention of recurrent stroke'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For children and young adults with sickle cell disease, we suggest chronic transfusion therapy to maintain hemoglobin S less than 30 percent of total hemoglobin. Similarly, consensus guidelines from the AHA recommend a long-term transfusion program for children with sickle cell disease and arterial ischemic stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27063/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Hypercoagulable state",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of hematologic disorders, including hypercoagulable states, may increase the risk of TIA and stroke. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/61/23513?source=see_link&amp;anchor=H7#H7\">",
"     \"Ischemic stroke in children and young adults: Etiology and clinical features\", section on 'Hematologic'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment of the underlying disorder may reduce this risk, but there are few data.",
"   </p>",
"   <p>",
"    No consensus exists regarding preventive treatment of recurrent arterial ischemic stroke in children with a hypercoagulable state. Guidelines from the Royal College of Physicians conclude that children with a prothrombotic tendency should be referred to a pediatric hematologist [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27063/abstract/1\">",
"     1",
"    </a>",
"    ]. The ACCP guidelines suggest daily",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/10/19624?source=see_link\">",
"     aspirin",
"    </a>",
"    therapy for a minimum of two years for children with arterial ischemic stroke, with or without thrombophilia, once arterial dissection or embolic causes have been excluded [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27063/abstract/4\">",
"     4",
"    </a>",
"    ]. For children on aspirin who have recurrent arterial ischemic stroke or TIA, the ACCP guidelines suggest changing to",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?15/49/16152?source=see_link\">",
"     clopidogrel",
"    </a>",
"    or anticoagulant therapy with low molecular weight",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/39/7801?source=see_link\">",
"     heparin",
"    </a>",
"    or vitamin K antagonist. The",
"    <span class=\"nowrap\">",
"     AHA/ASA",
"    </span>",
"    guidelines state that anticoagulation with low molecular weight heparin is useful, and anticoagulation with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/4/21578?source=see_link\">",
"     warfarin",
"    </a>",
"    is reasonable, for children with selected hypercoagulable states [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27063/abstract/2\">",
"     2",
"    </a>",
"    ]. However, the",
"    <span class=\"nowrap\">",
"     AHA/ASA",
"    </span>",
"    guidelines do not state the particular hypercoagulable states this recommendation applies to. Clinicians can glean some insight into approaches for treating these conditions in children from adult guidelines:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For adult patients with ischemic stroke or TIA and positive antiphospholipid antibodies, the",
"      <span class=\"nowrap\">",
"       AHA/ASA",
"      </span>",
"      guidelines state that antiplatelet therapy is reasonable [",
"      <a class=\"abstract\" href=\"UTD.htm?26/27/27063/abstract/3\">",
"       3",
"      </a>",
"      ]. For adult patients with ischemic stroke or TIA who meet criteria for the antiphospholipid syndrome with venous and arterial occlusive disease in multiple organs, miscarriages and livedo reticularis, the",
"      <span class=\"nowrap\">",
"       AHA/ASA",
"      </span>",
"      guidelines note that oral anticoagulation with a target INR of 2 to 3 is reasonable [",
"      <a class=\"abstract\" href=\"UTD.htm?26/27/27063/abstract/3\">",
"       3",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/12/23754?source=see_link\">",
"       \"Treatment of the antiphospholipid syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For adult patients with ischemic stroke or TIA who have an established inherited thrombophilia, the",
"      <span class=\"nowrap\">",
"       AHA/ASA",
"      </span>",
"      guidelines recommend evaluating for deep vein thrombosis, which is an indication for short- or long-term anticoagulation, depending on the clinical and hematologic circumstances [",
"      <a class=\"abstract\" href=\"UTD.htm?26/27/27063/abstract/3\">",
"       3",
"      </a>",
"      ]. In the absence of venous thrombosis, either anticoagulation or antiplatelet therapy for adults is considered reasonable. For adults with an inherited thrombophilia and a history of spontaneous cerebral venous thrombosis or recurrent thrombotic events, the guidelines state that long-term anticoagulation is probably indicated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    During the acute phase of arterial stroke in children with a confirmed hypercoagulable state, we suggest anticoagulation treatment with intravenous unfractionated",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/39/7801?source=see_link\">",
"     heparin",
"    </a>",
"    or subcutaneous low molecular weight heparin for five to seven days, followed by treatment with low molecular weight heparin or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/4/21578?source=see_link\">",
"     warfarin",
"    </a>",
"    for three to six months.",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/10/19624?source=see_link\">",
"     Aspirin",
"    </a>",
"    is used if there is a contraindication to anticoagulation. This issue is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/37/43608?source=see_link&amp;anchor=H13#H13\">",
"     \"Ischemic stroke in children: Evaluation, initial management, and prognosis\", section on 'Acute treatment for specific causes of arterial ischemic stroke'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For decisions about long-term secondary stroke prevention, we refer children with arterial ischemic stroke and a hypercoagulable state to a pediatric hematologist, since long-term oral anticoagulation may benefit patients who have venous thrombosis, recurrent thrombotic events, or the antiphospholipid syndrome. Because the precise role of prothrombotic states in stroke pathophysiology remains unclear, clinical practice regarding screening for prothrombotic states and subsequent treatment varies by center. We suggest long-term therapy with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/10/19624?source=see_link\">",
"     aspirin",
"    </a>",
"    (3 to 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) if long-term anticoagulation is not employed.",
"   </p>",
"   <p>",
"    The evaluation and management of a number of prothrombotic conditions is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/36/24136?source=see_link\">",
"     \"Antithrombin (ATIII) deficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/52/841?source=see_link\">",
"     \"Protein C deficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/55/13176?source=see_link\">",
"     \"Protein S deficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/35/28218?source=see_link\">",
"     \"Activated protein C resistance and factor V Leiden\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/16/20743?source=see_link\">",
"     \"Prothrombin gene mutation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/12/23752?source=see_link\">",
"     \"Management of inherited thrombophilia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/37/19034?source=see_link\">",
"     \"Overview of homocysteine\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The treatment of venous thromboembolism in children related to hereditary and acquired thrombotic disorders is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/57/14234?source=see_link\">",
"     \"Diagnosis and treatment of venous thrombosis and thromboembolism in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Vasculitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Consensus guidelines do not address the prevention of arterial ischemic stroke caused by vasculitis in children or adults, other than noting that immunosuppressive agents may be required [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27063/abstract/4\">",
"     4",
"    </a>",
"    ]. The treatment of vasculitis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/27/9657?source=see_link\">",
"     \"Overview of the management of vasculitis in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/17/28949?source=see_link\">",
"     \"Overview of the management of the vasculitides in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Cryptogenic stroke",
"    </span>",
"    &nbsp;&mdash;&nbsp;Under the TOAST classification scheme, which is the most commonly used system in clinical practice for adults, the category of cryptogenic stroke is defined as brain infarction that is not attributable to a source of definite cardioembolism, large artery atherosclerosis, small artery disease, or other determined etiology despite a comprehensive vascular, cardiac, and serologic evaluation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/10/40105?source=see_link&amp;anchor=H2#H2\">",
"     \"Cryptogenic stroke\", section on 'Definition'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The list of other determined etiologies for ischemic stroke is quite extensive and includes the following [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27063/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Abnormalities of thrombosis and hemostasis",
"     </li>",
"     <li>",
"      Acute and chronic arterial dissection",
"     </li>",
"     <li>",
"      Acute disseminated intravascular coagulation",
"     </li>",
"     <li>",
"      Cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy",
"     </li>",
"     <li>",
"      Cerebral vasculitis",
"     </li>",
"     <li>",
"      Cerebral venous thrombosis",
"     </li>",
"     <li>",
"      Clinically relevant cerebral aneurysm",
"     </li>",
"     <li>",
"      Drug-induced stroke",
"     </li>",
"     <li>",
"      Fibromuscular dysplasia",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/39/7801?source=see_link\">",
"       Heparin",
"      </a>",
"      -induced thrombocytopenia type II",
"     </li>",
"     <li>",
"      Hyperviscosity syndromes",
"     </li>",
"     <li>",
"      Hypoperfusion syndromes",
"     </li>",
"     <li>",
"      Iatrogenic causes",
"     </li>",
"     <li>",
"      Meningitis",
"     </li>",
"     <li>",
"      Migraine-induced stroke",
"     </li>",
"     <li>",
"      Mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes (MELAS)",
"     </li>",
"     <li>",
"      Moyamoya disease",
"     </li>",
"     <li>",
"      Primary antiphospholipid antibody syndrome",
"     </li>",
"     <li>",
"      Primary infection of the arterial wall",
"     </li>",
"     <li>",
"      Segmental vasoconstriction or vasospasm",
"     </li>",
"     <li>",
"      Sickle cell disease",
"     </li>",
"     <li>",
"      Sneddon syndrome",
"     </li>",
"     <li>",
"      Thrombotic thrombocytopenic purpura&ndash;hemolytic uremic syndrome",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the absence of these conditions, we suggest long-term therapy with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/10/19624?source=see_link\">",
"     aspirin",
"    </a>",
"    (3 to 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) rather than anticoagulation for children who have cryptogenic arterial ischemic stroke.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Recurrent ischemia despite aspirin",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the setting of recurrent ischemic stroke or TIA in children on",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/10/19624?source=see_link\">",
"     aspirin",
"    </a>",
"    therapy, we suggest changing therapy to either",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?15/49/16152?source=see_link\">",
"     clopidogrel",
"    </a>",
"    or anticoagulation (with low molecular weight",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/39/7801?source=see_link\">",
"     heparin",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/4/21578?source=see_link\">",
"     warfarin",
"    </a>",
"    ). Consensus guidelines make similar recommendations [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27063/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For children with cardioembolic stroke due to atrial fibrillation, we suggest long-term oral anticoagulation treatment using",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/4/21578?source=see_link\">",
"       warfarin",
"      </a>",
"      rather than",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/10/19624?source=see_link\">",
"       aspirin",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Cardioembolic stroke'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For children with arterial ischemic stroke and a cardioembolic source other than atrial fibrillation, we consult with a pediatric cardiologist for risk assessment and decisions about secondary stroke prevention and chronic anticoagulation. We suggest long-term therapy with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/10/19624?source=see_link\">",
"       aspirin",
"      </a>",
"      if chronic anticoagulation is not employed. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Cardioembolic stroke'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For children with ischemic stroke due to arterial dissection, we suggest anticoagulation with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/4/21578?source=see_link\">",
"       warfarin",
"      </a>",
"      or low molecular weight",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/39/7801?source=see_link\">",
"       heparin",
"      </a>",
"      for three to six months after stroke onset, followed by long-term therapy with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/10/19624?source=see_link\">",
"       aspirin",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Arterial dissection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For children with arterial ischemic stroke related to a noninflammatory vasculopathy other than dissection, we suggest long-term therapy with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/10/19624?source=see_link\">",
"       aspirin",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Noninflammatory vasculopathy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For children with ischemic-type moyamoya, we suggest surgical revascularization at a center with expertise in the surgical treatment of moyamoya (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). This issue is discussed in greater detail separately. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Moyamoya'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/36/7751?source=see_link\">",
"       \"Moyamoya disease: Prognosis and treatment\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For children with sickle cell disease, we suggest chronic transfusion therapy to maintain hemoglobin S less than 30 percent of total hemoglobin (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). This issue is discussed in greater detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/11/31930?source=see_link\">",
"       \"Cerebrovascular complications of sickle cell disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For children with stroke related to vasculitis, treatment of the underlying condition may be beneficial. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/27/9657?source=see_link\">",
"       \"Overview of the management of vasculitis in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/17/28949?source=see_link\">",
"       \"Overview of the management of the vasculitides in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For children with arterial ischemic stroke and a hypercoagulable state, we consult with a hematologist for decisions about secondary stroke prevention and long-term anticoagulation. We suggest long-term therapy with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/10/19624?source=see_link\">",
"       aspirin",
"      </a>",
"      if long-term anticoagulation is not employed. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Hypercoagulable state'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For children with cryptogenic arterial ischemic stroke, we suggest long-term therapy with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/10/19624?source=see_link\">",
"       aspirin",
"      </a>",
"      rather than anticoagulation (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Cryptogenic stroke'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For children on",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/10/19624?source=see_link\">",
"       aspirin",
"      </a>",
"      who have recurrent arterial ischemic stroke or TIA, we suggest changing to either",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?15/49/16152?source=see_link\">",
"       clopidogrel",
"      </a>",
"      monotherapy or anticoagulation (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Recurrent ischemia despite aspirin'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Paediatric Stroke Working Group. Stroke in childhood: Clinical guidelines for diagnosis, management and rehabilitation. 2004. file://bookshop.rcplondon.ac.uk/details.aspx?e=156 (Accessed on March 27, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27063/abstract/2\">",
"      Roach ES, Golomb MR, Adams R, et al. Management of stroke in infants and children: a scientific statement from a Special Writing Group of the American Heart Association Stroke Council and the Council on Cardiovascular Disease in the Young. Stroke 2008; 39:2644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27063/abstract/3\">",
"      Furie KL, Kasner SE, Adams RJ, et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the american heart association/american stroke association. Stroke 2011; 42:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27063/abstract/4\">",
"      Monagle P, Chan AK, Goldenberg NA, et al. Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e737S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27063/abstract/5\">",
"      Soman T, Rafay MF, Hune S, et al. The risks and safety of clopidogrel in pediatric arterial ischemic stroke. Stroke 2006; 37:1120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27063/abstract/6\">",
"      Schr&ouml;r K. Aspirin and Reye syndrome: a review of the evidence. Paediatr Drugs 2007; 9:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27063/abstract/7\">",
"      Bernard TJ, Goldenberg NA, Tripputi M, et al. Anticoagulation in childhood-onset arterial ischemic stroke with non-moyamoya arteriopathy: findings from the Colorado and German (COAG) collaboration. Stroke 2009; 40:2869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27063/abstract/8\">",
"      Ay H, Benner T, Arsava EM, et al. A computerized algorithm for etiologic classification of ischemic stroke: the Causative Classification of Stroke System. Stroke 2007; 38:2979.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6215 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.247-9F549ED38C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_27_27063=[""].join("\n");
var outline_f26_27_27063=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SECONDARY PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Risk factor reduction in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Cardioembolic stroke",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Arterial dissection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Noninflammatory vasculopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Moyamoya",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Hypercoagulable state",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Vasculitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Cryptogenic stroke",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Recurrent ischemia despite aspirin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/35/28218?source=related_link\">",
"      Activated protein C resistance and factor V Leiden",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/35/2618?source=related_link\">",
"      Antiplatelet therapy for secondary prevention of stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/36/24136?source=related_link\">",
"      Antithrombin (ATIII) deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/11/31930?source=related_link\">",
"      Cerebrovascular complications of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/10/40105?source=related_link\">",
"      Cryptogenic stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/57/14234?source=related_link\">",
"      Diagnosis and treatment of venous thrombosis and thromboembolism in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/26/7594?source=related_link\">",
"      Etiology, clinical features, and diagnosis of cerebral venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/61/23513?source=related_link\">",
"      Ischemic stroke in children and young adults: Etiology and clinical features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/37/43608?source=related_link\">",
"      Ischemic stroke in children: Evaluation, initial management, and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/12/23752?source=related_link\">",
"      Management of inherited thrombophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/36/7751?source=related_link\">",
"      Moyamoya disease: Prognosis and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/49/27414?source=related_link\">",
"      Neurologic manifestations of Fabry disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/37/19034?source=related_link\">",
"      Overview of homocysteine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/17/28949?source=related_link\">",
"      Overview of the management of the vasculitides in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/27/9657?source=related_link\">",
"      Overview of the management of vasculitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/52/841?source=related_link\">",
"      Protein C deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/55/13176?source=related_link\">",
"      Protein S deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/16/20743?source=related_link\">",
"      Prothrombin gene mutation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/18/27946?source=related_link\">",
"      Seasonal influenza vaccination in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/33/32281?source=related_link\">",
"      Secondary prevention for specific causes of ischemic stroke and transient ischemic attack",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39818?source=related_link\">",
"      Standard immunizations for children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/2/27690?source=related_link\">",
"      Stroke in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/23/40313?source=related_link\">",
"      Treatment of Fabry disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/12/23754?source=related_link\">",
"      Treatment of the antiphospholipid syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_27_27064="Pegylated interferon (peginterferon) alfa-2a: Drug information";
var content_f26_27_27064=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Pegylated interferon (peginterferon) alfa-2a: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?21/3/21558?source=see_link\">",
"    see \"Pegylated interferon (peginterferon) alfa-2a: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/61/8152?source=see_link\">",
"    see \"Pegylated interferon (peginterferon) alfa-2a: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709197\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information. For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F206899\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Pegasys&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F206900\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Pegasys&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F206919\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Interferon",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F206903\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chronic hepatitis C (monoinfection or coinfection with HIV):",
"     </b>",
"     SubQ: 180 mcg once weekly for 48 weeks as monotherapy or in combination with ribavirin (Copegus&reg;)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Duration of combination therapy: Monoinfection (based on genotype):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Genotypes 1,4: 48 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Genotypes 2,3: 24 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Genotypes 5,6: No dosing recommendations provided; data insufficient",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Duration of therapy: Coinfection with HIV: 48 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     <i>",
"      American Association for the Study of Liver Diseases (AASLD) guidelines recommendation:",
"     </i>",
"     Adults with chronic HCV infection (Ghany, 2009): Treatment of choice: Ribavirin plus",
"     <b>",
"      peginterferon",
"     </b>",
"     ; clinical condition and ability of patient to tolerate therapy should be evaluated to determine length and/or likely benefit of therapy. Recommended treatment duration (AASLD guidelines): Genotypes 1,4: 48 weeks; Genotypes 2,3: 24 weeks; Coinfection with HIV: 48 weeks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chronic hepatitis B:",
"     </b>",
"     SubQ: 180 mcg once weekly for 48 weeks",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F15043485\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/61/8152?source=see_link\">",
"      see \"Pegylated interferon (peginterferon) alfa-2a: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Chronic hepatitis C:",
"     </b>",
"     Children &ge;5 years and Adolescents: SubQ: 180 mcg/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     x body surface area (BSA) once weekly (maximum dose: 180 mcg) with ribavirin (Copegus&reg;)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Duration of therapy (based on genotype):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Genotypes 1,4,5,6: 48 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Genotypes 2,3: 24 weeks",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F3062247\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F206904\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Children: No dosage adjustment provided in manufacturer's labeling (has not been studied).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;30 mL/minute: No adjustment required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute: 135 mcg weekly; monitor for toxicity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     End-stage renal disease (ESRD) requiring hemodialysis: 135 mcg weekly; monitor for toxicity",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F206905\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children: HCV:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ALT &ge;5 but &lt;10 x ULN: Decrease interferon dose to 135 mcg/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     x BSA once weekly. Monitor weekly; further modify dose if needed until ALT stabilizes or decreases.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ALT &ge;10 x ULN (persistent): Discontinue interferon.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     HCV: ALT progressively rising above baseline: Decrease dose to 135 mcg weekly",
"     <b>",
"      and",
"     </b>",
"     monitor LFTs more frequently. If ALT continues to rise despite dose reduction or ALT increase is accompanied by increased bilirubin or hepatic decompensation, discontinue therapy immediately. Therapy may resume after ALT flare subsides.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     HBV:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     ALT &gt;5 x ULN: Consider decreasing dose to 135 mcg weekly or temporarily discontinuing (may resume after ALT flare subsides)",
"     <b>",
"      and",
"     </b>",
"     monitor LFTs more frequently. If ALT continues to rise despite dose reduction or ALT increase is accompanied by increased bilirubin or hepatic decompensation, discontinue therapy immediately.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     ALT &gt;10 x ULN: Consider discontinuing.",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F3022885\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;display:inline\">",
"     <b>",
"      Dosage modifications for adverse reactions and/or toxicity:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Children &ge;5 years: HCV:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Moderate-to-severe adverse reactions:",
"     </i>",
"     Decrease to 135 mcg/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     x BSA once weekly for initial dose reduction; further dose reductions to 90 mcg/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     x BSA once weekly or 45 mcg/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     x BSA once weekly may be necessary in some cases if reaction persists or recurs. Up to 3 dosing adjustments for toxicity may be made before discontinuation is considered.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Based on hematologic parameters:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     ANC 750-999/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Week 1-2: 135 mcg/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     x BSA once weekly; Weeks 3-48: No modification",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     ANC 500-749/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Week 1-2: Hold dose until ANC &gt;750/mm",
"     <sup>",
"      3",
"     </sup>",
"     then resume dose with 135 mcg/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     x BSA once weekly. Assess WBC weekly for 3 weeks to verify ANC &gt;750/mm",
"     <sup>",
"      3",
"     </sup>",
"     ; Weeks 3-48: 135 mcg/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     x BSA once weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     ANC 250-499/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Week 1-2: Hold dose until ANC &gt;750/mm",
"     <sup>",
"      3",
"     </sup>",
"     then resume dose with 90 mcg/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     x BSA once weekly; Weeks 3-48: Hold dose until ANC &gt;750/mm",
"     <sup>",
"      3",
"     </sup>",
"     then resume dose with 135 mcg/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     x BSA once weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     ANC &lt;250/mm",
"     <sup>",
"      3",
"     </sup>",
"     (or febrile neutropenia): Discontinue treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Platelet count &lt;50,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     : 90 mcg/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     x BSA once weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Depression (severity based on DSM-IV criteria",
"     </i>",
"     [similar to adult dosing adjustment recommendations]):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Mild depression: No dosage adjustment required; evaluate once weekly by visit/phone call. If depression remains stable, continue weekly visits. If depression improves, resume normal visit schedule",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Moderate depression: Decrease interferon dose to 135 mcg/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     x BSA once weekly (or to 90 mcg/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     x BSA once weekly",
"     <b>",
"      or",
"     </b>",
"     45 mcg/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     x BSA once weekly); evaluate once weekly with an office visit at least every other week. If depression remains stable, consider psychiatric evaluation and continue reduced dosing. If symptoms improve and remain stable for 4 weeks, resume normal visit schedule; continue reduced dosing or return to normal dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Severe depression: Discontinue interferon permanently. Obtain immediate psychiatric consultation. Discontinue ribavirin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Adults: HCV, HBV:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Moderate-to-severe adverse reactions:",
"     </i>",
"     Decrease to 135 mcg weekly for initial dose reduction; further dose reductions to 90 mcg weekly may be necessary in some cases if reaction persists or recurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Based on hematologic parameters:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     ANC &lt;750/mm",
"     <sup>",
"      3",
"     </sup>",
"     : 135 mcg weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     ANC &lt;500/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Suspend therapy until &gt;1000/mm",
"     <sup>",
"      3",
"     </sup>",
"     , then restart at 90 mcg weekly; monitor ANC",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Platelet count &lt;50,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     : 90 mcg weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Platelet count &lt;25,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Discontinue therapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Depression (severity based on DSM-IV criteria):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Mild depression: No dosage adjustment required; evaluate once weekly by visit/phone call. If depression remains stable, continue weekly visits. If depression improves, resume normal visit schedule",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Moderate depression: Decrease interferon dose to 135 mcg once weekly (or to 90 mcg once weekly); evaluate once weekly with an office visit at least every other week. If depression remains stable, consider psychiatric evaluation and continue with reduced dosing. If symptoms improve and remain stable for 4 weeks, resume normal visit schedule; continue reduced dosing or return to normal dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Severe depression: Discontinue interferon permanently. Obtain immediate psychiatric consultation.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F206881\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pegasys&reg;: 180 mcg/mL (1 mL) [contains benzyl alcohol, polysorbate 80; vial]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pegasys&reg;: 135 mcg/0.5 mL (0.5 mL); 180 mcg/0.5 mL (0.5 mL) [contains benzyl alcohol, polysorbate 80; autoinjector]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pegasys&reg;: 180 mcg/0.5 mL (0.5 mL) [contains benzyl alcohol, polysorbate 80; prefilled syringe]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F206867\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874941\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088679.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088679.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F206883\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     SubQ: Administer in the abdomen or thigh. Rotate injection site. Do not use if solution contains particulate matter or is discolored. Discard unused solution. Administration should be done on the same day and at approximately the same time each week.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F206882\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of chronic hepatitis C (CHC), in combination with ribavirin (unless contraindicated or significant intolerance to ribavirin), in patients &ge;5 years of age with compensated liver disease and not previously treated with alfa interferons, in patients with histological evidence of cirrhosis (Child-Pugh class A) and compensated liver disease; treatment of adults coinfected with CHC and clinically-stable HIV disease (CD4 count &gt;100 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     ); treatment (monotherapy) of adults with HBeAg-positive and HBeAg-negative chronic hepatitis B with compensated liver disease and evidence of viral replication and liver inflammation",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F206917\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Percentages are reported for peginterferon alfa-2a in chronic hepatitis C (CHC) patients. Other percentages indicated as &ldquo;with ribavirin&rdquo; or &ldquo;in HIV/CHC&rdquo; are those which significantly exceed incidence reported for peginterferon monotherapy in CHC patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (54%), fatigue (56%), fever (37%; 41% with ribavirin; 54% in hepatitis B), insomnia (19%; 30% with ribavirin), depression (18%), dizziness (16%), irritability/anxiety/nervousness (19%; 33% with ribavirin), pain (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Alopecia (23%; 28% with ribavirin), pruritus (12%; 19% with ribavirin), dermatitis (16% with ribavirin)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Growth suppression (children) percentile decrease (&ge;15 percentiles), weight (43%), height (25%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea/vomiting (24%), anorexia (17%; 24% with ribavirin), diarrhea (16%), weight loss (16% in HIV/CHC), abdominal pain (15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Neutropenia (21%; 27% with ribavirin; 40% in HIV/CHC), lymphopenia (14% with ribavirin), anemia (11% with ribavirin; 14% in HIV/CHC)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: ALT increases 5-10 x ULN during treatment (25% to 27% in hepatitis B); ALT increases &gt;10 x ULN during treatment (12% to 18% in hepatitis B); ALT increases 5-10 x ULN after treatment (13% to 16% in hepatitis B); ALT increases &gt;10 x ULN after treatment (7% to 12% in hepatitis B)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site reaction (22%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness (56%; 65% with ribavirin), myalgia (37%), rigors (35%; 25% to 27% in hepatitis B), arthralgia (28%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Dyspnea (13% with ribavirin)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Concentration impaired (8%), memory impaired (5%), mood alteration (3%; 9% in HIV/CHC)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Dermatitis (8%), rash (5%), dry skin (4%; 10% with ribavirin), eczema (1%; 5% with ribavirin)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypothyroidism (3% to 4%), hyperthyroidism (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Xerostomia (6%), dyspepsia (&lt;1%; 6% with ribavirin), weight loss (4%; 10% with ribavirin)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Thrombocytopenia (5%; 8% in HIV/CHC), lymphopenia (3%), anemia (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Hepatic decompensation (2% in CHC/HIV)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain (9%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Blurred vision (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Cough (4%; 10% with ribavirin), dyspnea (4%), exertional dyspnea (4% with ribavirin)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis (6%), bacterial infection (3%; 5% in HIV/CHC)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &le;1% (Limited to important or life-threatening): Aggression, anaphylaxis, angioedema, angina, aplastic anemia, arrhythmia, autoimmune disorders, bronchiolitis obliterans, bronchoconstriction, cerebral hemorrhage, chest pain, cholangitis, colitis, coma, corneal ulcer, cotton wool spots, dehydration, diabetes mellitus, endocarditis, erythema multiforme major, exertional dyspnea, exfoliative dermatitis, fatty liver, gastrointestinal bleeding, hallucination, hearing impairment, hearing loss, hemoglobin decreased, hematocrit decreased, hepatic dysfunction, hepatic graft rejection, hepatitis B flares, hyper-/hypoglycemia, hypersensitivity reactions, hypertension, influenza, interstitial pneumonitis, macular edema, MI, myositis, optic neuritis, papilledema, pancreatitis, peptic ulcer, peripheral neuropathy, pneumonia, psychiatric disorder, psychosis, pulmonary embolism, pulmonary infiltrates, pure red cell aplasia, renal graft rejection, retinal artery/vein thrombosis, retinal detachment, retinal hemorrhage, retinopathy, rheumatoid arthritis, sarcoidosis, seizures, Stevens-Johnson syndrome, substance overdose, suicidal ideation, suicide, supraventricular arrhythmia, systemic lupus erythematosus, thrombotic thrombocytopenic purpura, triglycerides (increased), urticaria, vesiculobullous eruptions, vision decreased/loss",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F206886\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to polyethylene glycol (PEG), interferon alfa, or any component of the formulation; autoimmune hepatitis; decompensated liver disease in cirrhotic patients (Child-Pugh score &gt;6); decompensated liver disease (Child-Pugh score &ge;6, class B and C) in CHC coinfected with HIV; neonates and infants",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F206870\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bone marrow suppression: May cause myelosuppression (including neutropenia, thrombocytopenia, lymphopenia, aplastic anemia). Use caution with baseline neutrophil count &lt;1500/mm",
"     <sup>",
"      3",
"     </sup>",
"     , platelet count &lt;90,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     or hemoglobin &lt;10 g/dL. Discontinue therapy (at least temporarily) if ANC &lt;500/mm",
"     <sup>",
"      3",
"     </sup>",
"     or platelet count &lt;25,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS effects: Patients who experience dizziness, confusion, somnolence, or fatigue should use caution when performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dermatologic effects: Serious cutaneous reactions, including vesiculobullous eruptions, Stevens-Johnson syndrome, and exfoliative dermatitis, have been reported (rarely) with use, with or without ribavirin therapy; discontinue with signs or symptoms of severe skin reactions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Flu-like symptoms: Interferon therapy is commonly associated with flu-like symptoms, including fever; however, rule out other causes/infection with persistent or high fever.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal effects: Gastrointestinal hemorrhage, ulcerative and hemorrhagic/ischemic colitis have been observed with interferon alfa treatment; may be severe and/or life-threatening; discontinue if symptoms of colitis (eg, abdominal pain, bloody diarrhea, and/or fever) develop. Colitis generally resolves within 1-3 weeks of discontinuation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic effects: Hepatic decompensation and death have been associated with the use of alpha interferons including Pegasys&reg;, in cirrhotic chronic hepatitis C patients; patients coinfected with HIV and receiving highly active antiretroviral therapy have shown an increased risk. Monitor hepatic function closely during use; discontinue if decompensation occurs (Child-Pugh score &gt;6) in monoinfected patients and (Child-Pugh score &ge;6, class B and C) in patients coinfected with HIV.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Severe acute hypersensitivity reactions, including anaphylaxis, have occurred rarely; prompt discontinuation is advised.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neuropsychiatric disorders:",
"     <b>",
"      [U.S. Boxed Warning]: May cause or exacerbate life-threatening neuropsychiatric disorders; monitor closely; discontinue treatment with worsening or persistently severe signs/symptoms of neuropsychiatric disorders. In most cases these effects were reversible following discontinuation, but not all cases.",
"     </b>",
"     Neuropsychiatric adverse effects include depression, suicidal ideation, suicide attempt, homicidal ideation, drug overdose, and relapse of drug addiction, and may occur in patients with or without a prior history of psychiatric disorder. Avoid use in severe psychiatric disorders; use with extreme caution in patients with a history of depression.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ocular effects: Discontinue if new or worsening ophthalmologic disorders occur including decreased vision, retinal hemorrhages, retinal detachment (serous), cotton wool spots, and retinal artery or vein obstruction; if any ocular symptoms occur during use, a complete eye exam should be performed promptly. Prior to use, all patients should have a visual exam and patients with pre-existing disorders (eg, diabetic or hypertensive retinopathy) should have exams periodically during therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pancreatitis: Discontinue therapy if known or suspected pancreatitis develops.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pulmonary effects: May cause or aggravate dyspnea, pulmonary infiltrates, pneumonia, bronchiolitis obliterans, interstitial pneumonia, and sarcoidosis, resulting in potentially fatal respiratory failure; may recur upon rechallenge with interferons. Discontinue with unexplained pulmonary infiltrates or evidence of impaired pulmonary function. Use with caution in patients with pulmonary dysfunction or a history of pulmonary disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anemia: Use with caution in patients with an increased risk for severe anemia (eg, spherocytosis, history of GI bleeding).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Autoimmune disease:",
"     <b>",
"      [U.S. Boxed Warning]: May cause or exacerbate autoimmune disorders; monitor closely; discontinue treatment in patients with worsening or persistently severe signs/symptoms of autoimmune disease.",
"     </b>",
"     Thyroiditis, thrombotic thrombocytopenic purpura, idiopathic thrombocytopenic purpura, rheumatoid arthritis, interstitial nephritis, systemic lupus erythematosus, and psoriasis have been reported with interferon therapy; use with caution in patients with autoimmune disorders.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with prior cardiovascular disease; hypertension, arrhythmia, chest pain, and MI have been observed with treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus; hyper/hypoglycemia have been reported; may require adjustments in antidiabetic medications; discontinue peginterferon alfa-2a if unable to effectively manage diabetes with medication.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatitis B: In hepatitis B patients, flares (transient and potentially severe increases in serum ALT) may occur during or after treatment; more frequent monitoring of LFTs and a dose reduction are recommended. Discontinue if ALT elevation continues despite dose reduction or if increased bilirubin or hepatic decompensation occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Infectious disorders:",
"     <b>",
"      [U.S. Boxed Warning]: May cause or aggravate infectious disorders; monitor closely; discontinue treatment in patients with worsening or persistently severe signs/symptoms of infectious disorders.",
"     </b>",
"     Serious and severe infections (bacterial, viral, and fungal) have been reported with treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ischemic disorders:",
"     <b>",
"      [U.S. Boxed Warning]: May cause or aggravate ischemic disorders and hemorrhagic cerebrovascular events; monitor closely; discontinue treatment in patients with worsening or persistent ischemia",
"     </b>",
"     . Has been reported in patients without risk factors for stroke.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal dysfunction (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute); dosage adjustment recommended; monitor for signs/symptoms of toxicity (dosage adjustment required if toxicity occurs).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid disorders: Use with caution in patients with pre-existing thyroid disease; thyroid disorders (hyper- or hypothyroidism) or exacerbations have been reported; discontinue peginterferon alfa-2a if unable to effectively manage with medication.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Combination therapy with ribavirin:",
"     <b>",
"      [U.S. Boxed Warning]: Combination treatment with ribavirin may cause birth defects and/or fetal mortality; hemolytic anemia (which may worsen cardiac disease), genotoxicity, mutagenicity, and may possibly be carcinogenic.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly; certain adverse effects (eg, neuropsychiatric, cardiac, flu-like reactions) may be more severe.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Delay in weight and height increases have been noted in children treated with interferon alfa and concomitant ribavirin for 48 weeks. At two-year follow up after treatment, most children had returned to their baseline growth curve percentiles.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pregnancy:",
"     <b>",
"      [U.S. Boxed Warning]: Combination therapy with ribavirin may cause birth defects; avoid pregnancy in females and female partners of male patients.",
"     </b>",
"     Combination therapy with ribavirin is contraindicated in pregnancy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Product variability:",
"     <b>",
"      Due to differences in dosage, patients should not change brands of interferon without the concurrence of their healthcare provider.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate monitoring: Pretreatment hematological and biochemical tests are recommended for all patients; pregnancy screening (if woman of childbearing age) and ECG (if preexisting cardiac abnormalities) are also recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Safety and efficacy have not been established in patients who have failed other alpha interferon therapy, have received liver or other organ transplants, have been coinfected with HBV",
"     <b>",
"      and",
"     </b>",
"     HCV or HIV, have been coinfected with HCV",
"     <b>",
"      and",
"     </b>",
"     HBV or HIV with a CD4",
"     <sup>",
"      +",
"     </sup>",
"     cell count &lt;100 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     , or been treated for &gt;48 weeks.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F206913\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F206874\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aldesleukin: Interferons (Alfa) may enhance the adverse/toxic effect of Aldesleukin. In particular, risks of myocardial and renal toxicity may be increased by this combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methadone: Interferons (Alfa) may increase the serum concentration of Methadone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegloticase: May diminish the therapeutic effect of Peginterferon Alfa-2a.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ribavirin: Interferons (Alfa) may enhance the adverse/toxic effect of Ribavirin. Hemolytic anemia has been observed.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telbivudine: Peginterferon Alfa-2a may enhance the adverse/toxic effect of Telbivudine. Specifically, the risk for peripheral neuropathy may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Interferons may decrease the metabolism of Theophylline Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dyphylline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zidovudine: Interferons may enhance the adverse/toxic effect of Zidovudine. Interferons may decrease the metabolism of Zidovudine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F206896\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ethanol: Avoid use in patients with hepatitis C virus.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F206876\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C / X in combination with ribavirin (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F206889\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reproduction studies with pegylated interferon alfa have not been conducted. Animal studies with nonpegylated interferon alfa-2b have demonstrated abortifacient effects. Disruption of the normal menstrual cycle was also observed in animal studies; therefore, the manufacturer recommends that reliable contraception is used in women of childbearing potential. Alfa interferon is endogenous to normal amniotic fluid.",
"     <i>",
"      In vitro",
"     </i>",
"     administration studies have reported that when administered to the mother, it does not cross the placenta. Case reports of use in pregnant women are limited. The Perinatal HIV Guidelines Working Group does not recommend that peginterferon-alfa be used during pregnancy. Peginterferon monotherapy should only be used in pregnancy when the potential benefit to the mother justifies the possible risk to the fetus.",
"     <b>",
"      [U.S. Boxed Warning]: Combination therapy with ribavirin may cause birth defects; avoid pregnancy in females and female partners of male patients;",
"     </b>",
"     combination therapy with ribavirin is contraindicated in pregnancy (refer to Ribavirin monograph); a pregnancy registry has been established for women inadvertently exposed to ribavirin while pregnant (800-593-2214).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F206908\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F5366118\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Breast milk samples obtained from a lactating mother prior to and after administration of interferon alfa-2b showed that interferon alfa is present in breast milk and administration of the medication did not significantly affect endogenous levels. Breast-feeding is not linked to the spread of hepatitis C virus; however, if nipples are cracked or bleeding, breast-feeding is not recommended. Mothers coinfected with HIV are discouraged from breast-feeding to decrease potential transmission of HIV.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F206890\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid ethanol use in patients with hepatitis C virus.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F206888\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Kit",
"     </b>",
"     (Pegasys Subcutaneous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     180 mcg/0.5 mL (1): $3233.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Pegasys ProClick Subcutaneous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     135 mcg/0.5 mL (0.5 mL): $808.38",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     180 mcg/0.5 mL (0.5 mL): $808.38",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Pegasys Subcutaneous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     180 mcg/0.5 mL (0.5 mL): $808.38",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     180 mcg/mL (1 mL): $808.38",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F206878\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Clinical studies tested as follows:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: Hematologic and biochemical assessments were made at weeks 1, 3, 5, and 8, and then every 4 weeks thereafter; TSH measured every 12 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: CBC (including hemoglobin, WBC, and platelets) and chemistries (including liver function tests and uric acid) measured at weeks 1, 2, 4, 6, and 8, and then every 4-6 weeks (more frequently if abnormal); TSH measured every 12 weeks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     In addition, the following baseline values were used as entrance criteria in adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Platelet count &ge;90,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     (as low as 75,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     in patients with cirrhosis or 70,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     in patients with CHC coinfected with HIV)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ANC &ge;1500/mm",
"     <sup>",
"      3",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Serum creatinine &lt;1.5 times ULN",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     TSH and T",
"     <sub>",
"      4",
"     </sub>",
"     within normal limits or adequately controlled",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     CD4",
"     <sup>",
"      +",
"     </sup>",
"     cell count &ge;200 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     or CD4",
"     <sup>",
"      +",
"     </sup>",
"     cell count &ge;100 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     , but &lt;200 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     <b>",
"      and",
"     </b>",
"     HIV-1 RNA &lt;5000 copies/mL in CHC patients coinfected with HIV",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hemoglobin &ge;12 g/dL for women and &ge;13 g/dL for men in CHC monoinfected patients",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hemoglobin &ge;11 g/dL for women and &ge;12 g/dL for men in CHC patients coinfected with HIV",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     Serum HCV RNA levels (pretreatment, 12- and 24 weeks after therapy initiation, 24 weeks after completion of therapy).",
"     <b>",
"      Note:",
"     </b>",
"     Discontinuation of therapy may be considered after 12 weeks in patients with HCV (genotype 1) who fail to achieve an early virologic response (EVR) (defined as &ge;2-log decrease in HCV RNA compared to pretreatment) or after 24 weeks with detectable HCV RNA. Treat patients with HCV (genotypes 2,3) for 24 weeks (if tolerated) and then evaluate HCV RNA levels (Ghany, 2009).",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     Prior to treatment, pregnancy screening should occur for women of childbearing age who are receiving treatment or who have male partners who are receiving treatment. In combination therapy with ribavirin, pregnancy tests should continue monthly up to 6 months after discontinuation of therapy. Evaluate for depression and other psychiatric symptoms before and during therapy; baseline eye examination and periodically in patients with baseline disorders; baseline echocardiogram in patients with cardiac disease.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F206891\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Pegasys (AR, AT, AU, BE, BG, BR, CH, CL, CN, CO, CZ, DE, DK, EC, EE, ES, FI, FR, GB, GR, HK, HN, ID, IE, IL, IT, MT, MX, MY, NL, NO, NZ, PE, PH, PK, PL, PT, PY, RU, SE, SG, SK, TH, TR, TW, UY, VE);",
"     </li>",
"     <li>",
"      Pegasys PFS (KP)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F206869\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Alpha interferons are a family of proteins, produced by nucleated cells that have antiviral, antiproliferative, and immune-regulating activity. There are 16 known subtypes of alpha interferons. Interferons interact with cells through high affinity cell surface receptors. Following activation, multiple effects can be detected including induction of gene transcription. Interferons inhibit cellular growth, alter the state of cellular differentiation, interfere with oncogene expression, alter cell surface antigen expression, increase phagocytic activity of macrophages, and augment cytotoxicity of lymphocytes for target cells.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F206885\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Terminal: 50-160 hours; increased with renal dysfunction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: 72-96 hours",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      ACOG Practice Bulletin No. 86: &ldquo;Viral Hepatitis in Pregnancy,&rdquo;",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2007, 110(4):941-56.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/27/27064/abstract-text/17906043/pubmed\" id=\"17906043\" target=\"_blank\">",
"        17906043",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/27/27064/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, \"Sexually Transmitted Diseases Treatment Guidelines, 2006,\"",
"      <i>",
"       MMWR",
"      </i>",
"      , 2006, 55(RR-11):1-94.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cohen V, Jellinek SP, Teperikidis L, et al, &ldquo;Room-Temperature Storage of Medications Labeled for Refrigeration,&rdquo;",
"      <i>",
"       Am J Health-Syst Pharm",
"      </i>",
"      , 2007, 64(16):1711-15.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/27/27064/abstract-text/17687059/pubmed\" id=\"17687059\" target=\"_blank\">",
"        17687059",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dienstag JL and McHutchison JG, &ldquo;American Gastroenterological Association Medical Position Statement on the Management of Hepatitis C,&rdquo;",
"      <i>",
"       Gastroenterology",
"      </i>",
"      , 2006, 130(1):225-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/27/27064/abstract-text/16401485/pubmed\" id=\"16401485\" target=\"_blank\">",
"        16401485",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fried MW, Shillman ML, Reddy KR, et al, &ldquo;Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C Virus Infection,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2002, 347:975-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/27/27064/abstract-text/12324553/pubmed\" id=\"12324553\" target=\"_blank\">",
"        12324553",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ghany MG, Nelson DR, Strader DB, et al, &ldquo;An Update on Treatment of Genotype 1 Chronic Hepatitis C Virus Infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases,&rdquo;",
"      <i>",
"       Hepatology",
"      </i>",
"      , 2011, 54(4):1433-44.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/27/27064/abstract-text/21898493/pubmed\" id=\"21898493\" target=\"_blank\">",
"        21898493",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ghany MG, Strader DB, Thomas DL, et al, &ldquo;Diagnosis, Management and Treatment of Hepatitis C: An Update,&rdquo;",
"      <i>",
"       Hepatology",
"      </i>",
"      , 2009, 49(4):1335-74.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/27/27064/abstract-text/19330875/pubmed\" id=\"19330875\" target=\"_blank\">",
"        19330875",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jonas MM, Balistreri W, Gonzalez-Peralta RP, et al, \"Peginterferon for Chronic Hepatitis C in Children Affects Growth and Body Composition: Results From the Pediatric Study of Hepatitis C (PEDS-C) Trial,\"",
"      <i>",
"       Hepatology",
"      </i>",
"      , 2012, 56(2):523-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/27/27064/abstract-text/22383118/pubmed\" id=\"22383118\" target=\"_blank\">",
"        22383118",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lebon P, Girard S, Thepot F, et al, &ldquo;The Presence of Alpha-Interferon in Human Amniotic Fluid,&rdquo;",
"      <i>",
"       J Gen Virol",
"      </i>",
"      , 1982, 59(Pt 2):393-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/27/27064/abstract-text/6176680/pubmed\" id=\"6176680\" target=\"_blank\">",
"        6176680",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lok AS and McMahon BJ, &ldquo;Chronic Hepatitis B: Update 2009,&rdquo;",
"      <i>",
"       Hepatology",
"      </i>",
"      , 2009, 50(3):661-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/27/27064/abstract-text/19714720/pubmed\" id=\"19714720\" target=\"_blank\">",
"        19714720",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Marcellin P, Lau GK, Bonino F, et al, \"Peginterferon Alfa-2a Alone, Lamivudine Alone, and the Two in Combination in Patients With HBeAg-Negative Chronic Hepatitis B,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2004, 351(12):1206-17.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/27/27064/abstract-text/15371578/pubmed\" id=\"15371578\" target=\"_blank\">",
"        15371578",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Murray KF, Rodrigue JR, Gonzalez-Peralta RP, et al, &ldquo;Design of the PEDS-C Trial: Pegylated Interferon +/- Ribavirin for Children With Chronic Hepatitis C Viral Infection,&rdquo;",
"      <i>",
"       Clin Trials",
"      </i>",
"      , 2007, 4(6):661-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/27/27064/abstract-text/18042575/pubmed\" id=\"18042575\" target=\"_blank\">",
"        18042575",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Perinatal HIV Guidelines Working Group. Public Health Service Task Force Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States,&rdquo; April 29, 2009, 1-90. Available at",
"      <a href=\"file://aidsinfo.nih.gov/ContentFiles/PerinatalGL.pdf\" target=\"_blank\">",
"       file://aidsinfo.nih.gov/ContentFiles/PerinatalGL.pdf",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schwarz KB, Gonzalez-Peralta RP, Murray KF, et al, &ldquo;The Combination of Ribavirin and Peginterferon is Superior to Peginterferon and Placebo for Children and Adolescents With Chronic Hepatitis C,&rdquo;",
"      <i>",
"       Gastroenterology",
"      </i>",
"      , 2011, 140(2):450-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/27/27064/abstract-text/21036173/pubmed\" id=\"21036173\" target=\"_blank\">",
"        21036173",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al, \"Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C Virus Infection in HIV-Infected Patients,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2004, 351(5):438-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/27/27064/abstract-text/15282351/pubmed\" id=\"15282351\" target=\"_blank\">",
"        15282351",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Waysbort A, Giroux M, Mansat V, et al, &ldquo;Experimental Study of Transplacental Passage of Alpha Interferon by Two Assay Techniques,&rdquo;",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 1993, 37(6):1232-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/27/27064/abstract-text/8328774/pubmed\" id=\"8328774\" target=\"_blank\">",
"        8328774",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10136 Version 43.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-88.81.100.162-4217E6CC24-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_27_27064=[""].join("\n");
var outline_f26_27_27064=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709197\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206899\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206900\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206919\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206903\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15043485\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3062247\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206904\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206905\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3022885\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206881\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206867\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874941\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206883\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206882\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206917\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206886\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206870\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206913\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206874\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206896\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206876\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206889\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206908\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5366118\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206890\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206888\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206878\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206891\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206869\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206885\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10136\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10136|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?21/3/21558?source=related_link\">",
"      Pegylated interferon (peginterferon) alfa-2a: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/61/8152?source=related_link\">",
"      Pegylated interferon (peginterferon) alfa-2a: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_27_27065="Pelosi technique 4";
var content_f26_27_27065=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F66859&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F66859&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 566px\">",
"   <div class=\"ttl\">",
"    Closure using Pelosi technique",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 546px; height: 500px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Exteriorization of the uterus through the abdominal incision is easily accomplished. (B) Following completion of the hysterotomy closure, the self-retaining retractor is removed. (C) The visceral and parietal peritoneum are not closed. (D) No suture approximation of the rectus muscles is performed. The fascia is closed in a continuous, non-locking fashion with delayed-absorbable sutures placed at least one cm from the fascial wound edge (arrows). (E) The subcutaneous tissue is not closed except when this layer is &ge;2 cm thick. The skin is closed with subcuticular sutures, or (F) metal staples.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Marco Pelosi, MD and Marco Pelosi III, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_27_27065=[""].join("\n");
var outline_f26_27_27065=null;
var title_f26_27_27066="Course and treatment of autosomal dominant polycystic kidney disease";
var content_f26_27_27066=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Course and treatment of autosomal dominant polycystic kidney disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/27/27066/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/27/27066/contributors\">",
"     Arlene B Chapman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/27/27066/contributors\">",
"     Frederic F Rahbari-Oskoui, MD, MSCR",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/27/27066/contributors\">",
"     William M Bennett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/27/27066/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/27/27066/contributors\">",
"     Ronald D Perrone, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/27/27066/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/27/27066/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/27/27066/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 1, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polycystic kidney disease (PKD) includes inherited diseases that cause an irreversible decline in kidney function. PKD may be inherited as an autosomal dominant or recessive trait. The autosomal dominant form (ADPKD) is the most common genetic cause of chronic kidney disease [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27066/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The majority of individuals with PKD eventually require renal replacement therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27066/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The course and treatment of ADPKD in adults are discussed here. The diagnosis, genetics and pathogenesis of ADPKD, and autosomal recessive PKD in children are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9433?source=see_link\">",
"     \"Diagnosis of and screening for autosomal dominant polycystic kidney disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/13/34009?source=see_link\">",
"     \"Genetics of autosomal dominant polycystic kidney disease and mechanisms of cyst growth\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/13/29913?source=see_link\">",
"     \"Autosomal recessive polycystic kidney disease in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autosomal dominant PKD (ADPKD) occurs in all races and has a reported prevalence of 1:400 to 1:1000 [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27066/abstract/3\">",
"     3",
"    </a>",
"    ]. ADPKD is the underlying cause of kidney disease in approximately five percent of patients who initiate dialysis annually in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27066/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    ADPKD is caused by mutations of either PKD1 (which encodes polycystin-1) on chromosome 16 or PKD2 (which encodes polycystin-2) on chromosome 4 [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27066/abstract/4\">",
"     4",
"    </a>",
"    ]. PKD1 mutations are more common (approximately 85 percent) than PKD2 mutations (approximately 15 percent). The relative frequency of PKD1 and PKD2 mutations depend on the age of the population being studied since patients with PKD2 mutations present at an older age and progress more slowly than patients with PKD1 mutations. As a result, PKD2 mutations may be underreported compared to PKD1, and the frequency of PKD2 underestimated among populations in which only symptomatic individuals are tested. This is demonstrated by the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      PKD1 mutations were present in 85 percent and PKD2 mutation in 15 percent of cases, respectively, in a study of patients who had known PKD [",
"      <a class=\"abstract\" href=\"UTD.htm?26/27/27066/abstract/6\">",
"       6",
"      </a>",
"      ]. By contrast, the frequency of PKD2 mutations was higher (27 percent) in population-based studies that included individuals who were at risk for ADPKD but had no evidence of clinical renal disease [",
"      <a class=\"abstract\" href=\"UTD.htm?26/27/27066/abstract/3,6\">",
"       3,6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Since patients with PKD1 reach end stage renal disease or die at a younger age compared to those with PKD2 [",
"      <a class=\"abstract\" href=\"UTD.htm?26/27/27066/abstract/7\">",
"       7",
"      </a>",
"      ], studies of older patients with ADPKD demonstrate a higher proportion of disease attributable to PKD2 [",
"      <a class=\"abstract\" href=\"UTD.htm?26/27/27066/abstract/2,8\">",
"       2,8",
"      </a>",
"      ]. In a study of 46 patients with ADPKD who had not yet started dialysis by age 63, 18 had mutations of PKD2. This contrasts to only 4 of the 40 patients with ADPKD younger than age 63 who served as a control group [",
"      <a class=\"abstract\" href=\"UTD.htm?26/27/27066/abstract/8\">",
"       8",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/13/34009?source=see_link\">",
"       \"Genetics of autosomal dominant polycystic kidney disease and mechanisms of cyst growth\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A few families have a defect unrelated to either gene locus; however, other gene mutations responsible for ADPKD have not been identified [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27066/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/13/34009?source=see_link\">",
"     \"Genetics of autosomal dominant polycystic kidney disease and mechanisms of cyst growth\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Virtually all individuals who inherit PKD1 or PKD2 eventually develop renal cysts that are visible by ultrasonographic imaging studies [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27066/abstract/10\">",
"     10",
"    </a>",
"    ]. The age at which affected individuals have clinical manifestations such as renal failure or hypertension is variable. As discussed above, patients with PKD1 present with symptoms at a younger age than those with PKD2. In one study the median age of patients who presented with renal failure was 54 and 74 years for those with PKD1 and PKD2, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27066/abstract/7\">",
"     7",
"    </a>",
"    ]. However, early onset disease has been described with both mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27066/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Genetic factors'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Patients with ADPKD can present with hypertension, hematuria, proteinuria or renal insufficiency detected by routine laboratory examinations. Flank pain due to renal hemorrhage, calculi, or urinary tract infection is the most common symptom reported by patients [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27066/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/11/30903?source=see_link\">",
"     \"Renal manifestations of autosomal dominant polycystic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hypertension is present in the majority of patients who have normal renal function and have reached the fourth decade of life; the prevalence of hypertension increases to almost 100 percent among patients with end stage renal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27066/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients may also present with symptoms that are secondary to cysts in other organs such as the liver, or pancreas, spleen, thyroid or epididymis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/33/30233?source=see_link\">",
"     \"Extrarenal manifestations of autosomal dominant polycystic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     COURSE AND PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among most patients, renal function remains intact until the fourth decade of life. Once the glomerular filtration rate starts to decline, the average reduction is 4.4 to 5.9",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per year [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27066/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Risk factors that have been identified for progressive renal disease in ADPKD include [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27066/abstract/13-24\">",
"     13-24",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Genetic factors (PKD1 versus PKD2)",
"     </li>",
"     <li>",
"      Hypertension",
"     </li>",
"     <li>",
"      Early onset of symptoms including proteinuria and hematuria",
"     </li>",
"     <li>",
"      Male gender",
"     </li>",
"     <li>",
"      Increased kidney size (kidney size is greater with PKD1 mutations)",
"     </li>",
"     <li>",
"      Increased left ventricular mass index",
"     </li>",
"     <li>",
"      Dipstick detectable proteinuria",
"     </li>",
"     <li>",
"      Low birth weight",
"     </li>",
"     <li>",
"      Decreased renal blood flow",
"     </li>",
"     <li>",
"      Increased urinary sodium excretion",
"     </li>",
"     <li>",
"      Increased LDL cholesterol",
"     </li>",
"     <li>",
"      Increased plasma copeptin (surrogate marker for vasopressin)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Genetic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major factor that determines the rate of progression in the individual patient is the causative gene mutation. Patients with PKD2 progress more slowly than those with PKD1 [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27066/abstract/7,25\">",
"     7,25",
"    </a>",
"    ]. This was shown in a review of 333 and 291 patients with PKD1 and PKD2, respectively, who were compared with 398 matched controls [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27066/abstract/7\">",
"     7",
"    </a>",
"    ]. The median age of the onset of end-stage renal failure was 54 and 74 years, for PKD1 and PKD2, respectively.",
"   </p>",
"   <p>",
"    In approximately two to three percent of patients, deletions involve both the PKD1 gene and the Tuberous Sclerosis Complex-2 gene resulting in a more severe cystic kidney disease called the contiguous gene syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27066/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other genetic factors, such as the location and type of mutation within the gene may contribute to the severity of disease [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27066/abstract/4\">",
"     4",
"    </a>",
"    ]. Patients who have mutations at the 5' site of PKD1 have earlier onset of end-stage renal disease and more severe extrarenal manifestations compared to those with mutations at the 3' site [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27066/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. In addition, truncating mutations in PKD1 produce more severe disease than missense mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27066/abstract/11\">",
"     11",
"    </a>",
"    ]. No clear association has been observed between severity of disease and mutation position among patients with PKD2, although specific types of mutations may be associated with less severe disease [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27066/abstract/29-31\">",
"     29-31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Extensive variability in disease severity is common within families. Intrafamilial variability may be explained by somatic mosaicism, in which the PKD1 mutation is not expressed in all cells [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27066/abstract/32,33\">",
"     32,33",
"    </a>",
"    ], or by modifier genes that are inherited independently of the PKD mutation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27066/abstract/4,13,34-36\">",
"     4,13,34-36",
"    </a>",
"    ]. Candidate modifier genes include the angiotensin I converting enzyme gene [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27066/abstract/37\">",
"     37",
"    </a>",
"    ], the cystic fibrosis transmembrane conductance regulator gene [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27066/abstract/38,39\">",
"     38,39",
"    </a>",
"    ], the endothelial nitric oxide synthase gene [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27066/abstract/3\">",
"     3",
"    </a>",
"    ], and the Dickkopf 3 (DKK3) gene [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27066/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertension is a risk factor for progressive disease and is associated with increased kidney size before loss of kidney function [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27066/abstract/17,22,41\">",
"     17,22,41",
"    </a>",
"    ]. Issues related to hypertension in ADPKD, including the goal blood pressure, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/55/30582?source=see_link\">",
"     \"Hypertension in autosomal dominant polycystic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Kidney size",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data from the Consortium for Radiologic Imaging of Polycystic kidney disease (CRISP) suggest that the decline in glomerular filtration rate (GFR) correlates with increasing kidney size and cyst volume, as well as a reduction in renal blood flow [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27066/abstract/18,42-44\">",
"     18,42-44",
"    </a>",
"    ]. The association between kidney volume and declining GFR was demonstrated by CRISP, which reported that baseline renal volume determined by magnetic resonance imaging (MRI) predicted the rate of kidney growth and decrease in function [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27066/abstract/17,18,42,45\">",
"     17,18,42,45",
"    </a>",
"    ]. Height adjusted kidney size appears to best predict the decline in GFR, with a height-adjusted volume greater than 600",
"    <span class=\"nowrap\">",
"     cc/m",
"    </span>",
"    a better predictor of CKD by eight years than age, baseline serum creatinine, BUN or proteinuria [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27066/abstract/46\">",
"     46",
"    </a>",
"    ]. Patients with PKD1 have larger kidneys at the time of diagnosis compared to those with PKD2 but do not grow at a faster rate, but greater numbers of cysts are present in PKD1 vs. PKD2 suggesting that the number of new cysts forming differs between the two genotypes rather than the rate of cyst growth.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Early onset of symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who present with symptoms at an early age are more likely to develop end stage renal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27066/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. In one study, patients diagnosed before the age of 30 had a mean renal survival 10 years less than those diagnosed after the age of 30 [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27066/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Male gender",
"    </span>",
"    &nbsp;&mdash;&nbsp;Male gender has been associated with more rapid progression of PKD1 in some [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27066/abstract/14,17,47\">",
"     14,17,47",
"    </a>",
"    ] but not all [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27066/abstract/25\">",
"     25",
"    </a>",
"    ] studies. The reasons for this are not known [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27066/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Proteinuria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who have dipstick positive proteinuria and microalbuminuria are at greater risk for progression to ESRD and account for a minority of PKD patients (27 percent). Proteinuria also associates with kidney size, hypertension and reduced kidney function [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27066/abstract/17,49-51\">",
"     17,49-51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14486329\">",
"    <span class=\"h2\">",
"     Low birth weight",
"    </span>",
"    &nbsp;&mdash;&nbsp;Low birth weight has been associated with a younger age of onset of end-stage renal disease (ESRD). This was shown in a study of 284 Danish ADPKD patients with ESRD whose birth weights were obtained from midwife protocols stored in the Danish State Archives [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27066/abstract/47\">",
"     47",
"    </a>",
"    ]. After adjusting for multiple variables including mean arterial pressure, gender, birth decade and antihypertensive treatment, every kilogram increase in birth weight was associated with a 1.7 year increase in the age of onset of ESRD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Identification of high risk patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;The identification of individuals who are at high risk for progression of chronic kidney disease may be important for prognostic reasons or to target patients who will benefit from specific therapies as they become available (see",
"    <a class=\"local\" href=\"#H16\">",
"     'Treatment'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Poor prognostic factors such as hypertension, early onset of symptoms and male gender may help to identify such patients. Other methods to identify patients at high risk for progressive disease include characterizing the causative mutation and measuring the rate of increase in cyst volume.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Predicting genotype",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genetic testing is available to identify the causative mutation in ADPKD, but is not commonly performed, except when a definitive diagnosis must be made (as in screening family members for possible kidney donation). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9433?source=see_link\">",
"     \"Diagnosis of and screening for autosomal dominant polycystic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among patients with known PKD and a family history of PKD of unknown genotype, the careful attention to family history may allow the prediction of the mutation. This was shown in a study of 484 patients from 90 families with well-characterized ADPKD mutations. To predict PKD1 or 2, various age cutoffs for the onset of end stage renal disease or for renal survival without end-stage renal disease of affected family members were analyzed [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27066/abstract/2\">",
"     2",
"    </a>",
"    ]. The following observations were made:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The presence of at least one family member who developed end stage renal disease before age 55 predicted a PKD1 mutation with a positive predictive value of 100 percent and a sensitivity of 72 percent.",
"     </li>",
"     <li>",
"      The presence of at least one family member who reached 70 years of age without end stage renal disease predicted a PKD2 mutation with a positive predictive value of 100 percent and a sensitivity of 74 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Since neither criterion had a negative predictive value of 100 percent, the absence of an affected family member who satisfied these criteria did not allow of exclusion of either mutation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Determining rate of progression of cyst volume",
"    </span>",
"    &nbsp;&mdash;&nbsp;Assessment of kidney size by MRI may provide prognostic information. Most studies that have examined the prognostic utility of imaging used MRI enhanced with or without gadolinium [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27066/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. In practice, the use of gadolinium is limited by its association with nephrogenic systemic fibrosis in patients with renal insufficiency. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/22/31082?source=see_link\">",
"     \"Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure\"",
"    </a>",
"    .) MRI images obtained in ADPKD patients with and without gadolinium are highly correlated with regard to kidney volume measurement, suggesting that MRI may also be used without gadolinium for the quantification of kidney size [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27066/abstract/52\">",
"     52",
"    </a>",
"    ]. Ultrasound does not appear to be sufficiently accurate to measure change in kidney volume over a short period of time [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27066/abstract/53\">",
"     53",
"    </a>",
"    ]. Measurements of total kidney volume have been utilized primarily in research and are not routinely available for clinical imaging. Assessment of total kidney volume in clinical practice may provide insights into rate of progression.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     CAUSES OF DEATH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with ADPKD die from cardiac causes [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27066/abstract/54\">",
"     54",
"    </a>",
"    ]. In one report of 129 patients with ADPKD, causes of death included heart disease (36 percent), infection (24 percent), and a neurologic event (12 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27066/abstract/55\">",
"     55",
"    </a>",
"    ]. Cardiac hypertrophy was seen in 89 percent of autopsied patients and coronary disease in 81 percent. Neurologic deaths were primarily due to ruptured intracranial aneurysm (6 percent) and hypertensive intracerebral hemorrhage (5 percent). No patient died of renal cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Like other causes of CKD, the effect of pregnancy in women with ADPKD depends on the underlying renal function. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/62/11241?source=see_link\">",
"     \"Pregnancy in women with underlying renal disease\"",
"    </a>",
"    .) In one study of 235 women with normal or near normal renal function (&le;1.2",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (105",
"    <span class=\"nowrap\">",
"     &micro;mol/L))",
"    </span>",
"    and 605 pregnancies, the following observations were noted [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27066/abstract/56\">",
"     56",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The fertility rate in men and women was similar to unaffected family members without ADPKD.",
"     </li>",
"     <li>",
"      Normotensive women usually had successful, uncomplicated pregnancies. Women with new-onset hypertension (16 percent) with or without preeclampsia were more likely to develop chronic hypertension.",
"     </li>",
"     <li>",
"      Hypertensive women were at increased risk for fetal loss and preeclampsia. Women who developed preeclampsia had higher rates of prematurity and perinatal mortality.",
"     </li>",
"     <li>",
"      There was an increased frequency of ectopic pregnancies in ADPKD women, suggesting that fallopian tube structure, cilial function, or movement is abnormal in ADPKD women.",
"     </li>",
"     <li>",
"      There was a suggestion that four or more pregnancies was associated with lower creatinine clearances, suggesting that repeated pregnancy may enhance the rate of disease progression.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;No specific treatment has been proven to prevent or delay progression of ADPKD. Promising therapies, including vasopressin receptor antagonists, increased fluid intake, maximal inhibition of the renin-angiotensin-aldosterone system, use of mTOR inhibitors, and rigorous blood pressure control are being evaluated.",
"   </p>",
"   <p>",
"    The treatment of patients with ADPKD includes non-specific measures, such as strict blood pressure control, dietary protein restriction, a low salt diet, and statins, which may prevent progression of disease and reduce cardiovascular mortality. In addition, supportive therapy including pain control, bed rest during gross hematuria, and treatment of infection are mainstays of therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rigorous control of blood pressure may prevent progression of renal disease and decrease the risk of cardiovascular morbidity that characterizes all patients with chronic kidney disease. As an example, a retrospective review of primary care electronic medical records in the United Kingdom showed that more intense antihypertensive drug regimens were associated with significant reductions in patient mortality and a delay in renal failure [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27066/abstract/57\">",
"     57",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/55/30582?source=see_link\">",
"     \"Hypertension in autosomal dominant polycystic kidney disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34298?source=see_link\">",
"     \"Chronic kidney disease and coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If there are no contraindications, an angiotensin converting enzyme (ACE) inhibitor should be the initial antihypertensive agent. Increased renin-angiotensin system activity and extracellular volume expansion play an important role in the pathogenesis of hypertension in patients with ADPKD, thus patients generally respond well to these agents [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27066/abstract/58\">",
"     58",
"    </a>",
"    ]. In addition, some studies have suggested that treatment with ACE inhibitors or angiotensin receptor blockers (ARBs) may slow the rate of progression of ADPKD, especially among patients with proteinuria. These studies are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/55/30582?source=see_link&amp;anchor=H3984957#H3984957\">",
"     \"Hypertension in autosomal dominant polycystic kidney disease\", section on 'Choice of agent'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Careful monitoring is indicated in high-risk patients (those with extremely large kidneys or with established renal insufficiency) after institution of an ACE inhibitor or whenever an episode of volume depletion or cyst hemorrhage occurs in someone already being treated with one of these agents. An ARB should be considered in those hypertensive patients who are intolerant of ACE inhibitors, either due to cough or angioedema.",
"   </p>",
"   <p>",
"    Patients who develop a clinically significant elevation in the plasma creatinine concentration should be monitored closely. If the serum creatinine or potassium increase significantly due to these agents, patients may be more safely treated with another agent, such as a calcium channel blocker; some experts prefer to use a beta-blocker as a second agent given the potentially detrimental effects of calcium blockers on cyst formation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/13/34009?source=see_link&amp;anchor=H7#H7\">",
"     \"Genetics of autosomal dominant polycystic kidney disease and mechanisms of cyst growth\", section on 'Role of cyclic AMP and intracellular calcium'",
"    </a>",
"    .)\"",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Statins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperlipidemia should be aggressively treated with statins among patients with ADPKD who have reduced kidney function since CKD is considered a CHD risk equivalent. Goals of therapy are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34298?source=see_link&amp;anchor=H11#H11\">",
"     \"Chronic kidney disease and coronary heart disease\", section on 'Reduction of CHD risk in patients with CKD'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/59/3002?source=see_link\">",
"     \"Intensity of lipid lowering therapy in secondary prevention of coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some, but not all, studies of patients with mild to moderate CKD from all causes have suggested that statins may help to preserve renal function. These studies are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/6/30824?source=see_link&amp;anchor=H7#H7\">",
"     \"Statins and chronic kidney disease\", section on 'Statins and kidney function'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/19/26938?source=see_link&amp;anchor=H11#H11\">",
"     \"Secondary factors and progression of chronic kidney disease\", section on 'Hyperlipidemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are no data that show that statins prevent end stage renal disease specifically among patients with ADPKD, although beneficial effects have been observed on renal blood flow and endothelial function in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27066/abstract/59,60\">",
"     59,60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Vasopressin receptor antagonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;In vitro evidence suggests that increased intracellular cyclic AMP (cAMP) plays a significant role in cystogenesis in polycystic kidney disease [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27066/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. A detailed discussion of this issue can be found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/13/34009?source=see_link\">",
"     \"Genetics of autosomal dominant polycystic kidney disease and mechanisms of cyst growth\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Based in part upon these observations, vasopressin V2 receptor antagonists, which lower renal epithelial cell intracellular cAMP levels, have been evaluated in animal models of autosomal dominant and recessive polycystic kidney disease:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The vasopressin V2 receptor antagonists OPC-31260 and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11654?source=see_link\">",
"       tolvaptan",
"      </a>",
"      (OPC-41061) decrease cAMP levels, inhibit cystogenesis and prevent renal enlargement and dysfunction in three different murine models [",
"      <a class=\"abstract\" href=\"UTD.htm?26/27/27066/abstract/63\">",
"       63",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      PCK rats without circulating vasopressin are protected from renal cyst formation but develop renal cysts when they are exposed to the V2 agonist, 1-deamino-8-D-arginine vasopressin (DDAVP) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/27/27066/abstract/64,65\">",
"       64,65",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Both V2 receptor antagonists",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11654?source=see_link\">",
"       tolvaptan",
"      </a>",
"      and OPC-31260 inhibit mitogen-activated protein kinase (MAPK) signaling, which may mediate the proliferative response to cAMP in the kidney. Similarly, PCK rats that do not express AVP have markedly reduced MAPK signaling [",
"      <a class=\"abstract\" href=\"UTD.htm?26/27/27066/abstract/64\">",
"       64",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The results of a multicenter, placebo-controlled, double-blinded trial (TEMPO 3:4 trial) indicated a beneficial effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11654?source=see_link\">",
"     tolvaptan",
"    </a>",
"    on the progression of kidney disease in ADPKD [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27066/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. Inclusion criteria included ages 18 to 50 years (mean of 40 years), estimated creatinine clearance &gt;60",
"    <span class=\"nowrap\">",
"     ml/min",
"     <sup>",
"     </sup>",
"    </span>",
"    (mean 81",
"    <span class=\"nowrap\">",
"     mL/min)",
"    </span>",
"    and total kidney volume &gt;750 mL (mean 1705 mL). The daily dose of tolvaptan varied from 60 to 120 mg with a median daily dose of 90 mg (divided into 60 mg in the morning and 30 mg at night). Among 1157 patients who were randomly assigned in a 2:1 ratio to tolvaptan or placebo and completed the study, the following findings were noted at three years:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The annual increase in total kidney volume was smaller among patients who received",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11654?source=see_link\">",
"       tolvaptan",
"      </a>",
"      compared with placebo (2.8 versus 5.5 percent, respectively).",
"     </li>",
"     <li>",
"      The annual decline in kidney function (assessed by the reciprocal of the serum creatinine concentration) was slower among patients who received",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11654?source=see_link\">",
"       tolvaptan",
"      </a>",
"      compared with placebo (-2.61 versus -3.81",
"      <span class=\"nowrap\">",
"       [mg/mL]",
"       <sup>",
"        -1",
"       </sup>",
"      </span>",
"      per year, respectively).",
"     </li>",
"     <li>",
"      A composite end point that included time to clinical progression (defined as worsening kidney function, kidney pain, hypertension, and albuminuria) and rate of kidney function decline, favored",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11654?source=see_link\">",
"       tolvaptan",
"      </a>",
"      over placebo (44 versus 50 events per 100 person-years of follow-up) with lower rates of worsening kidney function (2 versus 5 events per 100 person-years of follow-up) and kidney pain (5 versus 7 events per 100 person-years of follow-up).",
"     </li>",
"     <li>",
"      The rate of adverse events was similar between groups but the discontinuation rate was higher in the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11654?source=see_link\">",
"       tolvaptan",
"      </a>",
"      compared with placebo group (23 versus 14 percent, respectively). Patients who received tolvaptan had a higher frequency of adverse events due to increased aquaresis (polyuria, polydipsia, nocturia and urinary frequency), but a lower frequency of adverse events related to ADPKD (kidney pain, hematuria, urinary tract infection and back pain).",
"      <br/>",
"      <br/>",
"      Serious adverse events occurring in at least 0.5% of the patients included increased liver enzymes (0.9 percent in tolvaptan versus 0.4 percent in the placebo group), chest pain (0.8 percent in tolvaptan versus 0.4 percent in the placebo group), and headache (0.5 percent in tolvaptan versus 0 percent in placebo group). A greater than 2.5-fold increase in liver enzymes occurred more often among patients who received tolvaptan compared with placebo (4.9 percent versus 1.2 percent, respectively). In all cases, these abnormalities either resolved spontaneously or after withdrawal of tolvaptan. The mean increase in serum sodium concentration was 2.5",
"      <span class=\"nowrap\">",
"       meq/L,",
"      </span>",
"      with 4 and 1.4 percent of the tolvaptan and placebo groups achieving a sodium concentration of 150",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      or higher. Hyperuricemia",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      gout occurred in 2.9 and 1.4 percent of tolvaptan and placebo groups, but these events did not lead to serious adverse events.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The positive results of the study may have been blunted by the fact that all patients were asked to increase their water intake and avoid dehydration [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27066/abstract/68\">",
"     68",
"    </a>",
"    ]. This may have suppressed vasopressin levels in the placebo group, resulting in an underestimation of the beneficial effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11654?source=see_link\">",
"     tolvaptan",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    We suggest that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11654?source=see_link\">",
"     tolvaptan",
"    </a>",
"    not be used for the treatment of ADPKD pending further assessment of risks and benefits for individual patients and review by regulatory agencies for use for this indication. Based upon the adverse side effects observed in the TEMPO trial, the United States Food and Drug Administration (US FDA) has issued a safety warning about the possibility of irreversible liver injury associated with the use of tolvaptan, which is approved for use for hyponatremia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27066/abstract/69\">",
"     69",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/57/17306?source=see_link&amp;anchor=H14#H14\">",
"     \"Treatment of hyponatremia: Syndrome of inappropriate antidiuretic hormone secretion (SIADH) and reset osmostat\", section on 'Limitations to use of tolvaptan'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Increased fluid intake",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increasing fluid intake to suppress plasma vasopressin levels has been postulated as a possible therapeutic mechanism to inhibit cyst growth in ADPKD [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27066/abstract/70\">",
"     70",
"    </a>",
"    ]. In order to test this approach, a pilot study examined the effects of acute and chronic water loading on urine osmolality and cAMP concentrations in 13 subjects with ADPKD and 10 healthy controls [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27066/abstract/71\">",
"     71",
"    </a>",
"    ]. Exclusion criteria included a history of syndrome of antidiuresis, use of vasopressin agonists or antagonists, serum sodium &lt;135",
"    <span class=\"nowrap\">",
"     meq/L,",
"    </span>",
"    or estimated GFR&lt;60",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2. Chronic water loading (intake of at least 3",
"    <span class=\"nowrap\">",
"     L/day)",
"    </span>",
"    increased urine volume and decreased urine osmolality to mean values of 3.1",
"    <span class=\"nowrap\">",
"     L/day",
"    </span>",
"    and 270",
"    <span class=\"nowrap\">",
"     mosmol/L",
"    </span>",
"    in ADPKD subjects. The 24-hour cAMP excretion did not change with chronic water loading although it did with acute water loading (2 L over 2.5 hours).",
"   </p>",
"   <p>",
"    These data suggest that an increase in fluid intake to 3",
"    <span class=\"nowrap\">",
"     L/day",
"    </span>",
"    suppresses urine osmolality and partially suppresses serum ADH levels. A higher water intake may provide more complete suppression of ADH and cAMP.",
"   </p>",
"   <p>",
"    However, it is extremely difficult to drink the amount of fluid required to adequately suppress ADH levels. Since patients with ADPKD have concentrating defects early on, and are predisposed to nephrolithiasis, a liberal fluid intake should be encouraged with &gt;3",
"    <span class=\"nowrap\">",
"     L/day",
"    </span>",
"    fluid intake recommended. The serum sodium should be monitored in patients in whom the estimated GFR is less than 30",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2, or in those at risk for hyponatremia (such as patients on a thiazide diuretic). Patients who have an estimated GFR less than 15",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2 should not exceed this amount.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Somatostatin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Somatostatin may reduce renal and liver cyst fluid accumulation among patients with PKD [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27066/abstract/72-74\">",
"     72-74",
"    </a>",
"    ]. In a pilot study comparing somatostatin to placebo in patients with PKD, active therapy was associated with a smaller increase in cyst size and total kidney volume after six months of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27066/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The benefit of somatostatin was also shown at one year in a randomized trial in which 34 patients with ADPKD and 8 with autosomal dominant polycystic liver disease received a long-acting somatostatin (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    ) or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27066/abstract/74\">",
"     74",
"    </a>",
"    ]. In this study, the mean liver volume was decreased from baseline with octreotide but virtually unchanged with placebo (4.95 versus 0.92 percent, p&lt;0.045); and 21 of 28 patients who received octreotide had a reduction in liver volume. Among patients with ADPKD, the mean kidney volume was stable on octreotide (1143 and 1129 mL at baseline and one year, respectively) but increased on placebo (803 and 874 mL at baseline and one year, respectively) with a significantly lower percentage change on octreotide compared to placebo (0.25 versus 8.60 percent, respectively).",
"   </p>",
"   <p>",
"    Glomerular filtration rate (GFR) was decreased to the same degree in both groups at one year.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     Octreotide",
"    </a>",
"    was associated with improved perception of pain and physical activity.",
"   </p>",
"   <p>",
"    Side effects associated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    included mild diarrhea (11 patients), abdominal cramps (5 patients), nausea (6 patients), and gas (2 patients).",
"   </p>",
"   <p>",
"    The results of an open-label extension of this study were reported at two years [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27066/abstract/75\">",
"     75",
"    </a>",
"    ]. Among 14 patients who received placebo for one year followed by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    for one year, octreotide was associated with a reduction in liver volume (7.66 percent). Among 28 patients who received octreotide for the entire two years, the reduction in liver volume was maintained, although a further reduction was not observed.",
"   </p>",
"   <p>",
"    Larger multicenter studies are required to determine the long-term benefit of somatostatin [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27066/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Mammalian target of rapamycin (mTOR)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mammalian target of rapamycin (mTOR) signaling pathway may modulate disease progression in ADPKD [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27066/abstract/77-79\">",
"     77-79",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/13/34009?source=see_link\">",
"     \"Genetics of autosomal dominant polycystic kidney disease and mechanisms of cyst growth\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This was initially suggested by a retrospective analysis of PKD transplant patients that showed that both liver and kidney volume decrease more in patients who are receiving the mTOR inhibitor, rapamycin (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    ), compared to those that are not [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27066/abstract/80\">",
"     80",
"    </a>",
"    ]. A proof-of-concept randomized crossover study (SIRENA) suggested that rapamycin stabilized cyst growth at six months [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27066/abstract/81\">",
"     81",
"    </a>",
"    ]. However, two larger randomized trials showed discordant effects of mTOR inhibitors on cyst growth and no benefit on renal clearance function [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27066/abstract/82,83\">",
"     82,83",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a two year double-blind trial, 431 patients with ADPKD (mean baseline estimated GFR of approximately 55",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m2) received either the mTOR inhibitor,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"       everolimus",
"      </a>",
"      , or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?26/27/27066/abstract/83\">",
"       83",
"      </a>",
"      ]. The increase in total kidney volume, as measured by MRI, was smaller in the everolimus group compared with placebo at one (102 versus 157 mL, p = 0.02) and two (230 versus 301 mL, p = 0.06) years. However, there was no difference in the mean decrease in estimated GFR (8.9 versus 7.7",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m2), and the mean protein-to-creatinine ratio remained stable in the placebo group but increased in the everolimus group. Side effects associated with everolimus, including leukopenia, thrombocytopenia and hyperlipidemia, were common and resulted in a high rate of discontinuation (approximately 35 percent).",
"     </li>",
"     <li>",
"      In an 18 month open-label randomized trial, 100 patients with an estimated creatinine clearance of at least 70",
"      <span class=\"nowrap\">",
"       mL/min,",
"      </span>",
"      received",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"       sirolimus",
"      </a>",
"      (2 mg daily) or standard care [",
"      <a class=\"abstract\" href=\"UTD.htm?26/27/27066/abstract/82\">",
"       82",
"      </a>",
"      ]. There was no difference in the median kidney volume as determined by MRI, or in the estimated creatinine clearance between groups at eighteen months. Additionally, the albumin-to-creatinine ratio was 38 percent higher in the sirolimus group compared to the group that received standard care.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A suggested explanation for the lack of a functional benefit of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"     everolimus",
"    </a>",
"    despite the reduction in the rate of increase of kidney volume is that the drug was started too late; patients had already sustained marked decline in estimated GFR, and fibrosis rather than increased cyst volume may have driven the decline in kidney function observed during the study. In support of this hypothesis, the early but not late administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    inhibited mTOR signaling, cyst formation and fibrosis in animal models [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27066/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Alternatively",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"     everolimus",
"    </a>",
"    may have inhibited compensatory hypertrophy, which usually preserves GFR [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27066/abstract/85\">",
"     85",
"    </a>",
"    ]. The latter explanation suggests that everolimus may exert a protective effect over the long term, but the duration of this study was too short to demonstrate such an effect. Importantly, the known nephrotoxicity of the mTOR inhibitors as evidenced by increasing levels of proteinuria that are independent of cyst formation and expansion renders it difficult to establish the benefits of mTOR inhibition based on reduced changes in total kidney volume.",
"   </p>",
"   <p>",
"    The lack of effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    on kidney volume at eighteen months is potentially attributable to the low target drug level, which was much lower than those associated with a beneficial effect in animal studies [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27066/abstract/85\">",
"     85",
"    </a>",
"    ]. Supporting this hypothesis was the subsequent observation that sirolimus had no effect in animal models except at a ten-fold higher dose than that used in patients [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27066/abstract/84\">",
"     84",
"    </a>",
"    ]. In addition, a small pilot study that compared the effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/37/24152?source=see_link\">",
"     ramipril",
"    </a>",
"    plus high dose sirolimus (mean achieved serum concentration 6.4",
"    <span class=\"nowrap\">",
"     ng/mL)",
"    </span>",
"    to ramipril plus low dose sirolimus (mean achieved serum concentration 3.2",
"    <span class=\"nowrap\">",
"     ng/mL),",
"    </span>",
"    and to ramipril alone, suggested that the higher dose may have partially inhibited an increase in kidney volume and decline in eGFR [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27066/abstract/86\">",
"     86",
"    </a>",
"    ]. The achieved serum concentration in the study cited above, in which sirolimus was ineffective, ranged from 4.1 to 4.9",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27066/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However higher doses of mTOR inhibitors will almost certainly cause more adverse side effects. The kidney-targeted delivery of a folate-conjugated form of rapamycin inhibited MTOR activity in the kidney but not in other organs, and preserved kidney function in a mouse model [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27066/abstract/87\">",
"     87",
"    </a>",
"    ]. This approach may reduce toxicity without loss of efficacy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Other approaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/12/38085?source=see_link\">",
"     Amiloride",
"    </a>",
"    and caffeine restriction may inhibit cyst enlargement in animal models of cystic disease but have not been shown to be effective among patients with ADPKD [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27066/abstract/88-90\">",
"     88-90",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A variety of medical therapies including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    , urinary alkalinization, taxol,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/20/42312?source=see_link\">",
"     lovastatin",
"    </a>",
"    , epidermal growth factor receptor tyrosine kinase inhibitors, peroxisome proliferator-activated receptor agonists, cyclin-dependent kinase inhibitors, and mitogen-activated protein kinase inhibitors are being studied in animal models of ADPKD [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27066/abstract/1,91-103\">",
"     1,91-103",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    No clinical studies using any of these interventions are available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Protein restriction",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are conflicting findings on the efficacy of a low protein diet. These are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/45/2777?source=see_link\">",
"     \"Protein restriction and progression of chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     RENAL REPLACEMENT THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with ADPKD who progress to end-stage renal disease require renal replacement therapy. As with all patients, the options are either dialysis or renal transplantation. Peritoneal dialysis is less commonly performed than hemodialysis because it is difficult for the patients to accommodate large volumes of peritoneal dialysate fluid in the setting of massively enlarged kidneys. In addition, there may be an increased risk of peritonitis secondary to cyst infections or complications of diverticular disease [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27066/abstract/104\">",
"     104",
"    </a>",
"    ]. Nevertheless, some centers have found that peritoneal dialysis is well tolerated and results in no specific difficulties in the patient with ADPKD requiring renal replacement therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27066/abstract/105\">",
"     105",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with ADPKD and renal failure are therefore most commonly treated with hemodialysis or undergo renal transplantation. In general, such patients have equivalent or perhaps better overall outcomes with any renal replacement therapy compared to non-ADPKD patients [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27066/abstract/54,106-109\">",
"     54,106-109",
"    </a>",
"    ]. It is important to note that therapy for polycystic liver disease may continue in patients with ADPKD who have reached ESRD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Renal transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rate of complications following transplant are similar to those in the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27066/abstract/3\">",
"     3",
"    </a>",
"    ]. In preparation for transplantation, it is suggested that patients undergo screening for the presence of an intracranial aneurysm [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27066/abstract/110\">",
"     110",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/33/30233?source=see_link&amp;anchor=H6#H6\">",
"     \"Extrarenal manifestations of autosomal dominant polycystic kidney disease\", section on 'Recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A few specific complications may be more frequent or unique to this patient population; these include new onset diabetes, posttransplant erythrocytosis, symptomatic aneurysms, urinary tract infections, diverticulitis, and gastrointestinal disorders requiring surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27066/abstract/106,111-114\">",
"     106,111-114",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study of 874 consecutive renal transplant recipients, 114 of whom had ADPKD, compared the posttransplant outcomes and manifestations of patients with ADPKD with a matched control population [",
"      <a class=\"abstract\" href=\"UTD.htm?26/27/27066/abstract/106\">",
"       106",
"      </a>",
"      ]. At follow-up at 63 months, no difference in patient and graft survival was observed between the two groups. Clinical characteristics more frequently observed or unique to patients with ADPKD included elevated hematocrit levels, the requirement for nephrectomy (19 before and 7 after transplantation), diverticulitis (four patients, two with perforation) and symptomatic aortic aneurysms (death in two patients).",
"     </li>",
"     <li>",
"      A second series of 1417 renal transplant recipients, 145 of whom had ADPKD, found that gastrointestinal surgery was required twice as often in patients with polycystic disease (12 versus 6 percent for those without ADPKD) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/27/27066/abstract/112\">",
"       112",
"      </a>",
"      ]. A perforated colon was the most common abnormality in the ADPKD group, a possible reflection of the high frequency of colonic diverticulosis in patients with ADPKD who progress to end-stage renal disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/33/30233?source=see_link\">",
"       \"Extrarenal manifestations of autosomal dominant polycystic kidney disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Nephrectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nephrectomy is avoided whenever possible in ADPKD. Rarely, patients require nephrectomy of one or both cystic kidney(s) in order to better accommodate the allograft, or for recurrent urinary tract infection, chronic pain, renal cell carcinoma or chronic hematuria requiring ongoing transfusions [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27066/abstract/115,116\">",
"     115,116",
"    </a>",
"    ]. Nephrectomy is most often considered for pain that is constant and requires narcotic medications or is associated with reduced quality of life extending over a long (months) period of time.",
"   </p>",
"   <p>",
"    Nephrectomy may also benefit patients with recurrent renal infections that do not clear with antibiotics, often in association with low function and complicated nephrolithiasis (staghorn calculi). Isolated cystic infections should be first approached with long-term antibiotics or cyst decompression before considering nephrectomy.",
"   </p>",
"   <p>",
"    Laparoscopic removal of cystic kidneys is increasingly used rather than open nephrectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27066/abstract/3,117,118\">",
"     3,117,118",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In general, outcomes are similar with nephrectomy performed pre-, during or post-renal transplantation, but concomitant nephrectomy and transplantation are associated with increased patient satisfaction [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27066/abstract/115,116\">",
"     115,116",
"    </a>",
"    ]. In one series of 32 patients, 7, 16 and 9 patients underwent pre-, during and post-transplant nephrectomy, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27066/abstract/116\">",
"     116",
"    </a>",
"    ]. As expected, blood loss, operative time and hospitalization length were somewhat greater for the concomitant nephrectomy group (by approximately 50 mL, 160 minutes, and 1.5 to 2 days, respectively), but this does not account for the transplant surgery procedure in those who had nephrectomy post-transplant. Renal allograft function at a three-month follow-up was the same for the concomitant and post-transplant nephrectomy groups.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Hemodialysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Survival of patients with ADPKD undergoing hemodialysis may be better (by 10 to 15 percent at five years) to that of patients with other causes of end-stage renal disease, including nondiabetic patients [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27066/abstract/54,107,108\">",
"     54,107,108",
"    </a>",
"    ]. In one large survey using data from the United States Renal Data System, the relative risk (RR) of death was lower among patients with ADPKD compared to nondiabetic control dialysis patients (RR of 0.57, 95% CI 0.53-0.61) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27066/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This difference in survival is primarily due to a lower incidence of coronary artery disease in these generally more healthy patients with ADPKD. Clinical problems more frequently observed in patients with ADPKD include renal pain (36 versus 2 percent for non-ADPKD patients), gross hematuria (36 versus 16 percent), and renal infection (16 versus 2 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27066/abstract/108\">",
"     108",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Peritoneal dialysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A survival benefit among patients with ADPKD, compared to those without ADPKD, is also observed with peritoneal dialysis. In addition, limited evidence suggests that patients with ADPKD may have superior survival rates with peritoneal dialysis than with hemodialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27066/abstract/109\">",
"     109",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     CHRONIC PAIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abdominal and back pain from massively enlarged kidneys or liver may be disabling among a small group of patients with ADPKD [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27066/abstract/3\">",
"     3",
"    </a>",
"    ]. Among such patients surgical aspiration or sclerosis of cysts may provide effective pain relief. Nephrectomy or renal artery embolization may be considered among patients with end stage renal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?26/27/27066/abstract/60\">",
"     60",
"    </a>",
"    ]. A surgical approach by an experienced team may provide substantial improvement in refractory pain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?34/44/35523?source=see_link\">",
"       \"Patient information: Polycystic kidney disease (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?37/24/38277?source=see_link\">",
"       \"Patient information: Polycystic kidney disease (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Polycystic kidney disease (PKD) is inherited as an autosomal dominant or recessive trait. Autosomal dominant PKD (ADPKD) is caused by mutations of either PKD1 or PKD2 genes. PKD1 mutations are more common and cause more severe disease than PKD2 mutations. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with ADPKD from either PKD1 or PKD2 mutations present with hypertension, hematuria, renal insufficiency, or flank pain attributable to renal hemorrhage, calculi, or urinary tract infection. Patients may also present with symptoms that are secondary to cysts in other organs such as the liver or pancreas. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical presentation'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/33/30233?source=see_link\">",
"       \"Extrarenal manifestations of autosomal dominant polycystic kidney disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Renal function usually remains normal until the fourth decade. Thereafter GFR declines on average by 4.4 to 5.9",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per year. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Course and prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Genetic contribution to severity of disease includes the gene mutation (PKD1 versus PKD). Other clinical risk factors associated with progressive renal disease include hypertension, early onset of symptoms, male gender, and increased renal size. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Course and prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hypertension occurs early, prior to loss of kidney function, in close to two-thirds of patients with ADPKD and is associated with progressive renal disease. Issues related to goal blood pressure in these patients are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/55/30582?source=see_link&amp;anchor=H5#H5\">",
"       \"Hypertension in autosomal dominant polycystic kidney disease\", section on 'Blood pressure goal'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34298?source=see_link&amp;anchor=H11#H11\">",
"       \"Chronic kidney disease and coronary heart disease\", section on 'Reduction of CHD risk in patients with CKD'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Treatment with angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) may, in addition to lowering the blood pressure, slow the rate of progression of ADPKD, especially among patients with proteinuria. For patients who have no contraindications to an ACE inhibitor (such as pregnancy), we suggest using an ACE inhibitor as the initial antihypertensive agent (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/55/30582?source=see_link&amp;anchor=H3984957#H3984957\">",
"       \"Hypertension in autosomal dominant polycystic kidney disease\", section on 'Choice of agent'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      No specific therapy has been proven to prevent or delay progression of ADPKD. Promising specific therapies that are being evaluated include vasopressin receptor antagonists and increasing fluid intake to suppress plasma vasopressin levels. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Vasopressin receptor antagonists'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H20\">",
"       'Increased fluid intake'",
"      </a>",
"      above.).",
"     </li>",
"     <li>",
"      Patients with ADPKD and renal failure are most commonly treated with hemodialysis or undergo renal transplantation with equivalent or better overall outcomes compared to non-ADPKD patients. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Renal replacement therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/1\">",
"      Patel V, Chowdhury R, Igarashi P. Advances in the pathogenesis and treatment of polycystic kidney disease. Curr Opin Nephrol Hypertens 2009; 18:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/2\">",
"      Barua M, Cil O, Paterson AD, et al. Family history of renal disease severity predicts the mutated gene in ADPKD. J Am Soc Nephrol 2009; 20:1833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/3\">",
"      Torres VE, Harris PC. Autosomal dominant polycystic kidney disease: the last 3 years. Kidney Int 2009; 76:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/4\">",
"      Torres VE, Harris PC, Pirson Y. Autosomal dominant polycystic kidney disease. Lancet 2007; 369:1287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/5\">",
"      Harris PC, Torres VE. Polycystic kidney disease. Annu Rev Med 2009; 60:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/6\">",
"      Rossetti S, Consugar MB, Chapman AB, et al. Comprehensive molecular diagnostics in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 2007; 18:2143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/7\">",
"      Hateboer N, v Dijk MA, Bogdanova N, et al. Comparison of phenotypes of polycystic kidney disease types 1 and 2. European PKD1-PKD2 Study Group. Lancet 1999; 353:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/8\">",
"      Torra R, Badenas C, P&eacute;rez-Oller L, et al. Increased prevalence of polycystic kidney disease type 2 among elderly polycystic patients. Am J Kidney Dis 2000; 36:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/9\">",
"      de Almeida E, Martins Prata M, de Almeida S, Lavinha J. Long-term follow-up of a family with autosomal dominant polycystic kidney disease type 3. Nephrol Dial Transplant 1999; 14:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/10\">",
"      Igarashi P, Somlo S. Genetics and pathogenesis of polycystic kidney disease. J Am Soc Nephrol 2002; 13:2384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/11\">",
"      Rossetti S, Harris PC. Genotype-phenotype correlations in autosomal dominant and autosomal recessive polycystic kidney disease. J Am Soc Nephrol 2007; 18:1374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/12\">",
"      Bergmann C, Br&uuml;chle NO, Frank V, et al. Perinatal deaths in a family with autosomal dominant polycystic kidney disease and a PKD2 mutation. N Engl J Med 2008; 359:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/13\">",
"      Peters DJ, Breuning MH. Autosomal dominant polycystic kidney disease: modification of disease progression. Lancet 2001; 358:1439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/14\">",
"      Gabow PA, Johnson AM, Kaehny WD, et al. Factors affecting the progression of renal disease in autosomal-dominant polycystic kidney disease. Kidney Int 1992; 41:1311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/15\">",
"      Johnson AM, Gabow PA. Identification of patients with autosomal dominant polycystic kidney disease at highest risk for end-stage renal disease. J Am Soc Nephrol 1997; 8:1560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/16\">",
"      Fick-Brosnahan GM, Tran ZV, Johnson AM, et al. Progression of autosomal-dominant polycystic kidney disease in children. Kidney Int 2001; 59:1654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/17\">",
"      Fick-Brosnahan GM, Belz MM, McFann KK, et al. Relationship between renal volume growth and renal function in autosomal dominant polycystic kidney disease: a longitudinal study. Am J Kidney Dis 2002; 39:1127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/18\">",
"      King BF, Torres VE, Brummer ME, et al. Magnetic resonance measurements of renal blood flow as a marker of disease severity in autosomal-dominant polycystic kidney disease. Kidney Int 2003; 64:2214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/19\">",
"      Rizk D, Chapman AB. Cystic and inherited kidney diseases. Am J Kidney Dis 2003; 42:1305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/20\">",
"      Grantham JJ. Clinical practice. Autosomal dominant polycystic kidney disease. N Engl J Med 2008; 359:1477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/21\">",
"      Yium J, Gabow P, Johnson A, et al. Autosomal dominant polycystic kidney disease in blacks: clinical course and effects of sickle-cell hemoglobin. J Am Soc Nephrol 1994; 4:1670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/22\">",
"      Schrier RW, McFann KK, Johnson AM. Epidemiological study of kidney survival in autosomal dominant polycystic kidney disease. Kidney Int 2003; 63:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/23\">",
"      Torres VE, Grantham JJ, Chapman AB, et al. Potentially modifiable factors affecting the progression of autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2011; 6:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/24\">",
"      Boertien WE, Meijer E, Zittema D, et al. Copeptin, a surrogate marker for vasopressin, is associated with kidney function decline in subjects with autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 2012; 27:4131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/25\">",
"      Dicks E, Ravani P, Langman D, et al. Incident renal events and risk factors in autosomal dominant polycystic kidney disease: a population and family-based cohort followed for 22 years. Clin J Am Soc Nephrol 2006; 1:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/26\">",
"      Brook-Carter PT, Peral B, Ward CJ, et al. Deletion of the TSC2 and PKD1 genes associated with severe infantile polycystic kidney disease--a contiguous gene syndrome. Nat Genet 1994; 8:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/27\">",
"      Rossetti S, Burton S, Strmecki L, et al. The position of the polycystic kidney disease 1 (PKD1) gene mutation correlates with the severity of renal disease. J Am Soc Nephrol 2002; 13:1230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/28\">",
"      Rossetti S, Chauveau D, Kubly V, et al. Association of mutation position in polycystic kidney disease 1 (PKD1) gene and development of a vascular phenotype. Lancet 2003; 361:2196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/29\">",
"      Hateboer N, Veldhuisen B, Peters D, et al. Location of mutations within the PKD2 gene influences clinical outcome. Kidney Int 2000; 57:1444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/30\">",
"      Magistroni R, He N, Wang K, et al. Genotype-renal function correlation in type 2 autosomal dominant polycystic kidney disease. J Am Soc Nephrol 2003; 14:1164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/31\">",
"      Hateboer N, Lazarou LP, Williams AJ, et al. Familial phenotype differences in PKD11. Kidney Int 1999; 56:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/32\">",
"      Connor A, Lunt PW, Dolling C, et al. Mosaicism in autosomal dominant polycystic kidney disease revealed by genetic testing to enable living related renal transplantation. Am J Transplant 2008; 8:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/33\">",
"      Consugar MB, Wong WC, Lundquist PA, et al. Characterization of large rearrangements in autosomal dominant polycystic kidney disease and the PKD1/TSC2 contiguous gene syndrome. Kidney Int 2008; 74:1468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/34\">",
"      Rossetti S, Kubly VJ, Consugar MB, et al. Incompletely penetrant PKD1 alleles suggest a role for gene dosage in cyst initiation in polycystic kidney disease. Kidney Int 2009; 75:848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/35\">",
"      Fain PR, McFann KK, Taylor MR, et al. Modifier genes play a significant role in the phenotypic expression of PKD1. Kidney Int 2005; 67:1256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/36\">",
"      Persu A, Duyme M, Pirson Y, et al. Comparison between siblings and twins supports a role for modifier genes in ADPKD. Kidney Int 2004; 66:2132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/37\">",
"      Baboolal K, Ravine D, Daniels J, et al. Association of the angiotensin I converting enzyme gene deletion polymorphism with early onset of ESRF in PKD1 adult polycystic kidney disease. Kidney Int 1997; 52:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/38\">",
"      O'Sullivan DA, Torres VE, Gabow PA, et al. Cystic fibrosis and the phenotypic expression of autosomal dominant polycystic kidney disease. Am J Kidney Dis 1998; 32:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/39\">",
"      Persu A, Devuyst O, Lannoy N, et al. CF gene and cystic fibrosis transmembrane conductance regulator expression in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 2000; 11:2285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/40\">",
"      Liu M, Shi S, Senthilnathan S, et al. Genetic variation of DKK3 may modify renal disease severity in ADPKD. J Am Soc Nephrol 2010; 21:1510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/41\">",
"      Gabow PA, Chapman AB, Johnson AM, et al. Renal structure and hypertension in autosomal dominant polycystic kidney disease. Kidney Int 1990; 38:1177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/42\">",
"      Chapman AB, Guay-Woodford LM, Grantham JJ, et al. Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort. Kidney Int 2003; 64:1035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/43\">",
"      King BF, Reed JE, Bergstralh EJ, et al. Quantification and longitudinal trends of kidney, renal cyst, and renal parenchyma volumes in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 2000; 11:1505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/44\">",
"      Torres VE, King BF, Chapman AB, et al. Magnetic resonance measurements of renal blood flow and disease progression in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2007; 2:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/45\">",
"      Grantham JJ, Torres VE, Chapman AB, et al. Volume progression in polycystic kidney disease. N Engl J Med 2006; 354:2122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/46\">",
"      Chapman AB, Bost JE, Torres VE, et al. Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2012; 7:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/47\">",
"      Orskov B, Christensen KB, Feldt-Rasmussen B, Strandgaard S. Low birth weight is associated with earlier onset of end-stage renal disease in Danish patients with autosomal dominant polycystic kidney disease. Kidney Int 2012; 81:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/48\">",
"      Pei Y. Nature and nurture on phenotypic variability of autosomal dominant polycystic kidney disease. Kidney Int 2005; 67:1630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/49\">",
"      Chapman AB, Johnson AM, Gabow PA, Schrier RW. Overt proteinuria and microalbuminuria in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 1994; 5:1349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/50\">",
"      Sharp C, Johnson A, Gabow P. Factors relating to urinary protein excretion in children with autosomal dominant polycystic kidney disease. J Am Soc Nephrol 1998; 9:1908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/51\">",
"      Grantham JJ, Chapman AB, Torres VE. Volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes. Clin J Am Soc Nephrol 2006; 1:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/52\">",
"      Bae KT, Tao C, Zhu F, et al. MRI-based kidney volume measurements in ADPKD: reliability and effect of gadolinium enhancement. Clin J Am Soc Nephrol 2009; 4:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/53\">",
"      O'Neill WC, Robbin ML, Bae KT, et al. Sonographic assessment of the severity and progression of autosomal dominant polycystic kidney disease: the Consortium of Renal Imaging Studies in Polycystic Kidney Disease (CRISP). Am J Kidney Dis 2005; 46:1058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/54\">",
"      Perrone RD, Ruthazer R, Terrin NC. Survival after end-stage renal disease in autosomal dominant polycystic kidney disease: contribution of extrarenal complications to mortality. Am J Kidney Dis 2001; 38:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/55\">",
"      Fick GM, Johnson AM, Hammond WS, Gabow PA. Causes of death in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 1995; 5:2048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/56\">",
"      Chapman AB, Johnson AM, Gabow PA. Pregnancy outcome and its relationship to progression of renal failure in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 1994; 5:1178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/57\">",
"      Patch C, Charlton J, Roderick PJ, Gulliford MC. Use of antihypertensive medications and mortality of patients with autosomal dominant polycystic kidney disease: a population-based study. Am J Kidney Dis 2011; 57:856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/58\">",
"      Schrier RW. Renal volume, renin-angiotensin-aldosterone system, hypertension, and left ventricular hypertrophy in patients with autosomal dominant polycystic kidney disease. J Am Soc Nephrol 2009; 20:1888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/59\">",
"      Namli S, Oflaz H, Turgut F, et al. Improvement of endothelial dysfunction with simvastatin in patients with autosomal dominant polycystic kidney disease. Ren Fail 2007; 29:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/60\">",
"      Bremmer MS, Jacobs SC. Renal artery embolization for the symptomatic treatment of adult polycystic kidney disease. Nat Clin Pract Nephrol 2008; 4:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/61\">",
"      Grantham JJ. Lillian Jean Kaplan International Prize for advancement in the understanding of polycystic kidney disease. Understanding polycystic kidney disease: a systems biology approach. Kidney Int 2003; 64:1157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/62\">",
"      Calvet JP. Strategies to inhibit cyst formation in ADPKD. Clin J Am Soc Nephrol 2008; 3:1205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/63\">",
"      Torres VE, Wang X, Qian Q, et al. Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease. Nat Med 2004; 10:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/64\">",
"      Wang X, Wu Y, Ward CJ, et al. Vasopressin directly regulates cyst growth in polycystic kidney disease. J Am Soc Nephrol 2008; 19:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/65\">",
"      Grantham JJ. Therapy for polycystic kidney disease? It's water, stupid! J Am Soc Nephrol 2008; 19:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/66\">",
"      Higashihara E, Torres VE, Chapman AB, et al. Tolvaptan in autosomal dominant polycystic kidney disease: three years' experience. Clin J Am Soc Nephrol 2011; 6:2499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/67\">",
"      Torres VE, Chapman AB, Devuyst O, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 2012; 367:2407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/68\">",
"      W&uuml;thrich RP, Mei C. Aquaretic treatment in polycystic kidney disease. N Engl J Med 2012; 367:2440.",
"     </a>",
"    </li>",
"    <li>",
"     Samsca (tolvaptan): Drug Warning - Potential Risk of Liver Injury file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm336669.htm?source=govdelivery (Accessed on January 28, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/70\">",
"      Torres VE, Bankir L, Grantham JJ. A case for water in the treatment of polycystic kidney disease. Clin J Am Soc Nephrol 2009; 4:1140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/71\">",
"      Barash I, Ponda MP, Goldfarb DS, Skolnik EY. A pilot clinical study to evaluate changes in urine osmolality and urine cAMP in response to acute and chronic water loading in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2010; 5:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/72\">",
"      Ruggenenti P, Remuzzi A, Ondei P, et al. Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease. Kidney Int 2005; 68:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/73\">",
"      Caroli A, Antiga L, Cafaro M, et al. Reducing polycystic liver volume in ADPKD: effects of somatostatin analogue octreotide. Clin J Am Soc Nephrol 2010; 5:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/74\">",
"      Hogan MC, Masyuk TV, Page LJ, et al. Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease. J Am Soc Nephrol 2010; 21:1052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/75\">",
"      Hogan MC, Masyuk TV, Page L, et al. Somatostatin analog therapy for severe polycystic liver disease: results after 2 years. Nephrol Dial Transplant 2012; 27:3532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/76\">",
"      Schrier RW. Randomized intervention studies in human polycystic kidney and liver disease. J Am Soc Nephrol 2010; 21:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/77\">",
"      Shillingford JM, Murcia NS, Larson CH, et al. The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proc Natl Acad Sci U S A 2006; 103:5466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/78\">",
"      Longa L, Scolari F, Brusco A, et al. A large TSC2 and PKD1 gene deletion is associated with renal and extrarenal signs of autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 1997; 12:1900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/79\">",
"      W&uuml;thrich RP, Serra AL. Mammalian target of rapamycin and autosomal dominant polycystic kidney disease. Transplant Proc 2009; 41:S18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/80\">",
"      Qian Q, Du H, King BF, et al. Sirolimus reduces polycystic liver volume in ADPKD patients. J Am Soc Nephrol 2008; 19:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/81\">",
"      Perico N, Antiga L, Caroli A, et al. Sirolimus therapy to halt the progression of ADPKD. J Am Soc Nephrol 2010; 21:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/82\">",
"      Serra AL, Poster D, Kistler AD, et al. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N Engl J Med 2010; 363:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/83\">",
"      Walz G, Budde K, Mannaa M, et al. Everolimus in patients with autosomal dominant polycystic kidney disease. N Engl J Med 2010; 363:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/84\">",
"      Novalic Z, van der Wal AM, Leonhard WN, et al. Dose-dependent effects of sirolimus on mTOR signaling and polycystic kidney disease. J Am Soc Nephrol 2012; 23:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/85\">",
"      Watnick T, Germino GG. mTOR inhibitors in polycystic kidney disease. N Engl J Med 2010; 363:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/86\">",
"      Stallone G, Infante B, Grandaliano G, et al. Rapamycin for treatment of type I autosomal dominant polycystic kidney disease (RAPYD-study): a randomized, controlled study. Nephrol Dial Transplant 2012; 27:3560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/87\">",
"      Shillingford JM, Leamon CP, Vlahov IR, Weimbs T. Folate-conjugated rapamycin slows progression of polycystic kidney disease. J Am Soc Nephrol 2012; 23:1674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/88\">",
"      Grantham JJ, Uchic M, Cragoe EJ Jr, et al. Chemical modification of cell proliferation and fluid secretion in renal cysts. Kidney Int 1989; 35:1379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/89\">",
"      Gardner KD Jr, Burnside JS, Skipper BJ, et al. On the probability that kidneys are different in autosomal dominant polycystic disease. Kidney Int 1992; 42:1199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/90\">",
"      Belibi FA, Wallace DP, Yamaguchi T, et al. The effect of caffeine on renal epithelial cells from patients with autosomal dominant polycystic kidney disease. J Am Soc Nephrol 2002; 13:2723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/91\">",
"      Woo DD, Miao SY, Pelayo JC, Woolf AS. Taxol inhibits progression of congenital polycystic kidney disease. Nature 1994; 368:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/92\">",
"      Cowley, BD Jr, Gudapaty, S, Kraybill, AL, et al. Autosomal-dominant polycystic kidney disease in the rat. Kidney Int 1993; 43:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/93\">",
"      Gile RD, Cowley BD Jr, Gattone VH 2nd, et al. Effect of lovastatin on the development of polycystic kidney disease in the Han:SPRD rat. Am J Kidney Dis 1995; 26:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/94\">",
"      Keith DS, Torres VE, Johnson CM, Holley KE. Effect of sodium chloride, enalapril, and losartan on the development of polycystic kidney disease in Han:SPRD rats. Am J Kidney Dis 1994; 24:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/95\">",
"      Gattone VH 2nd, Cowley BD Jr, Barash BD, et al. Methylprednisolone retards the progression of inherited polycystic kidney disease in rodents. Am J Kidney Dis 1995; 25:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/96\">",
"      Nomura H, Turco AE, Pei Y, et al. Identification of PKDL, a novel polycystic kidney disease 2-like gene whose murine homologue is deleted in mice with kidney and retinal defects. J Biol Chem 1998; 273:25967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/97\">",
"      Tao Y, Kim J, Schrier RW, Edelstein CL. Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease. J Am Soc Nephrol 2005; 16:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/98\">",
"      Wahl PR, Serra AL, Le Hir M, et al. Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD). Nephrol Dial Transplant 2006; 21:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/99\">",
"      Sweeney WE Jr, Hamahira K, Sweeney J, et al. Combination treatment of PKD utilizing dual inhibition of EGF-receptor activity and ligand bioavailability. Kidney Int 2003; 64:1310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/100\">",
"      Muto S, Aiba A, Saito Y, et al. Pioglitazone improves the phenotype and molecular defects of a targeted Pkd1 mutant. Hum Mol Genet 2002; 11:1731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/101\">",
"      Omori S, Hida M, Fujita H, et al. Extracellular signal-regulated kinase inhibition slows disease progression in mice with polycystic kidney disease. J Am Soc Nephrol 2006; 17:1604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/102\">",
"      Smith LA, Bukanov NO, Husson H, et al. Development of polycystic kidney disease in juvenile cystic kidney mice: insights into pathogenesis, ciliary abnormalities, and common features with human disease. J Am Soc Nephrol 2006; 17:2821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/103\">",
"      Bukanov NO, Smith LA, Klinger KW, et al. Long-lasting arrest of murine polycystic kidney disease with CDK inhibitor roscovitine. Nature 2006; 444:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/104\">",
"      Lederman ED, McCoy G, Conti DJ, Lee EC. Diverticulitis and polycystic kidney disease. Am Surg 2000; 66:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/105\">",
"      Hadimeri H, Johansson AC, Haraldsson B, Nyberg G. CAPD in patients with autosomal dominant polycystic kidney disease. Perit Dial Int 1998; 18:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/106\">",
"      Hadimeri H, Nord&eacute;n G, Friman S, Nyberg G. Autosomal dominant polycystic kidney disease in a kidney transplant population. Nephrol Dial Transplant 1997; 12:1431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/107\">",
"      Zeier M, Jones E, Ritz E. Autosomal dominant polycystic kidney disease--the patient on renal replacement therapy. Nephrol Dial Transplant 1996; 11 Suppl 6:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/108\">",
"      Pirson Y, Christophe JL, Goffin E. Outcome of renal replacement therapy in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 1996; 11 Suppl 6:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/109\">",
"      Abbott KC, Agodoa LY. Polycystic kidney disease at end-stage renal disease in the United States: patient characteristics and survival. Clin Nephrol 2002; 57:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/110\">",
"      Ring T, Spiegelhalter D. Risk of intracranial aneurysm bleeding in autosomal-dominant polycystic kidney disease. Kidney Int 2007; 72:1400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/111\">",
"      Hamer RA, Chow CL, Ong AC, McKane WS. Polycystic kidney disease is a risk factor for new-onset diabetes after transplantation. Transplantation 2007; 83:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/112\">",
"      Andreoni KA, Pelletier RP, Elkhammas EA, et al. Increased incidence of gastrointestinal surgical complications in renal transplant recipients with polycystic kidney disease. Transplantation 1999; 67:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/113\">",
"      Wijdicks EF, Torres VE, Schievink WI, Sterioff S. Cerebral hemorrhage in recipients of renal transplantation. Mayo Clin Proc 1999; 74:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/114\">",
"      Stiasny B, Ziebell D, Graf S, et al. Clinical aspects of renal transplantation in polycystic kidney disease. Clin Nephrol 2002; 58:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/115\">",
"      Glassman DT, Nipkow L, Bartlett ST, Jacobs SC. Bilateral nephrectomy with concomitant renal graft transplantation for autosomal dominant polycystic kidney disease. J Urol 2000; 164:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/116\">",
"      Fuller TF, Brennan TV, Feng S, et al. End stage polycystic kidney disease: indications and timing of native nephrectomy relative to kidney transplantation. J Urol 2005; 174:2284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/117\">",
"      Whitten MG, Van der Werf W, Belnap L. A novel approach to bilateral hand-assisted laparoscopic nephrectomy for autosomal dominant polycystic kidney disease. Surg Endosc 2006; 20:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/27/27066/abstract/118\">",
"      Lipke MC, Bargman V, Milgrom M, Sundaram CP. Limitations of laparoscopy for bilateral nephrectomy for autosomal dominant polycystic kidney disease. J Urol 2007; 177:627.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1677 Version 20.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-85.214.214.87-4FABCF92AE-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_27_27066=[""].join("\n");
var outline_f26_27_27066=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H31\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      COURSE AND PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Genetic factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Hypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Kidney size",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Early onset of symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Male gender",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Proteinuria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14486329\">",
"      Low birth weight",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Identification of high risk patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Predicting genotype",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Determining rate of progression of cyst volume",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      CAUSES OF DEATH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Hypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Statins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Vasopressin receptor antagonists",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Increased fluid intake",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Somatostatin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Mammalian target of rapamycin (mTOR)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Other approaches",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Protein restriction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      RENAL REPLACEMENT THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Nephrectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Peritoneal dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      CHRONIC PAIN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/13/29913?source=related_link\">",
"      Autosomal recessive polycystic kidney disease in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34298?source=related_link\">",
"      Chronic kidney disease and coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9433?source=related_link\">",
"      Diagnosis of and screening for autosomal dominant polycystic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/33/30233?source=related_link\">",
"      Extrarenal manifestations of autosomal dominant polycystic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/13/34009?source=related_link\">",
"      Genetics of autosomal dominant polycystic kidney disease and mechanisms of cyst growth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/55/30582?source=related_link\">",
"      Hypertension in autosomal dominant polycystic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/59/3002?source=related_link\">",
"      Intensity of lipid lowering therapy in secondary prevention of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/22/31082?source=related_link\">",
"      Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?37/24/38277?source=related_link\">",
"      Patient information: Polycystic kidney disease (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?34/44/35523?source=related_link\">",
"      Patient information: Polycystic kidney disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/62/11241?source=related_link\">",
"      Pregnancy in women with underlying renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/45/2777?source=related_link\">",
"      Protein restriction and progression of chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/11/30903?source=related_link\">",
"      Renal manifestations of autosomal dominant polycystic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/19/26938?source=related_link\">",
"      Secondary factors and progression of chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/6/30824?source=related_link\">",
"      Statins and chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/57/17306?source=related_link\">",
"      Treatment of hyponatremia: Syndrome of inappropriate antidiuretic hormone secretion (SIADH) and reset osmostat",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_27_27067="Van Nuys Prognostic Index DCIS";
var content_f26_27_27067=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F62510&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F62510&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Van Nuys prognostic index for breast ductal carcinoma in situ",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Size score",
"       </td>",
"       <td class=\"subtitle1\">",
"        Margin score",
"       </td>",
"       <td class=\"subtitle1\">",
"        Pathologic classification score",
"       </td>",
"       <td class=\"subtitle1\">",
"        Age, yrs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1 = &le;15 mm",
"       </td>",
"       <td>",
"        1 = &ge;10 mm",
"       </td>",
"       <td>",
"        1 = Non-high-grade lesion without comedonecrosis (nuclear grade 1 or 2)",
"       </td>",
"       <td>",
"        1 = &ge;60",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2 = 16 to 40 mm",
"       </td>",
"       <td>",
"        2 = 1 to 9 mm",
"       </td>",
"       <td>",
"        2 = Non-high-grade lesion with comedonecrosis (nuclear grade 1 or 2)",
"       </td>",
"       <td>",
"        2 = 40 to 60",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3 = &ge;41 mm",
"       </td>",
"       <td>",
"        3 = &lt;1 mm (involved or close)",
"       </td>",
"       <td>",
"        3 = All high-grade lesions, with or without necrosis (nuclear grade 3)",
"       </td>",
"       <td>",
"        3 = &le;40",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Silverstein MJ. The University of Southern California/Van Nuys Prognostic Index. In: Ductal carcinoma In Situ of the Breast, 2nd ed, Silverstein MJ, Recht A, Lagios MD, eds, Lippincott Williams &amp; Wilkins, Philadelphia 2002. Copyright &copy; 2002 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_27_27067=[""].join("\n");
var outline_f26_27_27067=null;
var title_f26_27_27068="Periop rheumatologic agents";
var content_f26_27_27068=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F61808&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F61808&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Perioperative management of rheumatologic agents",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Name or class of drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical considerations",
"       </td>",
"       <td class=\"subtitle1\">",
"        Recommended strategy for surgery with brief NPO state",
"       </td>",
"       <td class=\"subtitle1\">",
"        Recommended strategy for surgery with prolonged NPO state",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nonsteroidal antiinflammatory drugs",
"       </td>",
"       <td>",
"        Continuation may cause perioperative hemorrhage.",
"       </td>",
"       <td>",
"        Hold for&nbsp;three days prior to surgery.",
"       </td>",
"       <td>",
"        Resume with oral intake.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Methotrexate",
"       </td>",
"       <td>",
"        Potential risk of bone marrow suppression",
"       </td>",
"       <td>",
"        Continue therapy up to and including day of surgery. In patients with renal insufficiency, hold two weeks prior to surgery.",
"       </td>",
"       <td>",
"        Continue therapy up to and including day of surgery. Resume with oral intake.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sulfasalazine and azathioprine",
"       </td>",
"       <td>",
"        Potential risk of bone marrow suppression",
"       </td>",
"       <td>",
"        Hold for one week prior to surgery.",
"       </td>",
"       <td>",
"        Hold for one week prior to surgery and resume with oral intake.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Leflunomide",
"       </td>",
"       <td>",
"        Potential risk of bone marrow suppression",
"       </td>",
"       <td>",
"        Hold for two weeks prior to surgery",
"       </td>",
"       <td>",
"        Hold for two weeks prior to surgery and resume with oral intake",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hydroxychloroqine",
"       </td>",
"       <td>",
"        Low risk of side effects",
"       </td>",
"       <td>",
"        Continue therapy up to and including day of surgery.",
"       </td>",
"       <td>",
"        Continue therapy up to and including day of surgery. Resume with oral intake.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Biologic response modifiers (etanercept, infliximab, anakinra, rituximab, adalimumab)",
"       </td>",
"       <td>",
"        Risk of infection",
"       </td>",
"       <td>",
"        Hold for one to two weeks prior to surgery and resume one to two weeks after surgery.",
"       </td>",
"       <td>",
"        Hold for one to two weeks prior to surgery and resume one to two weeks after surgery or with oral intake.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Agents used in gout (colchicine, allopurinol, probenecid)",
"       </td>",
"       <td>",
"        Abrupt discontinuation of allopurinol and probenecid may preciptate attack of acute gout. Probenecid interacts with numerous perioperative medications.",
"       </td>",
"       <td>",
"        Continue therapy up to the night of surgery and hold the morning dose.",
"       </td>",
"       <td>",
"        Continue therapy up to the night of surgery and hold the morning dose. Resume with oral intake. Intraarticular and systemic steroids are available for acute gouty flares in postop period.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_27_27068=[""].join("\n");
var outline_f26_27_27068=null;
var title_f26_27_27069="Categories of pulmonary nodules";
var content_f26_27_27069=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F62644&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F62644&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of solitary pulmonary nodules",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <colgroup span=\"2\" width=\"50%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Malignant",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Bronchogenic carcinoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Adenocarcinoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Squamous cell carcinoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Large cell carcinoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Small cell carcinoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Metastatic lesions",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Breast",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Head and neck",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Melanoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Colon",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Kidney",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Sarcoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Germ cell tumor",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Others",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Pulmonary carcinoid",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Benign",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Infectious granuloma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Histoplasmosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Coccidioidomycosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Tuberculosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Atypical mycobacteria",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Cryptococcosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Blastomycosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Other infections",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Bacterial abscess",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Dirofilaria immitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Echinococcus cyst",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Ascariasis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Pneumocystis carinii",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Aspergilloma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Benign neoplasms",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Hamartoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Lipoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Fibroma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Vascular",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Arteriovenous malformation",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Pulmonary varix",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Developmental",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Bronchogenic cyst",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Inflammatory",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Granulomatosis with polyangiitis (Wegener's)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Rheumatoid nodule",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Other",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Amyloidoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Rounded atelectasis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Intrapulmonary lymph nodes",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Hematoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Pulmonary infarct",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Pseudotumor (loculated fluid)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Mucoid impaction",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_27_27069=[""].join("\n");
var outline_f26_27_27069=null;
var title_f26_27_27070="Increasing plasma cholesterol and coronary risk";
var content_f26_27_27070=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F60146%7ECARD%2F50334&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F60146%7ECARD%2F50334&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Association of increasing plasma cholesterol and coronary risk",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 364px; height: 238px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Relation between plasma cholesterol concentration and six-year coronary heart disease risk in 361,662 men (ages 35 to 57) screened during the MRFIT study. There is a continuous, positive, graded correlation between the plasma cholesterol concentration and coronary risk. To convert plasma cholesterol to mmol/L, divide by 38.5.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Stamler J, Wentworth D, Neaton JD. JAMA 1986; 256:2823.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 548px\">",
"   <div class=\"ttl\">",
"    Plasma cholesterol and cardiovascular mortality",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 528px; height: 256px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Relation between the baseline plasma cholesterol concentration and ten-year cardiovascular death rate in patients without and with manifestations of coronary heart disease (CHD) in the Lipid Research Council study. Cumulative death rates were increased at higher plasma cholesterol levels in both groups, but the effect was more pronounced in patients with preexisting CHD.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Pekannen J, Linn S, Heiss G, et al. N Engl J Med 1990; 322:1700.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_27_27070=[""].join("\n");
var outline_f26_27_27070=null;
var title_f26_27_27071="3D reconstruction CT hamate fracture";
var content_f26_27_27071=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F75387&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F75387&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    3D reconstruction CT hamate fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 343px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This 3D reconstruction was created from multiple CT sections. The overlapping fragements resulting from a comminuted fracture of the hamate are shown (black arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kevin E Burroughs, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_27_27071=[""].join("\n");
var outline_f26_27_27071=null;
